U.S. patent application number 14/775649 was filed with the patent office on 2016-02-25 for novel pyrimidine and pyridine compounds and usage thereof.
The applicant listed for this patent is HUTCHISON MEDIPHARMA LIMITED. Invention is credited to Jinshui LI, Wei-Guo SU, Weihan ZHANG.
Application Number | 20160052926 14/775649 |
Document ID | / |
Family ID | 51535826 |
Filed Date | 2016-02-25 |
United States Patent
Application |
20160052926 |
Kind Code |
A1 |
SU; Wei-Guo ; et
al. |
February 25, 2016 |
NOVEL PYRIMIDINE AND PYRIDINE COMPOUNDS AND USAGE THEREOF
Abstract
The present invention relates to novel pyrimidine and pyridine
compounds of formula (I) or a pharmaceutical acceptable salt
thereof, ##STR00001## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4,
R.sup.5, X, Y and G are as defined in the description, to
pharmaceutical compositions containing them, a process for
preparing them, and their use in therapy of a disease responsive to
inhibition of FGFR, for example, cancer.
Inventors: |
SU; Wei-Guo; (Shanghai,
CN) ; ZHANG; Weihan; (Shanghai, CN) ; LI;
Jinshui; (Shanghai, CN) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
HUTCHISON MEDIPHARMA LIMITED |
Shanghai |
|
CN |
|
|
Family ID: |
51535826 |
Appl. No.: |
14/775649 |
Filed: |
March 15, 2013 |
PCT Filed: |
March 15, 2013 |
PCT NO: |
PCT/CN2013/072690 |
371 Date: |
September 11, 2015 |
Current U.S.
Class: |
514/210.2 ;
435/184; 514/235.8; 514/252.02; 514/252.14; 514/252.19; 514/252.2;
514/275; 544/122; 544/238; 544/295; 544/331; 544/360; 544/364 |
Current CPC
Class: |
C07D 487/04 20130101;
C07D 417/12 20130101; A61P 35/00 20180101; C07D 471/04 20130101;
C07D 401/12 20130101; C07D 401/14 20130101; C07D 405/12 20130101;
C07D 403/12 20130101; A61P 43/00 20180101; C07D 405/06 20130101;
C07D 239/42 20130101; C07D 405/14 20130101; C07D 403/14 20130101;
C07D 405/10 20130101; A61P 5/00 20180101; C07D 413/12 20130101 |
International
Class: |
C07D 487/04 20060101
C07D487/04; C07D 403/12 20060101 C07D403/12; C07D 405/06 20060101
C07D405/06; C07D 401/12 20060101 C07D401/12; C07D 403/14 20060101
C07D403/14; C07D 413/12 20060101 C07D413/12; C07D 471/04 20060101
C07D471/04; C07D 417/12 20060101 C07D417/12; C07D 401/14 20060101
C07D401/14; C07D 405/14 20060101 C07D405/14; C07D 239/42 20060101
C07D239/42; C07D 405/12 20060101 C07D405/12 |
Claims
1. A compound of formula (I); ##STR00286## or a pharmaceutically
acceptable salt thereof, wherein X is CH.sub.2, Y is selected from
CH.sub.2, O or S(O).sub.2; or X and Y together with the bond
there-between form --CH.dbd.CH-- or --C.ident.C--; G is N or CH;
R.sup.1 is aryl or heteroaryl, each of which is optionally
substituted with one or more substituents independently selected
from halo, --NR.sup.6R.sup.7, --OR.sup.8, --S(O).sub.nR.sup.9,
--(CH.sub.2).sub.r--C(O)R.sup.10, --CN, --C(O)NR.sup.6R.sup.7,
--NR.sup.6C(O)R.sup.10, --NR.sup.6S(O).sub.nR.sup.9,
--NR.sup.6S(O).sub.nNR.sup.11R.sup.12, --NR.sup.6C(O)OR.sup.8,
--NR.sup.6C(O)NR.sup.11R.sup.12, --NO.sub.2,
--S(O).sub.nNR.sup.6R.sup.7, oxo, optionally substituted alkyl,
--(CH.sub.2).sub.p-optionally substituted cycloalkyl,
--(CH.sub.2).sub.m-optionally substituted heterocyclyl,
--(CH.sub.2).sub.q-optionally substituted heteroaryl, optionally
substituted alkenyl, and optionally substituted alkynyl; R.sup.2 is
independently chosen from optionally substituted C.sub.1-C.sub.6
alkyl, optionally substituted C.sub.1-C.sub.6 alkoxy, or optionally
substituted C.sub.3-C.sub.8 cycloalkyl; R.sup.3, R.sup.4 are
independently chosen from hydrogen, halogen, --CN, or optionally
substituted C.sub.1-C.sub.6 alkyl, R.sup.5 is C.sub.1-C.sub.6
alkyl, or R.sup.3 and R.sup.5 together with the O atom to which
R.sup.5 is attached and the bond there-between form a 5- or
6-membered oxy-containing heterocyclic ring; n is 1 or 2; m, p, q
and r are independently chosen from 0, 1, 2, 3, 4, 5, 6; R.sup.6,
R.sup.7, R.sup.8, R.sup.9, R.sup.10, R.sup.11 and R.sup.12 are
independently selected from hydrogen, alkyl, cycloalkyl, aryl,
heteroaryl, heterocyclyl, each of which except for hydrogen, is
optionally substituted with one or more substituents independently
selected from halo, hydroxyl, mercapto, oxo, alkyl, cycloalkyl,
heterocyclyl, optionally substituted amino, and optionally
substituted amide, wherein each optionally substituted group above
for which the substituent(s) is (are) not specifically designated,
can be unsubstituted or independently substituted with one or more,
such as one, two or three, substituents independently chosen from
C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl, C.sub.2-C.sub.6
alkynyl, cycloalkyl, aryl, heterocyclyl, heteroaryl,
aryl-C.sub.1-C.sub.6 alkyl-, heteroaryl-C.sub.1-C.sub.6 alkyl-,
C.sub.1-C.sub.6 haloalkyl-, --OC.sub.1-C.sub.6 alkyl,
--OC.sub.2-C.sub.6 alkenyl, --OC.sub.1-C.sub.6 alkylphenyl,
--C.sub.1-C.sub.6 alkyl-OH, --C.sub.1-C.sub.6 alkyl-SH,
--C.sub.1-C.sub.6 alkyl-O--C.sub.1-C.sub.6 alkyl,
--OC.sub.1-C.sub.6 haloalkyl, halo, --OH, mercapto, --NH.sub.2,
--C.sub.1-C.sub.6 alkyl-NH.sub.2, --N(C.sub.1-C.sub.6 alkyl).sub.2,
--NH(C.sub.1-C.sub.6 alkyl), --N(C.sub.1-C.sub.6
alkyl)(C.sub.1-C.sub.6 alkylphenyl), --NH(C.sub.1-C.sub.6
alkylphenyl), cyano, nitro, oxo, --C(O)--OH, --C(O)OC.sub.1-C.sub.6
alkyl, --CON(C.sub.1-C.sub.6 alkyl).sub.2, --CONH(C.sub.1-C.sub.6
alkyl), --CONH.sub.2, --NHC(O)(C.sub.1-C.sub.6 alkyl),
--NHC(O)(phenyl), --N(C.sub.1-C.sub.6 alkyl)C(O)(C.sub.1-C.sub.6
alkyl), --N(C.sub.1-C.sub.6 alkyl)C(O)(phenyl),
--C(O)C.sub.1-C.sub.6 alkyl, --C(O)C.sub.1-C.sub.6 alkylphenyl,
--C(O)C.sub.1-C.sub.6 haloalkyl, --OC(O)C.sub.1-C.sub.6 alkyl,
--S(O).sub.2--C.sub.1-C.sub.6 alkyl, --S(O)--C.sub.1-C.sub.6 alkyl,
--S(O).sub.2-phenyl, --S(O).sub.2--C.sub.1-C.sub.6 haloalkyl,
--S(O).sub.2NH.sub.2, --S(O).sub.2NH(C.sub.1-C.sub.6 alkyl),
--S(O).sub.2NH(phenyl), --NHS(O).sub.2(C.sub.1-C.sub.6 alkyl),
--NHS(O).sub.2(phenyl), and --NHS(O).sub.2(C.sub.1-C.sub.6
haloalkyl).
2. The compound of formula (I) according to claim 1, wherein each
optionally substituted group for which the substituent(s) is(are)
not specifically designated can be unsubstituted or independently
substituted with one or more substituents independently chosen from
hydroxyl, mercapto, halo, C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6
alkenyl, C.sub.2-C.sub.6 alkynyl, --OC.sub.1-C.sub.6alkyl,
--NH.sub.2, --N(C.sub.1-C.sub.6 alkyl).sub.2,
--NH(C.sub.1-C.sub.6alkyl), cyano, nitro, oxo,
--S(O).sub.2--C.sub.1-C.sub.6 alkyl, --S(O)--C.sub.1-C.sub.6 alkyl,
--S(O).sub.2--C.sub.1-C.sub.6 haloalkyl, --C(O)--OH,
--C.sub.1-C.sub.6 alkyl-OH, --C.sub.1-C.sub.6 alkyl-SH,
heterocyclyl, or a pharmaceutical acceptable salt thereof.
3. The compound of formula (I) according to claim 1 or 2, wherein
R.sup.1 is aryl or heteroaryl, each of which is optionally
substituted by one or more substituents independently selected
from: (1) halo; (2) oxo; (3) optionally substituted alkyl; (4)
--(CH.sub.2).sub.m-optionally substituted heterocyclyl; (5)
--(CH.sub.2).sub.p-optionally substituted cycloalkyl; (6)
--(CH.sub.2).sub.q-optionally substituted heteroaryl; (7)
--S(O).sub.nR.sup.9; (8) --(CH.sub.2).sub.r--C(O)R.sup.10; (9)
optionally substituted alkenyl; (10) optionally substituted
alkynyl; (11) --OR.sup.8; wherein n is 1 or 2; m, p, q and r are
independently chosen from 0, 1, 2, 3, 4, 5, 6; R.sup.8, R.sup.9 and
R.sup.10 are independently selected from hydrogen, alkyl,
heterocyclyl, each of which except for hydrogen, is optionally
substituted with one or more substituents independently selected
from alkyl, oxo, heterocyclyl; wherein "optionally substituted
alkyl", "optionally substituted heterocyclyl", "optionally
substituted cycloalkyl", "optionally substituted heteroaryl",
"optionally substituted alkenyl" and "optionally substituted
alkynyl" in R.sup.1 above can be unsubstituted or independently
substituted with one or more substituents independently chosen from
hydroxyl, mercapto, halo, C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6
alkenyl, C.sub.2-C.sub.6 alkynyl, --OC.sub.1-C.sub.6 alkyl,
--NH.sub.2, --N(C.sub.1-C.sub.6 alkyl).sub.2, --NH(C.sub.1-C.sub.6
alkyl), cyano, nitro, oxo, --S(O).sub.2--C.sub.1-C.sub.6 alkyl,
--S(O)--C.sub.1-C.sub.6 alkyl, --S(O).sub.2--C.sub.1-C.sub.6
haloalkyl, --C(O)--OH, --C.sub.1-C.sub.6 alkyl-OH,
--C.sub.1-C.sub.6 alkyl-SH, heterocyclyl, or a pharmaceutical
acceptable salt thereof.
4. The compound of formula (I) according to claim 3, wherein
R.sup.1 is aryl or heteroaryl, each of which is optionally
substituted with one or more substituents independently selected
from: (1) halo; (2) oxo; (3) alkyl optionally substituted with one
or more substitutents independently selected from hydroxyl,
mercapto, halo, --OC.sub.1-C.sub.6 alkyl, --NH.sub.2,
--N(C.sub.1-C.sub.6 alkyl).sub.2, --NH(C.sub.1-C.sub.6 alkyl),
cyano, nitro, --S(O).sub.2--C.sub.1-C.sub.6 alkyl,
--S(O)--C.sub.1-C.sub.6 alkyl, --C(O)--OH; (4)
--(CH.sub.2).sub.m-heterocyclyl optionally substituted with one or
more substitutents independently selected from C.sub.1-C.sub.6
alkyl, --C.sub.1-C.sub.6 alkyl-OH, --C.sub.1-C.sub.6 alkyl-SH and
oxo, wherein m is 0, 1, 2, 3, 4, 5 or 6; (5)
--(CH.sub.2).sub.p-unsubstituted cycloalkyl, wherein p is 0, 1, 2,
3, 4, 5 or 6; (6) --(CH.sub.2).sub.q-heteroaryl optionally
substituted with one or more substituents independently selected
from C.sub.1-C.sub.6 alkyl, wherein q is 0, 1, 2, 3, 4, 5 or 6; (7)
--S(O).sub.nR.sup.9, wherein R.sup.9 is C.sub.1-C.sub.6 alkyl, and
n is 1 or 2; (8) --(CH.sub.2).sub.r--C(O)R.sup.10, wherein R.sup.10
is heterocyclyl optionally substituted with one or more
substitutents independently selected from C.sub.1-C.sub.6 alkyl and
oxo, wherein r is 0, 1, 2, 3, 4, 5 or 6; (9) unsubstituted
C.sub.2-C.sub.6 alkenyl; (10) unsubstituted C.sub.2-C.sub.6
alkynyl; (11) --OR.sup.8, wherein R.sup.8 is selected from
hydrogen, alkyl optionally substituted with one or more
substituents independently selected from heterocyclyl, or a
pharmaceutical acceptable salt thereof.
5. The compound of formula (I) according to claim 4, wherein
R.sup.1 is a radical of the ring or ring system chosen from
##STR00287## each of which is optionally substituted as defined in
claim 4, or a pharmaceutical acceptable salt thereof.
6. The compound of formula (I) according to claim 4, wherein
R.sup.1 is chosen from ##STR00288## each of which is optionally
substituted as defined in claim 4, or a pharmaceutical acceptable
salt thereof.
7. The compound of formula (I) according to claim 1, wherein
R.sup.8 is hydrogen, or C.sub.1-C.sub.6 alkyl optionally
substituted with heterocyclyl, or a pharmaceutical acceptable salt
thereof.
8. The compound of formula (I) according to claim 1, wherein
R.sup.10 is heterocyclyl optionally substituted with one or more
substituents independently selected from C.sub.1-C.sub.6 alkyl and
oxo, or a pharmaceutical acceptable salt thereof.
9. The compound of formula (I) according to claim 1, wherein
R.sup.1 is aryl optionally substituted by one or more substitutents
independently selected from: (1) halo; (2) alkyl optionally
substituted with --C(O)--OH; (3) --(CH.sub.2).sub.m-heterocyclyl
optionally substituted with one or more substitutents independently
selected from C.sub.1-C.sub.6 alkyl, --C.sub.1-C.sub.6 alkyl-OH,
--C.sub.1-C.sub.6 alkyl-SH and oxo, wherein m is 0, 1, 2, 3, 4, 5
or 6; (4) --(CH.sub.2).sub.q-heteroaryl optionally substituted with
one or more substituents independently selected from
C.sub.1-C.sub.6 alkyl, wherein q is 0; (5)
--(CH.sub.2).sub.r--C(O)R.sup.10, wherein R.sup.10 is heterocyclyl
optionally substituted with one or more substitutents independently
selected from C.sub.1-C.sub.6 alkyl and oxo, wherein r is 0; (6)
unsubstituted C.sub.2-C.sub.6 alkenyl; (7) unsubstituted
C.sub.2-C.sub.6 alkynyl; (8) --OR.sup.8, wherein R.sup.8 is
selected from hydrogen, alkyl optionally substituted with one or
more substituents independently selected from heterocyclyl, or a
pharmaceutical acceptable salt thereof.
10. The compound of formula (I) according to claim 9, wherein
R.sup.1 is phenyl substituted by piperazinyl, which piperizinyl is
optionally substituted by one or more C.sub.1-C.sub.6 alkyl,
preferably, R.sup.1 is phenyl substituted by piperazinyl, which is
optionally substituted by one or more methyl or ethyl, or a
pharmaceutical acceptable salt thereof.
11. The compound of formula (I) according to claim 1, wherein
R.sup.1 is pyrazolyl, which is optionally substituted with one or
more substituents selected from: (1) alkyl optionally substituted
with one or more substitutents independently selected from
hydroxyl, mercapto, halo, --OC.sub.1-C.sub.6 alkyl, --NH.sub.2,
--N(C.sub.1-C.sub.6 alkyl).sub.2, --NH(C.sub.1-C.sub.6 alkyl),
--S(O).sub.2--C.sub.1-C.sub.6 alkyl, --S(O)--C.sub.1-C.sub.6 alkyl;
(2) --(CH.sub.2).sub.m-heterocyclyl optionally substituted with one
or more substitutents independently selected from C.sub.1-C.sub.6
alkyl, wherein m is 0, 1, 2, 3, 4, 5 or 6; (3)
--(CH.sub.2).sub.p-unsubstituted cycloalkyl, wherein p is 0, 1, 2,
3, 4, 5 or 6; (4) --(CH.sub.2).sub.q-heteroaryl optionally
substituted with one or more substituents independently selected
from C.sub.1-C.sub.6 alkyl, wherein q is 0, 1, 2, 3, 4, 5 or 6; (5)
--S(O).sub.nR.sup.9, wherein R.sup.9 is C.sub.1-C.sub.6 alkyl, and
n is 1 or 2; (6) --(CH.sub.2).sub.r--C(O)R.sup.10, wherein R.sup.10
is heterocyclyl optionally substituted with one or more
substitutents independently selected from C.sub.1-C.sub.6 alkyl and
oxo, wherein r is 0, 1, 2, 3, 4, 5 or 6, or a pharmaceutical
acceptable salt thereof.
12. The compound of formula (I) according to any one of claims
1-11, wherein R.sup.2 is chosen from C.sub.1-C.sub.6 alkyl,
C.sub.1-C.sub.6 alkoxy optionally substituted with hydroxyl, or
C.sub.3-C.sub.8 cycloalkyl, or a pharmaceutical acceptable salt
thereof.
13. The compound of formula (I) according to claim 12, wherein
R.sup.2 is methyl, ethyl, methoxy, ethoxy substituted with
hydroxyl, isopropoxy or cyclopropyl, or a pharmaceutical acceptable
salt thereof.
14. The compound of formula (I) according to any one of claims
1-11, wherein R.sup.3, R.sup.4 are independently chosen from
hydrogen, halogen, --CN, or unsubstituted C.sub.1-C.sub.6 alkyl,
R.sup.5 is C.sub.1-C.sub.6 alkyl, or R.sup.3 and R.sup.5 together
with the O atom to which R.sup.5 is attached and the bond
there-between form a 5- or 6-membered oxy-containing heterocyclic
ring, or a pharmaceutical acceptable salt thereof.
15. The compound of formula (I) according to any one of claims
1-11, wherein R.sup.4 is hydrogen, and R.sup.3 and R.sup.5 together
with the O atom to which R.sup.5 is attached and the bond
there-between form furan or dihydrofuran ring, or a pharmaceutical
acceptable salt thereof.
16. The compound of formula (I) according to claim 1, wherein said
compound is selected from Compounds 1-223 prepared in the Examples,
or a pharmaceutical acceptable salt thereof.
17. The compound of formula (I) according to any one of claims 1-16
and/or a pharmaceutical acceptable salt thereof as a
medicament.
18. A pharmaceutical composition comprising at least one compound
of formula (I) according to any one of claims 1-16 and/or at least
one pharmaceutically acceptable salt thereof and optionally at
least one pharmaceutically acceptable carrier.
19. A method for in vivo or in vitro inhibiting the activity of
FGFR comprising contacting FGFR with an effective amount of at
least one compound of formula (I) according to any one of claims
1-16 and/or at least one pharmaceutically acceptable salt
thereof.
20. A method for treating a disease responsive to inhibition of
FGFR comprising administering to a subject in need thereof an
effective amount to treat said disease of at least one compound of
formula (I) according to any one of claims 1-16 and/or at least one
pharmaceutically acceptable salt thereof.
21. The method according to claim 20, wherein the disease
responsive to inhibition of FGFR is cancer, for example, lung
cancer, stomach cancer, liver cancer, breast cancer, ovarian
cancer, endometrial carcinoma, or bladder carcinoma.
22. Use of at least one compound of formula (I) according to any
one of claims 1-16 and/or at least one pharmaceutically acceptable
salt thereof in the manufacture of a medicament for treating a
disease responsive to inhibition of FGFR.
23. The use according to claim 22, wherein the disease responsive
to inhibition of FGFR is cancer, for example, lung cancer, stomach
cancer, liver cancer, breast cancer, ovarian cancer, endometrial
carcinoma, or bladder carcinoma.
Description
FIELD OF THE INVENTION
[0001] The present invention relates to novel pyrimidine and
pyridine compounds, pharmaceutical compositions containing them, a
process for preparing them, and their use in therapy.
BACKGROUND OF THE INVENTION
[0002] Fibroblast growth factor (FGF) has been recognized as an
important mediator in many physiological processes. The fibroblast
growth factor receptor family of receptor tyrosine kinases consists
of four members (FGFR1, FGFR2, FGFR3, and FGFR4). Fibroblast growth
factors (FGF) and their receptors (FGFR) play important roles in
cell proliferation, cell differentiation, cell migration, cell
survival, protein synthesis, and angiogenesis. There are many
evidences directly linking FGF signaling to cancer. Dysregulation
of FGFR signaling has been implicated in a number of cancers,
including squamous non-small cell lung cancer (NSCLC), small cell
lung cancer (SCLC), gastric, liver, breast, ovarian, endometrial,
and bladder carcinomas, such as FGFR1 has been be found to be
amplified in 22% squamous NSCLC, FGFR2 amplifications have been
reported in up to 10% gastric cancers, and FGFR3 mutation have been
found in approximately 50-60% nonmuscle invasion and 17% of
high-grade bladder cancers, fueling significant interest in FGFRs
as targets for therapeutic intervention.
[0003] Accordingly, new compounds and methods for modulating FGFR
genes and treating proliferation disorders, including cancer, are
needed. The present invention, addresses these needs.
SUMMARY OF THE INVENTION
[0004] The present invention provides a compound of formula
(I):
##STR00002##
and/or its prodrug, enantiomers, diastereomers, tautomers, or their
mixtures in any ratio, or a pharmaceutically acceptable salt
thereof; wherein [0005] X is CH.sub.2, Y is selected from CH.sub.2,
O or S(O).sub.2; or X and Y together with the bond there-between
form --CH.dbd.CH-- or --C.ident.C--; [0006] G is N or CH; [0007]
R.sup.1 is aryl or heteroaryl, which is optionally substituted with
one or more substituents independently selected from halo,
--NR.sup.6R.sup.7, --OR.sup.8, --S(O).sub.nR.sup.9,
--(CH.sub.2).sub.r--C(O)R.sup.10, --CN, --C(O)NR.sup.6R.sup.7,
--NR.sup.6C(O)R.sup.10, --NR.sup.6S(O).sub.nR.sup.9,
--NR.sup.6S(O).sub.nNR.sup.11R.sup.12, --NR.sup.6C(O)OR.sup.8,
--NR.sup.6C(O)NR.sup.11R.sup.12, --NO.sub.2,
--S(O).sub.nNR.sup.6R.sup.7, oxo, optionally substituted alkyl,
--(CH.sub.2).sub.p-optionally substituted cycloalkyl,
--(CH.sub.2).sub.m-optionally substituted heterocyclyl,
--(CH.sub.2).sub.q-optionally substituted heteroaryl, optionally
substituted alkenyl, and optionally substituted alkynyl; [0008]
R.sup.2 is independently chosen from optionally substituted
C.sub.1-C.sub.6 alkyl, optionally substituted C.sub.1-C.sub.6
alkoxy, or optionally substituted C.sub.3-C.sub.8 cycloalkyl;
[0009] R.sup.3, R.sup.4 are independently chosen from hydrogen,
halogen, --CN, or optionally substituted C.sub.1-C.sub.6 alkyl,
[0010] R.sup.5 is C.sub.1-C.sub.6 alkyl, [0011] or R.sup.3 and
R.sup.5 together with the O atom to which R.sup.5 is attached and
the bond there-between form a 5- or 6-membered oxy-containing
heterocyclic ring; [0012] n is 1 or 2; [0013] m, p, q and r are
independently chosen from 0, 1, 2, 3, 4, 5, 6; [0014] R.sup.6,
R.sup.7, R.sup.8, R.sup.9, R.sup.10, R.sup.11 and R.sup.12 are
independently selected from hydrogen, alkyl, cycloalkyl, aryl,
heteroaryl, heterocyclyl, each of which except for hydrogen, is
optionally substituted with one or more substituents independently
selected from halo, hydroxyl, mercapto, oxo, alkyl, cycloalkyl,
heterocyclyl, optionally substituted amino, and optionally
substituted amide, [0015] wherein each optionally substituted group
above for which the substituent(s) is (are) not specifically
designated, can be unsubstituted or independently substituted with
one or more, such as one, two or three, substituents independently
chosen from C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl,
C.sub.2-C.sub.6 alkynyl, cycloalkyl, aryl, heterocyclyl,
heteroaryl, aryl-C.sub.1-C.sub.6 alkyl-, heteroaryl-C.sub.1-C.sub.6
alkyl-, C.sub.1-C.sub.6 haloalkyl-, --OC.sub.1-C.sub.6 alkyl,
--OC.sub.2-C.sub.6 alkenyl, --OC.sub.1-C.sub.6 alkylphenyl,
--C.sub.1-C.sub.6 alkyl-OH, --C.sub.1-C.sub.6 alkyl-SH,
--C.sub.1-C.sub.6 alkyl-O--C.sub.1-C.sub.6 alkyl,
--OC.sub.1-C.sub.6 haloalkyl, halo, --OH, mercapto, --NH.sub.2,
--C.sub.1-C.sub.6 alkyl-NH.sub.2, --N(C.sub.1-C.sub.6 alkyl).sub.2,
--NH(C.sub.1-C.sub.6 alkyl), --N(C.sub.1-C.sub.6
alkyl)(C.sub.1-C.sub.6 alkylphenyl), --NH(C.sub.1-C.sub.6
alkylphenyl), cyano, nitro, oxo, --C(O)--OH, --C(O)OC.sub.1-C.sub.6
alkyl, --CON(C.sub.1-C.sub.6 alkyl).sub.2, --CONH(C.sub.1-C.sub.6
alkyl), --CONH.sub.2, --NHC(O)(C.sub.1-C.sub.6 alkyl),
--NHC(O)(phenyl), --N(C.sub.1-C.sub.6 alkyl)C(O)(C.sub.1-C.sub.6
alkyl), --N(C.sub.1-C.sub.6 alkyl)C(O)(phenyl),
--C(O)C.sub.1-C.sub.6 alkyl, --C(O)C.sub.1-C.sub.6 alkylphenyl,
--C(O)C.sub.1-C.sub.6 haloalkyl, --OC(O)C.sub.1-C.sub.6 alkyl,
--S(O).sub.2--C.sub.1-C.sub.6 alkyl, --S(O)--C.sub.1-C.sub.6 alkyl,
--S(O).sub.2-phenyl, --S(O).sub.2--C.sub.1-C.sub.6 haloalkyl,
--S(O).sub.2NH.sub.2, --S(O).sub.2NH(C.sub.1-C.sub.6 alkyl),
--S(O).sub.2NH(phenyl), --NHS(O).sub.2(C.sub.1-C.sub.6 alkyl),
--NHS(O).sub.2(phenyl), and --NHS(O).sub.2(C.sub.1-C.sub.6
haloalkyl), in which each of phenyl, aryl, heterocyclyl, and
heteroaryl is optionally substituted by one or more substituents
chosen from halo, cycloalkyl, heterocyclyl, C.sub.1-C.sub.4 alkyl,
C.sub.1-C.sub.6 haloalkyl-, --OC.sub.1-C.sub.6 alkyl,
C.sub.1-C.sub.6 alkyl-OH, --C.sub.1-C.sub.6
alkyl-O--C.sub.1-C.sub.6 alkyl, --OC.sub.1-C.sub.6 haloalkyl,
cyano, nitro, --NH.sub.2, --C(O)--OH, --C(O)OC.sub.1-C.sub.6 alkyl,
--CON(C.sub.1-C.sub.6 alkyl).sub.2, --CONH(C.sub.1-C.sub.6 alkyl),
--CONH.sub.2, --NHC(O)(C.sub.1-C.sub.6 alkyl), --NH(C.sub.1-C.sub.6
alkyl)C(O)(C.sub.1-C.sub.6 alkyl), --SO.sub.2(C.sub.1-C.sub.6
alkyl), --SO.sub.2(phenyl), --SO.sub.2(C.sub.1-C.sub.6 haloalkyl),
--SO.sub.2NH.sub.2, --SO.sub.2NH(C.sub.1-C.sub.6 alkyl),
--SO.sub.2NH(phenyl), --NHSO.sub.2(C.sub.1-C.sub.6 alkyl),
--NHSO.sub.2(phenyl), and --NHSO.sub.2(C.sub.1-C.sub.6
haloalkyl).
[0016] Also provided is a pharmaceutical composition, comprising at
least one compound of formula (I) and/or at least one
pharmaceutically acceptable salt thereof described herein and
optionally at least one pharmaceutically acceptable carrier.
[0017] Also provided is a method of in vive or in vitro inhibiting
the activity of FGFR comprising contacting FGFR with an effective
amount of at least one compound of formula (I) and/or at least one
pharmaceutically acceptable salt thereof described herein.
[0018] Also provided is a method of treating a disease responsive
to inhibition of FGFR comprising administering to a subject in need
thereof an effective amount to treat said disease of at least one
compound of formula (I) and/or at least one pharmaceutically
acceptable salt thereof described herein.
[0019] Also provided is use of at least one compound of formula (I)
and/or at least one pharmaceutically acceptable salt thereof
described herein for treating a disease responsive to inhibition of
FGFR.
[0020] Also provided is use of at least one compound of formula (I)
and/or at least one pharmaceutically acceptable salt thereof
described herein in the manufacture of a medicament for treating a
disease responsive to inhibition of FGFR.
DETAILED DESCRIPTION OF THE INVENTION
Definitions
[0021] As used in the present application, the following words,
phrases and symbols are generally intended to have the meanings as
set forth below, except to the extent that the context in which
they are used indicates otherwise.
[0022] A dash ("-") that is not between two letters or symbols is
used to indicate a point of attachment for a substituent. For
example, --C(O)NH.sub.2 is attached through the carbon atom.
[0023] The term "alkyl" as used herein refers to a straight or
branched saturated hydrocarbon radical, containing 1-18, preferably
1-12, more preferably 1-6, further preferably 1-4, especially 1-3
carbon atoms. Examples of alkyl groups include, but are not limited
to, methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl
and t-butyl.
[0024] The term "alkoxy" as used herein refers to the group
--O-alkyl, wherein the alkyl is as defined above. Examples of
alkoxy groups include, but are not limited to, methoxy, ethoxy,
n-propyloxy, i-propyloxy, n-butyloxy, i-butyloxy, t-butyloxy,
pentyloxy, hexyloxy, including their isomers.
[0025] The term "alkenyl" as used herein refers to a straight or
branched hydrocarbon radical, containing one or more C.dbd.C double
bonds and 2-10, preferably 2-6, more preferably 2-4 carbon atoms.
Examples of alkenyl groups include, but are not limited to, vinyl,
2-propenyl, and 2-butenyl.
[0026] The term "alkynyl" as used herein refers to a straight or
branched hydrocarbon radical, containing one or more C.ident.C
triple bonds and 2-10, preferably 2-6, more preferably 2-4 carbon
atoms. Examples of alkynyl groups include, but are not limited to,
ethynyl, 2-propynyl, and 2-butynyl.
[0027] The term "cycloalkyl" as used herein refers to saturated and
partially unsaturated cyclic hydrocarbon radical having 3 to 12,
preferably 3 to 8, more preferably 3 to 6 carbon atoms. Examples of
cycloalkyl groups include, but are not limited to, cyclopropyl,
cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl,
cycloheptyl, and cyclooctyl. The ring of the cycloalkyl group may
be saturated or has one or more, for example, one or two double
bonds (i.e. partially unsaturated), but not fully conjugated, and
not aryl as defined herein.
[0028] The term "aryl" as used herein refers to 5- and 6-membered
monocyclic carbocyclic aromatic hydrocarbon radical and 8- to
12-membered bicyclic carbocyclic hydrocarbon radical wherein at
least one ring is aromatic, for example, phenyl, naphthalenyl,
1,2,3,4-tetrahydronaphthalenyl, indenyl, indanyl, azulenyl.
[0029] The term "halo" as used herein includes fluoro, chloro,
bromo, and iodo, and the term "halogen" as used herein includes
fluorine, chlorine, bromine, and iodine.
[0030] The term "heteroaryl" as used herein refers to [0031] 5- to
6-membered monocyclic aromatic hydrocarbon radical containing one
or more, for example, from 1 to 4, or, in some embodiments, from 1
to 3, in some embodiments, 1 or 2 heteroatoms independently
selected from N, O, and S, with the remaining ring atoms being
carbon; and [0032] 8- to 12-membered bicyclic hydrocarbon radical
containing one or more, for example, from 1 to 4, or, in some
embodiments, from 1 to 3, in some embodiments, 1 or 2 heteroatoms
independently selected from N, O, and S, with the remaining ring
atoms being carbon, wherein at least one of the rings is aromatic.
For example, the bicyclic heteroaryl includes a 5- to 6-membered
heterocyclic aromatic ring fused to a 5- to 6-membered cycloalkyl
ring. [0033] When the total number of S and O atoms in the
heteroaryl group exceeds 1, those heteroatoms are not adjacent to
one another. In some embodiments, the total number of S and O atoms
in the heteroaryl group is not more than 2. In some embodiments,
the total number of S and O atoms in the heteroaryl group is not
more than 1. [0034] The heteroaryl group also includes those
wherein the N heteroatom occurs as N-oxide, such as pyridinyl
N-oxides. [0035] Examples of the heteroaryl group include, but are
not limited to, pyridyl, pyridyl N-oxide, such as pyrid-2-yl,
pyrid-3-yl, pyrid-4-yl or N-oxide thereof; pyrazinyl, such as
pyrazin-2-yl, pyrazin-3-yl; pyrimidinyl, such as pyrimidin-2-yl,
pyrimidin-4-yl; pyrazolyl, such as pyrazol-1-yl, pyrazol-3-yl,
pyrazol-4-yl, pyrazol-5-yl; imidazolyl, imidazol-2-yl,
imidazolin-4-yl; oxazolyl; isoxazolyl; thiazolyl; isothiazolyl;
thiadiazolyl; tetrazolyl; triazolyl; thienyl; furyl; pyranyl;
pyrrolyl; pyridazinyl; benzodioxolyl, such as
benzo[d][1,3]dioxolyl; benzoxazolyl, such as benzo[d]oxazolyl;
imidazopyridinyl, such as imidazo[1,2-a]pyridinyl;
triazolopyridinyl, such as [1,2,4]triazolo[4,3-a]pyridinyl and
[1,2,4]triazolo[1,5-a]pyridinyl; indazolyl, 2H-indazolyl;
pyrazolopyrimidinyl, such as pyrazolo[1,5-a]pyrimidinyl;
tetrazolopyridinyl, such as tetrazolo[1,5-a]pyridinyl;
benzothienyl; benzofuryl; benzoimidazolinyl; indolyl; indolinyl;
quinolinyl, isoquinolinyl, 1,2,3,4-tetrahydroquinolinyl and
5,6,7,8-tetrahydroisoquinolinyl.
[0036] The term "heterocyclyl" as used herein refers to 3- to
14-membered, preferably 4- to 12-membered, monocyclic, bicyclic or
tricyclic saturated or partially unsaturated hydrocarbon radical
containing at least 2 carbon atoms and 1, 2 or 3 heteroatoms
independently selected from oxygen, sulfur, and nitrogen. More
preferably, "heterocyclyl" refers to 4- to 8-membered, especially
4-, 5- or 6-membered monocyclic heterocyclyl group containing 1 or
2 heteroatoms independently selected from N, O, and S.
"Heterocyclyl" also refers to an aliphatic spirocyclic ring
containing one or more heteroatoms independently selected from N,
O, and S. The rings may be saturated or have one or more double
bonds (i.e. partially unsaturated). The point of the attachment may
be carbon or heteroatom in the heterocyclyl group. However, any of
the rings in the heterocylyl group is not aromatic so that the
heterocylyl group is not a heteroaryl as defined herein. The
heterocyclyl group also includes those wherein the N or S
heteroatom occurs as oxide thereof. Examples of heterocyclyl
include, but are not limited to, oxetanyl, such as oxetan-2-yl or
oxetan-3-yl; azetidinyl, such as azetidin-2-yl or azetidin-3-yl;
pyrrolidinyl, such as pyrrolidin-1-yl, pyrrolidin-2-yl,
pyrrolidin-3-yl; tetrahydrofuranyl, such as tetrahydrofuran-2-yl,
tetrahydrofuran-3-yl; tetrahydropyranyl, such as
tetrahydropyran-2-yl, tetrahydropyran-3-yl, tetrahydropyran-4-yl;
morpholinyl, morpholinyl-N-oxide, such as morpholin-2-yl,
morpholin-3-yl, morpholin-4-yl (morpholino) (numbered wherein the
oxygen is assigned priority 1); thiomorpholinyl,
1-oxo-thiomorpholin-4-yl, 1,1-dioxo-thiomorpholin-4-yl;
imidazolinyl, such as imidazolidin-2-yl, imidazolidin-4-yl;
pyrazolidinyl, such as pyrazolidin-2-yl, pyrazolidin-3-yl;
piperidinyl or piperidinyl N-oxide, such as piperidin-1-yl and
piperidin-2-yl, piperidin-3-yl, piperidin-4-yl or N-oxide thereof;
and piperazinyl, such as piperazin-1-yl, piperazin-2-yl,
piperazin-3-yl.
[0037] The term "5- or 6-membered oxy-containing heterocyclic ring"
as used herein refers to a 5- or 6-membered unsaturated ring
optionally containing one or two heteroatoms independently selected
from N, O or S, in addition to the oxy heteroatom linking the
phenyl ring and the group R.sup.5 in formula (I), with the
remaining ring atoms being carbon. "5- or 6-membered oxy-containing
heterocyclic ring" is preferably furan, dihydrofuran, pyran or
dihydropyran.
[0038] "Hydroxyl" refers to the --OH radical.
[0039] "Nitro" refers to the --NO.sub.2 radical.
[0040] "Mercapto" refers to the --SH radical.
[0041] "Cyano" refers to the --CN radical.
[0042] "Oxo" refers to the .dbd.O radical.
[0043] "Carboxyl" refers to the --C(O)--OH radical.
[0044] The term "optional" or "optionally" means that the
subsequently described event or circumstance may or may not occur,
and that the description includes instances where the event or
circumstance occurs and instances in which it does not. For
example, "optionally substituted alkyl" encompasses both
"unsubstituted alkyl" and "substituted alkyl" as defined herein. It
will be understood by those skilled in the art, with respect to any
group containing one or more substituents, that such groups are not
intended to introduce any substitution or substitution patterns
that are sterically impractical, chemically incorrect,
synthetically non-feasible and/or inherently unstable.
[0045] The term "substituted", as used herein, means that one or
more hydrogens on the designated atom or group are replaced with
one or more selections from the indicated group of substituents,
provided that the designated atom's normal valence is not exceeded.
When a substituent is oxo (i.e., .dbd.O), then 2 hydrogens on a
single atom are replaced. Combinations of substituents and/or
variables are permissible only if such combinations result in a
chemically correct and stable compound. A chemically correct and
stable compound is meant to imply a compound that is sufficiently
robust to survive isolation from a reaction mixture, and subsequent
formulation as an agent having at least practical utility. Unless
otherwise specified, substituents are named into the core
structure. For example, it is to be understood that when
(cycloalkyl)alkyl is listed as a possible substituent, the point of
attachment of this substituent to the core structure is in the
alkyl portion.
[0046] The term "substituted with one or more substitutents" as
used herein means that one or more hydrogens on the designated atom
or group are independently replaced with one or more selections
from the indicated group of substituents. In some embodiments,
"substituted with one or more substitutents" means that the
designated atom or group is substituted with two substitutents
independently selected from the indicated group of substituents. In
some embodiments, "substituted with one or more substitutents"
means that the designated atom or group is substituted with three
substitutents independently selected from the indicated group of
substituents. In some embodiments, "substituted with one or more
substitutents" means that the designated atom or group is
substituted with four substitutents independently selected from the
indicated group of substituents.
[0047] It will be appreciated by those skilled in the art that some
of the compounds of formula (I) may contain one or more chiral
centers and therefore exist in two or more stereoisomeric forms.
The racemates of these isomers, the individual isomers and mixtures
enriched in one enantiomer, as well as diastereomers when there are
two chiral centers, and mixtures partially enriched with specific
diastereomers are within the scope of the present invention. It
will be further appreciated by those skilled in the art that the
present invention includes all the individual stereoisomers (e.g.
enantiomers), racemic mixtures or partially resolved mixtures of
the compounds of formula (I) and, where appropriate, the individual
tautomeric forms thereof.
[0048] The racemates can be used as such or can be resolved into
their individual isomers. The resolution can afford
stereochemically pure compounds or mixtures enriched in one or more
isomers. Methods for separation of isomers are well known (cf
Allinger N. L. and Eliel E. L. in "Topics in Stereochemistry", Vol.
6, Wiley Interscience, 1971) and include physical methods such as
chromatography using a chiral adsorbent. Individual isomers can be
prepared in chiral form from chiral precursors. Alternatively
individual isomers can be separated chemically from a mixture by
forming diastereomeric salts with a chiral acid, such as the
individual enantiomers of 10-camphorsulfonic acid, camphoric acid,
alpha-bromocamphoric acid, tartaric acid, diacetyltartaric acid,
malic acid, pyrrolidone-5-carboxylic acid, and the like,
fractionally crystallizing the salts, and then freeing one or both
of the resolved bases, optionally repeating the process, so as
obtain either or both substantially free of the other; i.e., in a
form having an optical purity of >95%. Alternatively the
racemates can be covalently linked to a chiral compound (auxiliary)
to produce diastereomers which can be separated by chromatography
or by fractional crystallization after which time the chiral
auxiliary is chemically removed to afford the pure enantiomers.
[0049] "Pharmaceutically acceptable salt" include, but are not
limited to, acid addition salts formed by the compound of formula
(I) with an inorganic acid, such as hydrochloride, hydrobromide,
carbonate, bicarbonate, phosphate, sulfate, sulfite, nitrate and
the like; as well as with an organic acid, such as formate,
acetate, malate, maleate, fumarate, tartrate, succinate, citrate,
lactate, methanesulfonate, p-toluenesulfonate,
2-hydroxyethylsulfonate, benzoate, salicylate, stearate, and salts
with alkane-dicarboxylic acid of formula
HOOC--(CH.sub.2).sub.n--COOH where n is 0-4, and the like. Also,
"pharmaceutically acceptable salt" includes base addition salts
formed by the compound of formula (I) carring an acidic moiety with
pharmaceutically acceptable cations, for example, sodium,
potassium, calcium, aluminum, lithium, and ammonium.
[0050] In addition, if a compound described herein is obtained as
an acid addition salt, the free base can be obtained by basifying a
solution of the acid addition salt. Conversely, if the product is a
free base, an acid addition salt, particularly a pharmaceutically
acceptable acid addition salt, may be produced by dissolving the
free base in a suitable solvent and treating the solution with an
acid, in accordance with conventional procedures for preparing acid
addition salts from base compounds. Those skilled in the art will
recognize various synthetic methodologies that may be used without
undue experimentation to prepare non-toxic pharmaceutically
acceptable acid addition salts.
[0051] The term "solvates" means solvent addition forms that
contain either stoichiometric or non stoichiometric amounts of
solvent. Some compounds have a tendency to trap a fixed molar ratio
of solvent molecules in the solid state, thus forming a solvate. If
the solvent is water the solvate formed is a hydrate, when the
solvent is alcohol, the solvate formed is an alcoholate. Hydrates
are formed by the combination of one or more molecules of water
with one of the substances in which the water retains its molecular
state as H.sub.2O, such combination being able to form one or more
hydrates, for example, hemihydrates, monohydrate and dihydrate.
[0052] A "prodrug" is a compound which is converted to a
therapeutically active compound after administration, and the term
should be interpreted as broadly herein as is generally understood
in the art. While not intending to limit the scope of the
invention, conversion may occur by hydrolysis of an ester group or
some other biologically labile group. Generally, but not
necessarily, a prodrug is inactive or less active than the
therapeutically active compound to which it is converted. For
example, an ester may be derived from a carboxylic acid of C1 (i.e.
the terminal carboxylic acid of a natural prostaglandin), or an
ester may be derived from a carboxylic acid functional group on
another part of the molecule, such as on a phenyl ring. While not
intending to be limiting, an ester may be an alkyl ester, an aryl
ester, or a heteroaryl ester.
[0053] As used herein, the terms "group", "radical" and "moiety"
are synonymous and are intended to indicate functional groups or
fragments of molecules attachable to other fragments of
molecules.
[0054] The terms "treating", "treat" or "treatment" of a disease or
disorder refers to administering one or more pharmaceutical
substances, especially at least one compound of formula (I) and/or
at least one pharmaceutically acceptable salt thereof described
herein to a subject that has the disease or disorder, or has a
symptom of a disease or disorder, or has a predisposition toward a
disease or disorder, with the purpose to cure, heal, alleviate,
relieve, alter, remedy, ameliorate, improve, or affect a disease or
disorder, the symptoms of the disease or disorder, or the
predisposition toward the disease or disorder. In some embodiments,
the disease or disorder is cancer.
[0055] The terms "treating", "contacting" and "reacting" when
referring to a chemical reaction mean adding or mixing two or more
reagents under appropriate conditions to produce the indicated
and/or the desired product. It should be appreciated that the
reaction which produces the indicated and/or the desired product
may not necessarily result directly from the combination of two
reagents which were initially added, i.e., there may be one or more
intermediates which are produced in the mixture which ultimately
lead to the formation of the indicated and/or the desired
product.
[0056] The term "effective amount" as used herein refers to an
amount of at least one compound of formula (I) and/or at least one
pharmaceutically acceptable salt thereof described herein effective
to "treat", as defined above, a disease or disorder in a subject
responsive to the inhibition of FGFR. The effective amount may
cause any of the changes observable or measurable in a subject as
described in the definition of "treating" "treat" or "treatment"
above. For example, in the case of cancer, the effective amount can
reduce the number of cancer or tumor cells; reduce the tumor size;
inhibit or stop tumor cell infiltration into peripheral organs
including, for example, the spread of tumor into soft tissue and
bone; inhibit and stop tumor metastasis; inhibit and stop tumor
growth; relieve to some extent one or more of the symptoms
associated with the cancer, reduce morbidity and mortality; improve
quality of life; or a combination of such effects. An effective
amount may be an amount sufficient to decrease the symptoms of a
disease responsive to inhibition of FGFR. The term "effective
amount" may also refer to an amount of at least one compound of
formula (I) and/or at least one pharmaceutically acceptable salt
described herein effective to inhibit the activity of FGFR in a
subject responsive to the inhibition of FGFR.
[0057] The term "inhibition" or "inhibiting" indicates a decrease
in the baseline activity of a biological activity or process.
"Inhibition of FGFR" refers to a decrease in the activity of FGFR
as a direct or indirect response to the presence of at least one
compound of formula (I) and/or at least one pharmaceutically
acceptable salt thereof described herein, relative to the activity
of FGFR in the absence of the at least one compound of formula (I)
and/or the at least one pharmaceutically acceptable salt thereof.
The decrease in activity may be due to the direct interaction of
the at least one compound of formula (I) and/or at least one
pharmaceutically acceptable salt thereof described herein with the
FGFR, or due to the interaction of the at least one compound of
formula (I) and/or at least one pharmaceutically acceptable salt
thereof described herein, with one or more other factors that in
turn affect the FGFR activity. For example, the presence of at
least one compound of formula (I) and/or at least one
pharmaceutically acceptable salt thereof described herein, may
decrease the FGFR activity by directly binding to the FGFR, by
causing (directly or indirectly) another factor to decrease the
FGFR activity, or by (directly or indirectly) decreasing the amount
of FGFR present in the cell or organism.
[0058] The term "subject" as used herein means mammals and
non-mammals. Mammals means any member of the mammalia class
including, but not limited to, humans; non-human primates such as
chimpanzees and other apes and monkey species; farm animals such as
cattle, horses, sheep, goats, and swine; domestic animals such as
rabbits, dogs, and cats; laboratory animals including rodents, such
as rats, mice, and guinea pigs; and the like. Examples of
non-mammals include, but are not limited to, birds, and the like.
The term "subject" does not denote a particular age or sex.
[0059] The term "pharmaceutically acceptable" means that the
substance following this term is useful in preparing a
pharmaceutical composition and is generally safe, non-toxic, and
neither biologically nor otherwise undesirable, especially for
human pharmaceutical use.
[0060] The term "about" is used herein to mean approximately, in
the region of, roughly, or around. When the term "about" is used in
conjunction with a numerical range, it modifies that range by
extending the boundaries above and below the numerical values set
forth. In general, the term "about" is used herein to modify a
numerical value above and below the stated value by a variance of
20%.
[0061] Technical and scientific terms used herein and not
specifically defined have the meaning commonly understood by those
skilled in the art to which the present invention pertains.
Embodiments of the Invention
[0062] In one aspect, the present invention provides a compound of
formula (I):
##STR00003##
and/or prodrug, its enantiomers, diastereomers, tautomers, or their
mixtures in any ratio, or a pharmaceutically acceptable salt
thereof; wherein [0063] X is CH.sub.2, Y is selected from CH.sub.2,
O or S(O).sub.2; or X and Y together with the bond there-between
form --CH.dbd.CH-- or --C.ident.C--; [0064] G is N or CH; [0065]
R.sup.1 is aryl or heteroaryl, each of which is optionally
substituted with one or more substituents independently selected
from halo, --NR.sup.6R.sup.7, --OR.sup.8, --S(O).sub.nR.sup.9,
--(CH.sub.2).sub.r--C(O)R.sup.10, --CN, --C(O)NR.sup.6R.sup.7,
--NR.sup.6C(O)R.sup.10, --NR.sup.6S(O).sub.nR.sup.9,
--NR.sup.6S(O).sub.nNR.sup.11R.sup.12, --NR.sup.6C(O)OR.sup.8,
--NR.sup.6C(O)NR.sup.11R.sup.12, --NO.sub.2,
--S(O).sub.nNR.sup.6R.sup.7, oxo, optionally substituted alkyl,
--(CH.sub.2).sub.p-optionally substituted cycloalkyl,
--(CH.sub.2).sub.m-optionally substituted heterocyclyl,
--(CH.sub.2).sub.q-optionally substituted heteroaryl, optionally
substituted alkenyl, and optionally substituted alkynyl; [0066]
R.sup.2 is independently chosen from optionally substituted
C.sub.1-C.sub.6 alkyl, optionally substituted C.sub.1-C.sub.6
alkoxy, or optionally substituted C.sub.3-C.sub.8 cycloalkyl;
[0067] R.sup.3, R.sup.4 are independently chosen from hydrogen,
halogen, --CN, or optionally substituted C.sub.1-C.sub.6 alkyl,
[0068] R.sub.5 is C.sub.1-C.sub.6 alkyl, [0069] or R.sup.3 and
R.sup.5 together with the O atom to which R.sup.5 is attached and
the bond there-between form a 5- or 6-membered oxy-containing
heterocyclic ring; [0070] n is 1 or 2; [0071] m, p, q and r are
independently chosen from 0, 1, 2, 3, 4, 5, 6; [0072] R.sup.6,
R.sup.7, R.sup.8, R.sup.9, R.sup.10, R.sup.11 and R.sup.12 are
independently selected from hydrogen, alkyl, cycloalkyl, aryl,
heteroaryl, heterocyclyl, each of which except for hydrogen, is
optionally substituted with one or more substituents independently
selected from halo, hydroxyl, mercapto, oxo, alkyl, cycloalkyl,
heterocyclyl, optionally substituted amino, and optionally
substituted amide, [0073] wherein each optionally substituted group
above for which the substituent(s) is (are) not specifically
designated, can be unsubstituted or independently substituted with
one or more, such as one, two or three, substituents independently
chosen from C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl,
C.sub.2-C.sub.6 alkynyl, cycloalkyl, aryl, heterocyclyl,
heteroaryl, aryl-C.sub.1-C.sub.6 alkyl-,
heteroaryl-C.sub.1-C.sub.6alkyl-, C.sub.1-C.sub.6 haloalkyl-,
--OC.sub.1-C.sub.6 alkyl, --OC.sub.2-C.sub.6 alkenyl,
--OC.sub.1-C.sub.6 alkylphenyl, --C.sub.1-C.sub.6 alkyl-OH,
--C.sub.1-C.sub.6 alkyl-SH, --C.sub.1-C.sub.6
alkyl-O--C.sub.1-C.sub.6 alkyl, --OC.sub.1-C.sub.6 haloalkyl, halo,
--OH, mercapto, --NH.sub.2, --C.sub.1-C.sub.6 alkyl-NH.sub.2,
--N(C.sub.1-C.sub.6 alkyl).sub.2, --NH(C.sub.1-C.sub.6 alkyl),
--N(C.sub.1-C.sub.6 alkyl)(C.sub.1-C.sub.6 alkylphenyl),
--NH(C.sub.1-C.sub.6 alkylphenyl), cyano, nitro, oxo, --C(O)--OH,
--C(O)OC.sub.1-C.sub.6 alkyl, --CON(C.sub.1-C.sub.6 alkyl).sub.2,
--CONH(C.sub.1-C.sub.6 alkyl), --CONH.sub.2,
--NHC(O)(C.sub.1-C.sub.6 alkyl), --NHC(O)(phenyl),
--N(C.sub.1-C.sub.6 alkyl)C(O)(C.sub.1-C.sub.6 alkyl),
--N(C.sub.1-C.sub.6 alkyl)C(O)(phenyl), --C(O)C.sub.1-C.sub.6
alkyl, --C(O)C.sub.1-C.sub.6 alkylphenyl, --C(O)C.sub.1-C.sub.6
haloalkyl, --OC(O)C.sub.1-C.sub.6 alkyl,
--S(O).sub.2--C.sub.1-C.sub.6 alkyl, --S(O)--C.sub.1-C.sub.6 alkyl,
--S(O).sub.2-phenyl, --S(O).sub.2--C.sub.1-C.sub.6 haloalkyl,
--S(O).sub.2NH.sub.2, --S(O).sub.2NH(C.sub.1-C.sub.6 alkyl),
--S(O).sub.2NH(phenyl), --NHS(O).sub.2(C.sub.1-C.sub.6 alkyl),
--NHS(O).sub.2(phenyl), and --NHS(O).sub.2(C.sub.1-C.sub.6
haloalkyl).
[0074] In a preferred embodiment of the compound of formula (I)
above, each optionally substituted group above can be unsubstituted
or independently substituted with one or more substituents
independently chosen from hydroxyl, mercapto, halo, C.sub.1-C.sub.6
alkyl, C.sub.2-C.sub.6 alkenyl, C.sub.2-C.sub.6 alkynyl,
--OC.sub.1-C.sub.6 alkyl, --NH.sub.2, --N(C.sub.1-C.sub.6
alkyl).sub.2, --NH(C.sub.1-C.sub.6 alkyl), cyano, nitro, oxo,
--S(O).sub.2--C.sub.1-C.sub.6 alkyl, --S(O)--C.sub.1-C.sub.6 alkyl,
--S(O).sub.2--C.sub.1-C.sub.6 haloalkyl, --C(O)--OH,
--C.sub.1-C.sub.6 alkyl-OH, --C.sub.1-C.sub.6 alkyl-SH,
heterocyclyl.
[0075] In any one of the preceding embodiments, R.sup.1 is aryl or
heteroaryl, each of which is optionally substituted by one or more
substituents independently selected from halo, oxo, optionally
substituted alkyl, --(CH.sub.2).sub.m-optionally substituted
heterocyclyl, --(CH.sub.2).sub.p-optionally substituted cycloalkyl,
--(CH.sub.2).sub.q-optionally substituted heteroaryl,
--S(O).sub.nR.sup.9, --(CH.sub.2).sub.r--C(O)R.sup.10, optionally
substituted alkenyl, optionally substituted alkynyl, --OR.sup.8,
wherein n is 1 or 2; m, p, q and r are independently chosen from 0,
1, 2, 3, 4, 5, 6; R.sup.8, R.sup.9 and R.sup.10 are independently
selected from hydrogen, alkyl, heterocyclyl, each of which except
for hydrogen, is optionally substituted with one or more
substituents independently selected from alkyl, oxo, heterocyclyl;
wherein "optionally substituted alkyl", "optionally substituted
heterocyclyl", "optionally substituted cycloalkyl", "optionally
substituted heteroaryl", "optionally substituted alkenyl" and
"optionally substituted alkynyl" in R.sup.1 above can be
unsubstituted or independently substituted with one or more
substituents independently chosen from hydroxyl, mercapto, halo,
C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl, C.sub.2-C.sub.6
alkynyl, --OC.sub.1-C.sub.6 alkyl, --NH.sub.2, --N(C.sub.1-C.sub.6
alkyl).sub.2, --NH(C.sub.1-C.sub.6 alkyl), cyano, nitro, oxo,
--S(O).sub.2--C.sub.1-C.sub.6 alkyl, --S(O)--C.sub.1-C.sub.6 alkyl,
--S(O)--C.sub.2-C.sub.6 haloalkyl, --C(O)--OH, --C.sub.1-C.sub.6
alkyl-OH, --C.sub.1-C.sub.6 alkyl-SH, heterocyclyl.
[0076] In any one of the preceding embodiments, R.sup.1 is aryl or
heteroaryl, each of which is optionally substituted with one or
more substituents independently selected from: (1) halo; (2) oxo;
(3) alkyl optionally substituted with one or more substitutents
independently selected from hydroxyl, mercapto, halo,
--OC.sub.1-C.sub.6 alkyl, --NH.sub.2, --N(C.sub.1-C.sub.6
alkyl).sub.2, --NH(C.sub.1-C.sub.6 alkyl), cyano, nitro,
--S(O).sub.2--C.sub.1-C.sub.6 alkyl, --S(O)--C.sub.1-C.sub.6 alkyl,
--C(O)--OH; (4) --(CH.sub.2).sub.m-heterocyclyl optionally
substituted with one or more substitutents independently selected
from C.sub.1-C.sub.6 alkyl, --C.sub.1-C.sub.6 alkyl-OH,
--C.sub.1-C.sub.6 alkyl-SH and oxo, wherein m is 0, 1, 2, 3, 4, 5
or 6; (5) --(CH.sub.2).sub.p-unsubstituted cycloalkyl, wherein p is
0, 1, 2, 3, 4, 5 or 6; (6) --(CH.sub.2).sub.q-heteroaryl optionally
substituted with one or more substituents independently selected
from C.sub.1-C.sub.6 alkyl, wherein q is 0, 1, 2, 3, 4, 5 or 6; (7)
--S(O).sub.nR.sup.9, wherein R.sup.9 is C.sub.1-C.sub.6 alkyl, and
n is 1 or 2; (8) --(CH.sub.2).sub.r--C(O)R.sup.10, wherein R.sup.10
is heterocyclyl optionally substituted with one or more
substitutents independently selected from C.sub.1-C.sub.6 alkyl and
oxo, wherein r is 0, 1, 2, 3, 4, 5 or 6; (9) unsubstituted
C.sub.2-C.sub.6 alkenyl; (10) unsubstituted C.sub.2-C.sub.6
alkynyl; (11) --OR.sup.8, wherein R.sup.8 is selected from
hydrogen, alkyl optionally substituted with one or more
substituents independently selected from heterocyclyl.
[0077] In any one of the preceding embodiments, R.sup.1 is a
radical of the ring or ring system chosen from
##STR00004##
each of which is optionally substituted as defined above.
[0078] In any one of the preceding embodiments, R.sup.1 is chosen
from
##STR00005##
each of which is optionally substituted as defined above.
[0079] In any one of the preceding embodiments, R.sup.8 is hydrogen
or C.sub.1-C.sub.6 alkyl optionally substituted with
heterocyclyl.
[0080] In any one of the preceding embodiments, R.sup.10 is
heterocyclyl optionally substituted with one or more substituents
independently selected from C.sub.1-C.sub.6 alkyl and oxo.
[0081] In an embodiment of formula (I) above, R.sup.1 is phenyl
optionally substituted by one or more substitutents independently
selected from: (1) halo; (2) alkyl optionally substituted with
--C(O)--OH; (3) --(CH.sub.2).sub.m-heterocyclyl optionally
substituted with one or more substitutents independently selected
from C.sub.1-C.sub.6 alkyl, --C.sub.1-C.sub.6 alkyl-OH,
--C.sub.1-C.sub.6 alkyl-SH and oxo, wherein m is 0, 1, 2, 3, 4, 5
or 6; (4) --(CH.sub.2).sub.q-heteroaryl optionally substituted with
one or more substituents independently selected from
C.sub.1-C.sub.6 alkyl, wherein q is 0; (5)
--(CH.sub.2).sub.r--C(O)R.sup.10, wherein R.sup.10 is heterocyclyl
optionally substituted with one or more substitutents independently
selected from C.sub.1-C.sub.6 alkyl and oxo, wherein r is 0; (6)
unsubstituted C.sub.2-C.sub.6 alkenyl; (7) unsubstituted
C.sub.2-C.sub.6 alkynyl; (8) --OR.sup.8, wherein R.sup.8 is
selected from hydrogen, alkyl optionally substituted with one or
more substituents independently selected from heterocyclyl. In a
specific embodiment, R.sup.1 is phenyl substituted by piperazinyl,
which piperizinyl is optionally substituted by one or more
C.sub.1-C.sub.6 alkyl. In a specific embodiment, R.sup.1 is phenyl
substituted by piperazinyl, which is optionally substituted by one
or more methyl or ethyl.
[0082] In an embodiment of formula (I) above, R.sup.1 is pyrazolyl,
which is optionally substituted with one or more substituents
selected from: (1) alkyl optionally substituted with one or more
substitutents independently selected from hydroxyl, mercapto, halo,
--OC.sub.1-C.sub.6 alkyl, --NH.sub.2, --N(C.sub.1-C.sub.6
alkyl).sub.2, --NH(C.sub.1-C.sub.6 alkyl),
--S(O).sub.2--C.sub.1-C.sub.6 alkyl, --S(O)--C.sub.1-C.sub.6 alkyl;
(2) --(CH.sub.2).sub.m-heterocyclyl optionally substituted with one
or more substitutents independently selected from C.sub.1-C.sub.6
alkyl, wherein m is 0, 1, 2, 3, 4, 5 or 6; (3)
--(CH.sub.2).sub.p-unsubstituted cycloalkyl, wherein p is 0, 1, 2,
3, 4, 5 or 6; (4) --(CH.sub.2).sub.q-heteroaryl optionally
substituted with one or more substituents independently selected
from C.sub.1-C.sub.6 alkyl, wherein q is 0, 1, 2, 3, 4, 5 or 6; (5)
--S(O).sub.nR.sup.9, wherein R.sup.9 is C.sub.1-C.sub.6 alkyl, and
n is 1 or 2; (6) --(CH.sub.2).sub.r--C(O)R.sup.10, wherein R.sup.10
is heterocyclyl optionally substituted with one or more
substitutents independently selected from C.sub.1-C.sub.6 alkyl and
oxo, wherein r is 0, 1, 2, 3, 4, 5 or 6.
[0083] In any one of the preceding embodiments, R.sup.2 is chosen
from C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 alkoxy optionally
substituted with hydroxyl, or C.sub.3-C.sub.8 cycloalkyl
(preferably C.sub.3-C.sub.6 cycloalkyl). In a specific embodiment,
R.sup.2 is methyl, ethyl, methoxy, ethoxy substituted with
hydroxyl, isopropoxy or cyclopropyl. In a specific embodiment,
R.sup.2 is methyl.
[0084] In any one of the preceding embodiments, R.sup.3, R.sup.4
are independently chosen from hydrogen, halogen, --CN, or
unsubstituted C.sub.1-C.sub.6 alkyl (preferably unsubstituted
C.sub.1-C.sub.3 alkyl), R.sup.5 is C.sub.1-C.sub.6 alkyl,
preferably C.sub.1-C.sub.3 alkyl, or R.sup.3 and R.sup.5 together
with the O atom to which R.sup.5 is attached and the bond
there-between form a 5- or 6-membered oxy-containing heterocyclic
ring. In a specific embodiment, R.sup.3 is hydrogen, F, Cl, Br,
--CN, methyl, R.sup.4 is hydrogen or F, R.sup.5 is methyl or ethyl.
In another specific embodiment, R.sup.4 is hydrogen, and R.sup.3
and R.sup.5 together with the O atom to which R.sup.5 is attached
and the bond there-between form furan or dihydrofuran ring.
[0085] In a specific embodiment, the compound of formula (I) is
selected from Compounds 1-223 prepared in the Examples.
[0086] In another aspect, the present invention provided a
pharmaceutical composition, comprising at least one compounds of
formula (I) and/or at least one pharmaceutically acceptable salt
thereof described herein and optionally at least one
pharmaceutically acceptable carrier.
[0087] In another aspect, the present invention provides a method
of in vive or in vitro inhibiting the activity of FGFR, comprising
contacting FGFR with an effective amount of at least one compound
of formula (I) and/or at least one pharmaceutically acceptable salt
thereof described herein.
[0088] In another aspect, the present invention provides a method
of treating a disease responsive to inhibition of FGFR, comprising
administering to a subject in need thereof an effective amount to
treat said disease of at least one compound of formula (I) and/or
at least one pharmaceutically acceptable salt thereof described
herein.
[0089] In another aspect, the present invention provides use of at
least one compound of formula (I) and/or at least one
pharmaceutically acceptable salt thereof described herein for
treating a disease responsive to inhibition of FGFR.
[0090] In another aspect, the present invention provides use of at
least one compound of formula (I) and/or at least one
pharmaceutically acceptable salt thereof described herein in the
manufacture of a medicament for treating a disease responsive to
inhibition of FGFR.
[0091] In some embodiments, said disease responsive to inhibition
of FGFR is cancer, for example, lung cancer, stomach cancer, liver
cancer, breast cancer, ovarian cancer, endometrial carcinoma, or
bladder carcinoma.
[0092] The compound of formula (I) described herein and/or a
pharmaceutically acceptable salt thereof described herein can be
synthesized from commercially available starting materials by
methods well known in the art, taken together with the disclosure
in this patent application. The following schemes illustrate
methods for preparation of some of the compounds disclosed
herein.
##STR00006##
[0093] As shown in Scheme I, compounds of formula (I) can be
obtained from the reduction of compounds of formula (V). The
reduction could be conducted with hydrogen in the precence of a
catalyst such as palladium or platinum etc, or conducted with other
reductants such as 4-methylbenzenesulfonohydrazide etc. Compounds
of formula (V) can be obtained from compounds of formula (IV) with
the aminolysis reaction without or with other reagent such as
trimethylaluminum. In other embodiments compounds of formula (I)
can be obtained from compounds of formula (III), which can be
obtained from the reduction of compounds of formula (IV), with the
method of hydrolysis reaction and then the coupling reaction or
with other suitable methods that could be recognized by one skilled
in the art. And R.sup.1, R.sup.2 and R.sup.3 are as defined
hereinbefore.
##STR00007##
[0094] As shown in Scheme II, compounds of formula (VIII) can be
obtained from the compounds of formula (VI) under the conditions
described in Scheme I. And R.sup.1, R.sup.2, R.sup.3 and Y are as
defined hereinbefore. The compounds thus obtained can be further
modified at their peripheral positions to provide the desired
compounds. Synthetic chemistry transformations are described, for
example, in R. Larock, Comprehensive Organic Transformations, VCH
Publishers (1989); T. W. Greene and P. G. M. Wuts, Protective
Groups in Organic Synthesis, 3.sup.rd Ed., John Wiley and Sons
(1999); L. Fieser and M. Fieser, Fieser and Fieser's Reagents for
Organic Synthesis, John Wiley and Sons (1994); and L. Paquette,
ed., Encyclopedia of Reagents for Organic Synthesis, John Wiley and
Sons (1995) and subsequent editions thereof.
[0095] Before use, the compound of formula (I) and/or a
pharmaceutically acceptable salt thereof described herein can be
purified by column chromatography, high performance liquid
chromatography, crystallization or other suitable methods.
Pharmaceutical Compositions and Utility
[0096] A composition comprising at least one compounds of formula
(I) and/or at least one pharmaceutically acceptable salt thereof
described herein can be administered in various known manners, such
as orally, parenterally, by inhalation spray, or via an implanted
reservoir. The term "parenteral" as used herein includes
subcutaneous, intracutaneous, intravenous, intramuscular,
intraarticular, intraarterial, intrasynovial, intrasternal,
intrathecal, intralesional and intracranial injection or infusion
techniques.
[0097] An oral composition can be any orally acceptable dosage form
including, but not limited to, tablets, capsules, emulsions, and
aqueous suspensions, dispersions and solutions. Commonly used
carriers for tablets include lactose and corn starch. Lubricating
agents, such as magnesium stearate, are also typically added to
tablets. For oral administration in a capsule form, useful diluents
include lactose and dried corn starch. When aqueous suspensions or
emulsions are administered orally, the active ingredient can be
suspended or dissolved in an oily phase combined with emulsifying
or suspending agents. If desired, certain sweetening, flavoring, or
coloring agents can be added.
[0098] A sterile injectable composition (e.g., aqueous or
oleaginous suspension) can be formulated according to techniques
known in the art using suitable dispersing or wetting agents (such
as, for example, Tween 80) and suspending agents. The sterile
injectable Intermediate can also be a sterile injectable solution
or suspension in a non-toxic parenterally acceptable diluent or
solvent, for example, as a solution in 1,3-butanediol. Among the
pharmaceutically acceptable vehicles and solvents that can be
employed are mannitol, water, Ringer's solution and isotonic sodium
chloride solution. In addition, sterile, fixed oils are
conventionally employed as a solvent or suspending medium (e.g.,
synthetic mono- or di-glycerides). Fatty acids, such as oleic acid
and its glyceride derivatives are useful in the Intermediate of
injectables, as are natural pharmaceutically-acceptable oils, such
as olive oil or castor oil, especially in their polyoxyethylated
versions. These oil solutions or suspensions can also contain a
long-chain alcohol diluent or dispersant, or carboxymethyl
cellulose or similar dispersing agents.
[0099] An inhalation composition can be prepared according to
techniques well known in the art of pharmaceutical formulation and
can be prepared as solutions in saline, employing benzyl alcohol or
other suitable preservatives, absorption promoters to enhance
bioavailability, fluorocarbons, and/or other solubilizing or
dispersing agents known in the art.
[0100] A topical composition can be formulated in form of oil,
cream, lotion, ointment, and the like. Suitable carriers for the
composition include vegetable or mineral oils, white petrolatum
(white soft paraffin), branched chain fats or oils, animal fats and
high molecular weight alcohols (greater than C12). In some
embodiments, the pharmaceutically acceptable carrier is one in
which the active ingredient is soluble. Emulsifiers, stabilizers,
humectants and antioxidants may also be included as well as agents
imparting color or fragrance, if desired. Additionally, transdermal
penetration enhancers may be employed in those topical
formulations. Examples of such enhancers can be found in U.S. Pat.
Nos. 3,989,816 and 4,444,762.
[0101] Creams may be formulated from a mixture of mineral oil,
self-emulsifying beeswax and water in which mixture the active
ingredient, dissolved in a small amount of an oil, such as almond
oil, is admixed. An example of such a cream is one which includes,
by weight, about 40 parts water, about 20 parts beeswax, about 40
parts mineral oil and about 1 part almond oil. Ointments may be
formulated by mixing a solution of the active ingredient in a
vegetable oil, such as almond oil, with warm soft paraffin and
allowing the mixture to cool. An example of such an ointment is one
which includes about 30% by weight almond oil and about 70% by
weight white soft paraffin.
[0102] A pharmaceutically acceptable carrier refers to a carrier
that is compatible with active ingredients of the composition (and
in some embodiments, capable of stabilizing the active ingredients)
and not deleterious to the subject to be treated. For example,
solubilizing agents, such as cyclodextrins (which form specific,
more soluble complexes with the the compound of formula (I) and/or
a pharmaceutically acceptable salt thereof described herein), can
be utilized as pharmaceutical excipients for delivery of the active
ingredients. Examples of other carriers include colloidal silicon
dioxide, magnesium stearate, cellulose, sodium lauryl sulfate, and
pigments such as D&C Yellow #10.
[0103] Suitable in vitro assays can be used to preliminarily
evaluate the efficacy of the compound of formula (I) and/or a
pharmaceutically acceptable salt thereof described herein, in
inhibiting the activity of Syk kinase. The compound of formula (I)
and/or a pharmaceutically acceptable salt thereof described herein
can further be examined for efficacy in treating inflammatory
disease by in vive assays. For example, the compound of formula (I)
and/or a pharmaceutically acceptable salt thereof described herein
can be administered to an animal (e.g., a mouse model) having
inflammatory disease and its therapeutic effects can be accessed.
Based on the results, an appropriate dosage range and
administration route for animals, such as humans, can also be
determined.
[0104] The compound of formula (I) and/or a pharmaceutically
acceptable salt thereof described herein can be used to achieve a
beneficial therapeutic or prophylactic effect, for example, in
subjects with cancer. As used herein, the term "cancer" refers to a
cellular disorder characterized by uncontrolled or disregulated
cell proliferation, decreased cellular differentiation,
inappropriate ability to invade surrounding tissue, and/or ability
to establish new growth at ectopic sites. The term "cancer"
includes, but is not limited to, solid tumors and bloodborne
tumors. The term "cancer" encompasses diseases of skin, tissues,
organs, bone, cartilage, blood, and vessels. The term "cancer"
further encompasses primary and metastatic cancers.
[0105] Non-limiting examples of solid tumors include pancreatic
cancer; bladder cancer; colorectal cancer; breast cancer, including
metastatic breast cancer; prostate cancer, including
androgen-dependent and androgen-independent prostate cancer; renal
cancer, including, e.g., metastatic renal cell carcinoma;
hepatocellular cancer; lung cancer, including, e.g., non-small cell
lung cancer (NSCLC), bronchioloalveolar carcinoma (BAC), and
adenocarcinoma of the lung; ovarian cancer, including, e.g.,
progressive epithelial or primary peritoneal cancer; cervical
cancer; gastric cancer; esophageal cancer; head and neck cancer,
including, e.g., squamous cell carcinoma of the head and neck; skin
cancer, including e.g., malignant melanoma; neuroendocrine cancer,
including metastatic neuroendocrine tumors; brain tumors,
including, e.g., glioma, anaplastic oligodendroglioma, adult
glioblastoma multiforme, and adult anaplastic astrocytoma; bone
cancer, soft tissue sarcoma; and thyroid carcinoma.
[0106] Non-limiting examples of hematologic malignancies include
acute myeloid leukemia (AML); chronic myelogenous leukemia (CML),
including accelerated CML and CML blast phase (CML-BP); acute
lymphoblastic leukemia (ALL); chronic lymphocytic leukemia (CLL);
Hodgkin's disease (HD); non-Hodgkin's lymphoma (NHL), including
follicular lymphoma and mantle cell lymphoma; B-cell lymphoma;
T-cell lymphoma; multiple myeloma (MM); Waldenstrom's
macroglobulinemia; myelodysplastic syndromes (MDS), including
refractory anemia (RA), refractory anemia with ringed siderblasts
(RARS), (refractory anemia with excess blasts (RAEB), and RAEB in
transformation (RAEB-T); and myeloproliferative syndromes.
[0107] In some embodiments, the examples of the cancer to be
treated include, but are not limited to lung cancer (such as
squamous non-small cell lung cancer (NSCLC), small cell lung cancer
(SCLC)), stomach cancer, liver cancer, breast cancer, ovarian
cancer, endometrial carcinoma, and bladder carcinomas.
[0108] In some embodiments, the compound of formula (I) and/or a
pharmaceutically acceptable salt thereof described herein is
administered in conjunction with another therapeutic agent. In some
embodiments, the other therapeutic agent is one that is normally
administered to patients with the disease or condition being
treated. The compound of formula (I) and/or a pharmaceutically
acceptable salt thereof described herein may be administered with
the other therapeutic agent in a single dosage form or as a
separate dosage form. When administered as a separate dosage form,
the other therapeutic agent may be administered prior to, at the
same time as, or following administration of the compound of
formula (I) and/or a pharmaceutically acceptable salt thereof
described herein.
[0109] In some embodiments, the compound of formula (I) and/or a
pharmaceutically acceptable salt thereof described herein is
administered in conjunction with an anti-neoplastic agent. As used
herein, the term "anti-neoplastic agent" refers to any agent that
is administered to a subject with cancer for purposes of treating
the cancer. Nonlimiting examples anti-neoplastic agents include:
radiotherapy; immunotherapy; DNA damaging chemotherapeutic agents;
and chemotherapeutic agents that disrupt cell replication.
[0110] Non-limiting examples of DNA damaging chemotherapeutic
agents include topoisomerase I inhibitors (e.g., irinotecan,
topotecan, camptothecin and analogs or metabolites thereof, and
doxorubicin); topoisomerase II inhibitors (e.g., etoposide,
teniposide, and daunorubicin); alkylating agents (e.g., melphalan,
chlorambucil, busulfan, thiotepa, ifosfamide, carmustine,
lomustine, semustine, streptozocin, decarbazine, methotrexate,
mitomycin C, and cyclophosphamide); DNA intercalators (e.g.,
cisplatin, oxaliplatin, and carboplatin); DNA intercalators and
free radical generators such as bleomycin; and nucleoside mimetics
(e.g., 5-fluorouracil, capecitibine, gemcitabine, fludarabine,
cytarabine, mercaptopurine, thioguanine, pentostatin, and
hydroxyurea).
[0111] Chemotherapeutic agents that disrupt cell replication
include: paclitaxel, docetaxel, and related analogs; vincristine,
vinblastin, and related analogs; thalidomide and related analogs
(e.g., CC-5013 and CC-4047); protein tyrosine kinase inhibitors
(e.g., imatinib mesylate and gefitinib); proteasome inhibitors
(e.g., bortezomib); NF-kappa B inhibitors, including inhibitors of
I kappa B kinase; antibodies which bind to proteins overexpressed
in cancers and thereby downregulate cell replication (e.g.,
trastuzumab, rituximab, cetuximab, and bevacizumab); and other
inhibitors of proteins or enzymes known to be upregulated,
over-expressed or activated in cancers, the inhibition of which
downregulates cell replication.
EXAMPLES
[0112] The examples below are intended to be purely exemplary and
should not be considered to be limiting in any way. Efforts have
been made to ensure accuracy with respect to numbers used (for
example, amounts, temperature, etc.) but some experimental errors
and deviations should be accounted for. Unless indicated otherwise,
parts are parts by weight, temperature is in degrees Centigrade,
and pressure is at or near atmospheric. All MS data were checked by
agilent 6120 and/or agilent 1100. .sup.1H-NMR spectra were recorded
on an instrument operating at 400 MHz. NMR spectra were obtained as
CDCl.sub.3 solutions (reported in ppm), using chloroform as the
reference standard (7.26 ppm), or internally tetramethylsilane
(0.00 ppm) when appropriate. Other NMR solvents were used as
needed. When peak multiplicities are reported, the following
abbreviations are used: s (singlet), d (doublet), t (triplet), m
(multiplet), q (quarter), br (broadened), dd (doublet of doublets)
dt (doublet of triplets). Coupling constants, when given, are
reported in Herz (Hz). All reagents, except intermediates, used in
this invention are commercially available. All compound names
except the reagents were generated by Chemdraw 10.0.
[0113] In addition, for convenience and as clearly understood by
those skilled in the art, not all hydrogen atoms have been
expressly indicated as bonding to each carbon and/or nitrogen atom.
For example, Compound 17 is depicted by the formula
##STR00008##
in Example 3 below, wherein one hydrogen atom bonding to the
nitrogen atom between the pyrimidine ring and the phenyl ring has
been omitted. Correspondingly, this formula represents the same
compound as the formula
##STR00009##
[0114] In the following examples, the abbreviations below are used:
[0115] AIBN a,a'-azo-isobutyronnitrile [0116] CCl.sub.4
perchloromethane [0117] DCM dichloromethane [0118] DEAD Diethyl
azodicarboxylate [0119] DIPEA N,N-diisopropylethylamine [0120] DMF
N,N-dimethylformamide [0121] EA ethyl acetate [0122] h hour(s)
[0123] HATU
O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetra-methyluronium
hexafluorophosphate [0124] ISCO combiflash chromatograph [0125]
KHMDS potassium bis(trimethylsilyl)amide [0126] mL milliliter(s)
[0127] min minute(s) [0128] MeOH methanol [0129] NBS
N-bromosuccinimide [0130] NIS N-iodosuccinimide [0131] PE petroleum
ether [0132] Pd(dppf)Cl.sub.2.CH.sub.2Cl.sub.2
1,1'-Bis(diphenylphosphino)ferrocene-palladium(II)dichloride
dichloromethane complex [0133] Pd(PPh.sub.3).sub.4
tetrakis(triphenylphosphine)palladium(0) [0134]
PdCl.sub.2(PPh.sub.3).sub.2
bis(triphenylphosphine)palladium(II)dichloride [0135] PPh.sub.3
triphenylphosphine [0136] PTLC preparative thin-layer
chromatography [0137] THF tetrahydrofuran [0138] TFA
trifluoroacetic acid [0139] Xantphos
(2,3-dimethyl-9H-xanthene-1,9-diyl)bis(diphenylphosphine)
Intermediate 1
Methyl 3-bromo-4-fluoro-5-methoxybenzoate
##STR00010##
[0140] (A) 3-bromo-4-fluoro-5-iodobenzoic acid
[0141] To a mixture of 3-bromo-4-fluorobenzoic acid (45 g, 0.21
mol) in H.sub.2SO.sub.4 (96%) was added NIS (50 g, 0.22 mol) in
portions at 0.degree. C. in 30 min. The mixture was stirred at room
temperature for 2 h. Then the mixture was diluted by ice water,
filtered. The filter cake was washed by ice water, dried to afford
the title compound as a yellow solid (60 g, 84.7% yield). MS (m/z):
342.7, 344.7 (M-H).sup.-.
(B) 3-bromo-4-fluoro-5-hydroxybenzoic acid
[0142] A mixture of 3-bromo-4-fluoro-5-iodobenzoic acid (60 g, 0.17
mol), Cu.sub.2O (3.0 g, 0.021 mol) and NaOH (35 g, 0.88 mol) in
water (600 mL) was heated at 100.degree. C. for 16 h. The reaction
mixture was then cooled to room temperature and filtered. The
filtrate was acidified with aq. HCl (5N) and extracted with EA. The
organic layer was separated, concentrated and dried to afford the
title compound as a yellow solid (35 g, 85.6% yield).
(C) Methyl 3-bromo-4-fluoro-5-methoxybenzoate
[0143] To a mixture of 3-bromo-4-fluoro-5-hydroxybenzoic acid (35
g, 0.15 mol) and K.sub.2CO.sub.3 (45 g, 0.32 mol) in DMF (150 mL)
was added iodomethane (45 g, 0.32 mol) at room temperature. The
mixture was stirred at 80.degree. C. for 4 h. The mixture was then
diluted by water, extracted by EA. The organic layer was separated
and concentrated, and the residue was then purified via silica gel
chromatography (PE/EA) to afford the title compound as a white
solid (15 g, 38.3% yield). MS (m/z): 263.2, 265.2 (M+H).sup.+.
[0144] The following intermediates were prepared according to the
procedures of intermediate 1 using the corresponding intermediates
and reagents under appropriate conditions that could be recognized
by one skilled in the art.
TABLE-US-00001 Intermediate Structure MS (m/z) (M + H).sup.+ 2
##STR00011## 199.1 3 ##STR00012## 215.0 4 ##STR00013## 245.0/247.0
5 ##STR00014## 259.0/261.0 6 ##STR00015## 262.8/264.8 7
##STR00016## 278.9/280.9 8 ##STR00017## 297.0/299.0
Intermediate 9
Methyl 4-bromo-3-iodo-5-methoxybenzoate
##STR00018##
[0145] (A) 4-bromo-3,5-diiodobenzoic acid
[0146] To a mixture of 4-bromobenzoic acid (2.7 g, 13 mmol) in
H.sub.2SO.sub.4 (96%, 50 mL) was added NIS (7.5 g, 33 mmol) in
portions at 0.degree. C. in 15 min and the resulting mixture was
stirred at room temperature for 2 h. Then the mixture was diluted
by ice water, followed by Na.sub.2SO.sub.3 aqueous solution. Then
the mixture was filtered. The filter cake was washed by ice water,
dried to afford the title compound as a slight pink solid (5.8 g,
95.4% yield). MS (m/z): 450.5, 452.5 (M-H).sup.-.
(B) 4-bromo-3-hydroxy-5-iodobenzoic acid
[0147] A mixture of 4-bromo-3,5-diiodobenzoic acid (3.0 g, 6.6
mmol), Cu.sub.2O (0.10 g, 0.70 mmol) and NaOH (1.4 g; 35 mmol) in
water (30 mL) was heated at 80.degree. C. for 3 h. The reaction
mixture was then diluted by water, acidified by aq. HCl (10 N),
then filtered. The filter cake was washed by ice water and dried to
afford the title compound as a yellow solid (1.8 g, 79.2% yield).
MS (m/z): 340.6, 342.6 (M-H).sup.-.
(C) Methyl 4-bromo-3-iodo-5-methoxybenzoate
[0148] To a mixture of 4-bromo-3-hydroxy-5-iodobenzoic acid (1.8 g,
5.3 mmol) and K.sub.2CO.sub.3 (1.8 g, 13 mmol) in DMF (30 mL) was
added iodomethane (1.7 g, 12 mmol) at room temperature and then the
mixture was stirred at 80.degree. C. for 4 h. The mixture was then
diluted by water, extracted by EA. The organic layer was separated
and concentrated to afford the title compound as a grey solid (1.9
g, 97.6% yield). MS (m/z): 370.7, 372.7 (M+H).sup.+.
Intermediate 10
3-bromo-N,5-dimethoxybenzamide
##STR00019##
[0149] (A) 3-bromo-5-iodo-N-methoxybenzamide
[0150] To a solution of 3-bromo-5-iodobenzoic acid (5.0 g, 15 mmol)
and methoxylamine hydrochloride (1.3 g, 16 mmol) in DCM (70 mL) was
added HATU (7.0 g, 18 mmol) and DIPEA (4.0 g, 31 mmol). The
resulting mixture was stirred at room temperature for 16 h, diluted
by water and extracted by DCM. The combined organic layers were
concentrated and the residue was purified via silica gel
chromatography (DCM/MeOH) to afford the title compound as a white
solid (4.2 g, 77.1% yield). MS (m/z): 356.2, 358.2 (M+H).sup.+.
(B) 3-bromo-N,5-dimethoxybenzamide
[0151] A mixture of 3-bromo-5-iodo-N-methoxybenzamide (3.6 g, 10
mmol), CuI (0.20 g, 1.1 mmol), 1,10-phenanthroline (0.38 g, 2.1
mmol) and Cs.sub.2CO.sub.3 (4.6 g, 14 mmol) in MeOH (20 mL) was
heated at 100.degree. C. for 1 h under microwave. The mixture was
then filtered and the filter cake was washed by MeOH (20 mL). The
filtrate was concentrated and the residue was purified via silica
gel chromatography (PE/EA) to afford the title compound as a coffee
solid (1.1 g, 41.8% yield). MS (m/z): 262.0, 260.0 (M+H).sup.+.
Intermediate 11
Methyl 2,4-difluoro-5-methoxy-3-methylbenzoate
##STR00020##
[0152] (A) Methyl 2,4-difluoro-5-methoxy-3-methylbenzoate
[0153] To a solution of methyl 4-fluoro-3-methoxy-5-methylbenzoate
(5.0 g, 25.23 mmol) and
1-(chloromethyl)-4-fluoro-1,4-diazabicyclo[2.2.2]octane-1,4-diium
tetrafluoroborate (9.8 g, 27.66 mmol) in acetonitrile (150 mL) was
added acetic acid (30 mL) and the resulting mixture was stirred at
70.degree. C. for 18 h under nitrogen atmosphere. The volatiles
were removed under reduced pressure and the residue was purified
via silica gel column chromatography (eluted with EA in PE
0.about.100%) to afford the title compound as a white solid (1.50
g, 27.5% yield). MS (m/z): 217.0 (M+H).sup.+.
Intermediate 12
Methyl 3-(bromomethyl)-4-chloro-5-methoxybenzoate
##STR00021##
[0154] (A) Methyl 3-(bromomethyl)-4-chloro-5-methoxybenzoate
[0155] To a solution of methyl 4-chloro-3-methoxy-5-methylbenzoate
(2.00 g, 9.32 mmol) in CCl.sub.4 (40 mL) were added NBS (1.99 g,
11.18 mmol) and AIBN (153 mg, 0.93 mmol). Then the mixture was
stirred at 70.degree. C. for overnight. After cooled to room
temperature, the mixture was partitioned between DCM and water. The
aqueous layer was extracted with DCM. The combined organic layers
was washed with water and brine, dried over anhydrous sodium
sulfate and concentrated. The residue was suspended in PE (5 mL)
and stirred for 1 h at room temperature. After filtration, the
filter cake was washed with PE (2*2 mL), dried under reduced
pressure at 60.degree. C. for 1 h to give a yellow solid (2.66 g,
97.3% yield). MS (m/z): 293.0/295.0 (M+H).sup.+.
[0156] The following intermediate was prepared according to the
procedures of intermediate 12 using the corresponding intermediates
and reagents under appropriate conditions that could be recognized
by one skilled in the art.
TABLE-US-00002 Intermediate Structure MS (m/z) (M + H).sup.+ 13
##STR00022## 277.0/279.0 14 ##STR00023## 295.3/297.3
Intermediate 15
1-ethyl-1H-pyrazol-4-amine
##STR00024##
[0157] (A) 1-Ethyl-1H-pyrazol-4-amine
[0158] To a solution of 4-nitro-1H-pyrazole (500 mg, 4.42 mmol) in
anhydrous THF (20 mL) was added NaH (60% dispersion in mineral oil,
353 mg, 8.84 mmol) in portions at 0.quadrature.. The resulting
mixture was stirred at 0.quadrature. for 10 min. Then 1-bromoethane
(723 mg, 6.64 mmol) in anhydrous THF (2 mL) was added dropwise at
0.quadrature.. The mixture was stirred at ambient temperature for
16 h. Then reaction was quenched with H.sub.2O (20 mL) and the
volatiles were removed under reduced pressure. The resulting
aqueous layer was extracted with EA (2*30 mL). The combined
extracts were concentrated under reduced pressure. The residue was
dissolved in MeOH (30 mL) and then Pd/C (10%, 100 mg) was added.
The mixture was stirred at ambient temperature under hydrogen
atmosphere for 16 h. The catalyst was filtered off. The filtrate
was concentrated and the residue was purified via ISCO (eluted with
MeOH in H.sub.2O 0.about.100%) to afford the title compound as
brown oil (260 mg, 52.9% yield, 2 steps). MS (m/z): 112.1
(M+H).sup.+.
Intermediate 16
(R)-tert-butyl
3-(4-amino-1H-pyrazol-1-yl)piperidine-1-carboxylate
##STR00025##
[0159] (A) (R)-tert-butyl
3-(4-nitro-1H-pyrazol-1-yl)piperidine-1-carboxylate
[0160] To a solution of 4-nitro-1H-pyrazole (1, 2.0 g, 17.7 mmol),
(S)-tert-butyl 3-hydroxypiperidine-1-carboxylate (4.2 g, 21.2 mmol)
and PPh.sub.3 (6.9 g, 26.6 mmol) in THF (35 mL) was added DEAD (4.6
g, 26.6 mmol) dropwise with ice-water bath cooling. After addition,
the mixture was stirred at room temperature for further 12 h. The
resulting mixture was concentrated in vacuo. The residue was
purified via silica gel chromatography (eluted with EA in PE 0-60%)
to give a yellow oil (2.5 g, 47.7% yield). MS (m/z): 197.0
(M+H-100).sup.+.
(B) (R)-tert-butyl
3-(4-amino-1H-pyrazol-1-yl)piperidine-1-carboxylate
[0161] A mixture of (R)-tert-butyl
3-(4-nitro-1H-pyrazol-1-yl)piperidine-1-carboxylate (1.0 g, 3.37
mmol) and Pd/C (5%, 200 mg) in MeOH (20 mL) was stirred under 1 atm
of H.sub.2 at room temperature for 12 h. The resulting mixture was
filtered and the filtrate was concentrated in vacuo to give a brown
oil (920 mg, quantative yield). MS (m/z): 267.0 (M+H).sup.+.
[0162] The following intermediates were prepared according to the
procedures of intermediate 16 using the corresponding intermediates
and reagents under appropriate conditions that could be recognized
by one skilled in the art.
TABLE-US-00003 MS (m/z) Intermediate Structure (M + H).sup.+ 17
##STR00026## 140.0 18 ##STR00027## 154.0 19 ##STR00028## 154.1 20
##STR00029## 168.0 21 ##STR00030## 182.9 (M + H - 56).sup.+ 22
##STR00031## 153.0 (M + H - 100).sup.+ 23 ##STR00032## 153.1 (M + H
- 100).sup.+ 24 ##STR00033## 167.0 (M + H - 100).sup.+ 25
##STR00034## 267.1
Intermediate 26
(R)-1-(4-amino-1H-pyrazol-1-yl)propan-2-ol
##STR00035##
[0163] (A) (R)-1-(4-Nitro-1H-pyrazol-1-yl)propan-2-ol
[0164] To a solution of 4-nitro-1H-pyrazole (500 mg, 4.42 mmol) in
DMF (5 mL) was added (R)-2-methyloxirane (282 mg, 4.86 mmol) and
K.sub.2CO.sub.3 (1.2 g, 8.84 mmol). The resulting mixture was
stirred at 60.quadrature. in a sealed tube for 16 h. The reaction
mixture was partitioned between H.sub.2O (30 mL) and EA (30 mL).
The organic layer was concentrated and purified via ISCO (PE/EA) to
afford the title compound as a colorless oil (360 mg, 47.6% yield).
MS (m/z): 171.9 (M+H).sup.+
(B) (R)-1-(4-Amino-1H-pyrazol-1-yl)propan-2-ol
[0165] To a solution of (R)-1-(4-nitro-1H-pyrazol-1-yl) propan-2-ol
(140 mg, 0.82 mmol) in MeOH (30 mL) was added Pd/C (10%, 50 mg).
The mixture was stirred at ambient temperature under hydrogen
atmosphere for 16 h. The catalyst was filtered off and the filtrate
was concentrated to afford the title compound as a brown oil (115
mg, 0.82 mmol, quantative yield). MS (m/z): 142.1 (M+H).sup.+.
[0166] The following intermediate was prepared according to the
procedures of intermediate 26 using the corresponding intermediates
and reagents under appropriate conditions that could be recognized
by one skilled in the art.
TABLE-US-00004 Intermediate Structure MS (m/z) (M + H).sup.+ 27
##STR00036## 142.0
Intermediate 28
3-(4-ethylpiperazin-1-yl)aniline
##STR00037##
[0167] (A) 1-ethyl-4-(3-nitrophenyl)piperazine
[0168] A mixture of 1-ethylpiperazine (3.23 g, 0.0283 mol) and
1-fluoro-3-nitrobenzene (2.0 g, 0.0142 mol) was heated at reflux
for 2 days. The resulting mixture was cooled and concentrated in
vacuo. The residue was poured into water (50 mL), extracted with EA
(2*50 mL). The combined extracts were washed with brine,
concentrated in vacuo. The residue was purified via ISCO (eluted
with EA in PE 0-70%) to give a yellow solid (1.80 g, 54.0% yield).
MS (m/z): 236.1 (M+H).sup.+.
(B) 3-(4-ethylpiperazin-1-yl)aniline
[0169] A mixture of 1-ethyl-4-(3-nitrophenyl)piperazine (1.8 g,
0.00765 mol) and Rany-Ni (1.0 g) in MeOH (20 mL) was stirred under
1 atm of H.sub.2 at room temperature for 6 h. The resulting mixture
was filtered and the filtrate was concentrated in vacuo to give a
grey slurry (1.5 g, 95.5% yield). MS (m/z): 206.2 (M+H).sup.+.
[0170] The following intermediates were prepared according to the
procedures of intermediate 28 using the corresponding intermediates
and reagents under appropriate conditions that could be recognized
by one skilled in the art.
TABLE-US-00005 MS (m/z) Intermediate Structure (M + H).sup.+ 29
##STR00038## 178.1 30 ##STR00039## 206.1
Intermediate 31
5-bromo-N-(4-((3R,5S)-3,5-dimethylpiperazin-1-yl)phenyl)pyrimidin-2-amine
##STR00040##
[0171] (A)
5-bromo-N-(4-((3R,5S)-3,5-dimethylpiperazin-1-yl)phenyl)pyrimid-
in-2-amine
[0172] A mixture of 5-bromo-2-chloropyrimidine (392 mg, 2.03 mmol),
4-((3R,5S)-3,5-dimethylpiperazin-1-yl)aniline (416 mg, 1.968 mmol)
and TFA (0.5 mL, 6.09 mmol) in propan-2-ol (5 mL) was stirred at
150.degree. C. for 80 min under microwave. The resulting mixture
was concentrated, basified with ammonia water, purified via ISCO
(DCM/MeOH) to afford the title compound as a yellow solid (550 mg,
74.9% yield). MS (m/z): 362.0 (M+H).sup.+.
[0173] The following intermediates were prepared according to the
procedures of intermediate 31 using the corresponding intermediates
and reagents under appropriate conditions that could be recognized
by one skilled in the art.
TABLE-US-00006 Intermediate Structure MS (m/z) (M + H).sup.+ 32
##STR00041## 206.1 33 ##STR00042## 267.9/269.9 34 ##STR00043##
361.1/363.1 35 ##STR00044## 362.1/364.1 36 ##STR00045##
362.1/364.1
Intermediate 37
4-((6-bromopyridin-3-yl)methyl)morpholine
##STR00046##
[0174] (A) 4-((6-bromopyridin-3-yl)methyl)morpholine
[0175] To a solution of 6-bromonicotinaldehyde (1.0 g, 5.4 mmol)
and morpholine (0.50 g, 5.7 mmol) in 1,2-dichloroethane (30 mL) was
added sodium triacetoxyborohydride (1.8 g, 8.5 mmol) and the
resulting mixture was stirred at room temperature for 2 h. The
mixture was concentrated and purified via ISCO (eluted with MeOH in
H.sub.2O 0.about.100%) to afford the title compound as a yellow
solid (0.80 g, 57.9% yield). MS (m/z): 256.9/258.9 (M+H).sup.+.
Intermediate 38
1-(4-aminophenyl)pyridin-2(1H)-one
##STR00047##
[0176] (A) 1-(4-aminophenyl)pyridin-2(1H)-one
[0177] A mixture of pyridin-2-ol (2.00 g, 21.0 mmol), 4-iodoaniline
(4.61 g, 21.0 mmol), 8-quinolinol (0.61 g, 4.2 mmol), CuI (0.80 g,
4.2 mmol) and Cs.sub.2CO.sub.3 (10.26 g, 31.5 mmol) in DMSO (50 mL)
was stirred at 120.degree. C. for overnight. After filtration, the
filtrate was partitioned between EA and water and the aqueous layer
was further extracted with EA. The combined organic layers was
washed with water and brine, dried over anhydrous sodium sulfate
and concentrated to afford the title compound as a green solid
(1.56 g, 39.8% yield). MS (m/z): 186.9 (M+H).sup.+.
Intermediate 39
(E)-Methyl
4-chloro-3-methoxy-5-(2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-
-2-yl)vinyl)benzoate
##STR00048##
[0178] (A) (E)-Methyl
4-chloro-3-methoxy-5-(2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)viny-
l)benzoate
[0179] A mixture of methyl 3-bromo-4-chloro-5-methoxybenzoate (24
g, 86 mmol), 4,4,5,5-tetramethyl-2-vinyl-1,3,2-dioxaborolane (26.5
g, 172 mmol), Pd(PPh.sub.3).sub.4 (6 g, 5.16 mmol) and DIPEA (27.7
g, 215 mmol) in anisole (450 mL) was stirred at 140.degree. C.
under nitrogen atmosphere for 16 h. The volatiles were removed
under reduced pressure and the residue was purified via silica gel
chromatography (eluted with PE/EA=10:1). The crude product after
the purification was washed with PE again to afford the title
compound as a yellow solid (14.5 g, 47.9% yield). MS (m/z): 353.1
(M+H).sup.+.
[0180] The following intermediates were prepared according to the
procedures of intermediate 39 using the corresponding intermediates
and reagents under appropriate conditions that could be recognized
by one skilled in the art.
TABLE-US-00007 Intermediate Structure MS (m/z) (M + H).sup.+ 40
##STR00049## 319.2 41 !! EMBED 333.2 42 ##STR00050## 334.5 43
##STR00051## 337.0 44 ##STR00052## 337.4 45 ##STR00053## 347.2 46
##STR00054## 342.1 47 ##STR00055## 436.3
Intermediate 48
(E)-Methyl
4-chloro-3-(2-(2-chloropyrimidin-5-yl)vinyl)-5-methoxybenzoate
##STR00056##
[0181] (A) (E)-methyl
4-chloro-3-(2-(2-chloropyrimidin-5-yl)vinyl)-5-methoxybenzoate
[0182] A mixture of (E)-methyl
4-chloro-3-methoxy-5-(2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)viny-
l)benzoate (8.0 g, 23 mmol), 5-bromo-2-chloropyrimidine (5.5 g, 28
mmol), K.sub.2CO.sub.3 (7.8 g, 56 mmol) and
Pd(dppf)Cl.sub.2.CH.sub.2Cl.sub.2 (0.80 g, 1.1 mmol) in dioxane
(100 mL) and water (20 mL) was heated at 80.degree. C. for 30 min.
Then the mixture was concentrated and the residue was partitioned
between water (400 mL) and DCM (300 mL). The aqueous layer was
extrated with DCM (2*150 mL). The combined organic layers were
concentrated. Then the residue was dispersed in ethanol (50 mL) and
filtered. The filter cake was washed by ethanol (3*20 mL) and then
dried to afford the title compound as a yellow solid (5.5 g, 71.5%
yield). MS (m/z): 338.9 (M+H).sup.+.
[0183] The following intermediates were prepared according to the
procedures of intermediate 48 using the corresponding intermediates
and reagents under appropriate conditions that could be recognized
by one skilled in the art.
TABLE-US-00008 Intermediate Structure MS (m/z) (M + H).sup.+ 49
##STR00057## 304.0 50 ##STR00058## 305.0 51 ##STR00059## 323.0 52
##STR00060## 348.0/350.0 53 ##STR00061## 365.8/367.8
Example 1
Synthesis of Compounds 1-8
Compound 1
3-(2-(2-((4-(4-ethylpiperazin-1-yl)phenyl)amino)pyrimidin-5-yl)ethyl)-5-me-
thoxy-N-methylbenzamide
##STR00062##
[0184] (A) (E)-methyl
3-(2-(2-(4-(4-ethylpiperazin-1-yl)phenylamino)pyrimidin-5-yl)vinyl)-5-met-
hoxybenzoate
[0185] A mixture of
(E)-N-(4-(4-ethylpiperazin-1-yl)phenyl)-5-(2-(4,4,5,5-tetramethyl-1,3,2-d-
ioxaborolan-2-yl)vinyl)pyrimidin-2-amine (170 mg, 0.39 mmol),
methyl 3-bromo-5-methoxybenzoate (96 mg, 0.39 mmol),
Pd(dppf)Cl.sub.2.CH.sub.2Cl.sub.2 (16 mg, 0.020 mmol) and
Na.sub.2CO.sub.3 (103 mg, 0.975 mmol) in 1,4-dioxane (4 mL) and
water (1 mL) was stirred at 120.degree. C. for 30 min under
microwave. The resulting mixture was partitioned between 2N HCl (20
mL) and EA (30 mL). Then the aqueous layer was based with 2N NaOH
to pH=8 and extracted with EA (2*30 mL). The combined extracts were
concentrated to afford the title compound as an orange solid (100
mg, 54.1% yield). MS (m/z): 474.0 (M+H).sup.+.
(B)(E)-3-(2-(2-(4-(4-ethylpiperazin-1-yl)phenylamino)pyrimidin-5-yl)vinyl)-
-5-methoxy-N-methylbenzamide
[0186] A mixture of (E)-methyl
3-(2-(2-(4-(4-ethylpiperazin-1-yl)phenylamino)pyrimidin-5-yl)vinyl)-5-met-
hoxybenzoate (100 mg, 0.211 mmol) and methylamine (5 mL, 35%
solution in ethanol) was stirred at 120.degree. C. for 50 min under
microwave. The resulting mixture was partitioned between water (20
mL) and EA (20 mL). The aqueous layer was extracted with EA (2*20
mL). The combined organic layer was concentrated to afford the
title compound as a yellow solid (60 mg, 60.1% yield). MS (m/z):
472.9 (M+H).sup.+.
(C)
3-(2-(2-(4-(4-ethylpiperazin-1-yl)phenylamino)pyrimidin-5-yl)ethyl)-5--
methoxy-N-methylbenzamide
[0187] To a mixture of (E)-methyl
3-(2-(2-(4-(4-ethylpiperazin-1-yl)phenylamino)pyrimidin-5-yl)vinyl)-5-met-
hoxybenzoate (60 mg, 0.127 mmol) in MeOH (20 mL) was added Pd/C
(10%, 20 mg). The resulting mixture was stirred at ambient
temperature under hydrogen atmosphere for overnight. The resulting
mixture was filtered through celite, the filtrate was concentrated,
purified via PTLC (DCM/MeOH=15:1) to afford the title compound as a
yellow solid (19 mg, 31.5% yield). MS (m/z): 474.9 (M+H).sup.+.
.sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 8.11 (s, 2H), 7.44 (d,
J=9.0 Hz, 2H), 7.21 (s, 1H), 7.19 (s, 1H), 6.95 (d, J=9.0 Hz, 2H),
6.88 (s, 1H), 3.79 (s, 3H), 3.18-3.12 (m, 4H), 2.94 (t, J=7.4 Hz,
2H), 2.92 (s, 3H), 2.82 (t, J=7.4 Hz, 2H), 2.67-2.62 (m, 4H), 2.49
(q, J=7.2 Hz, 2H), 1.14 (t, J=7.2 Hz, 3H).
[0188] The following compound was prepared according to the
procedures of Compound 1 using the corresponding intermediates and
reagents under appropriate conditions that could be recognized by
one skilled in the art.
TABLE-US-00009 LC-MS Com- (m/z) pound Structure (M + H).sup.+
.sup.1H NMR 2 ##STR00063## 431.2 .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. 8.58 (s, 2H), 7.91 (s, 1H), 7.58 (d, J = 6.6 Hz, 1H), 7.53
(s, 1H), 7.12 (s, 2H), 6.96 (s, 1H), 6.78 (d, J = 9.3 Hz, 1H), 4.18
(q, J = 7.3 Hz, 2H), 3.96 (s, 3H), 3.06 (d, J = 4.8 Hz, 3H), 1.52
(t, J = 7.4 Hz, 3H). 3 ##STR00064## 457.1/ 459.1 .sup.1H NMR (400
MHz, CD.sub.3OD) .delta. 8.59 (s, 2H), 7.94 (s, 1H), 7.71 (d, J =
1.8 Hz, 1H), 7.57 (s, 1H), 7.44 (d, J = 16.3 Hz, 1H), 7.32 (d, J =
1.6 Hz, 1H), 7.00 (d, J = 16.3 Hz, 1H), 4.17 (q, J = 7.3 Hz, 2H),
3.98 (s, 3H), 2.99 (s, 3H), 1.51 (t, J = 7.3 Hz, 3H). 4
##STR00065## 485.2 .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 8.06
(s, 2H), 7.85-7.82 (m, 2H), 7.55- 7.52 (m, 1H), 7.46 (d, J = 9.0
Hz, 2H), 6.97 (d, J = 9.0 Hz, 2H), 6.91- 6.89 (m, 1H), 3.40-3.32
(m, 4H), 3.27-3.23 (m, 4H), 3.19 (t, J = 7.6 Hz, 2H), 3.07 (q, J =
7.6 Hz, 2H), 2.95-2.90 (m, 5H), 1.33 (t, J = 7.6 Hz, 3H). 5
##STR00066## 501.2 .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 8.05
(s, 2H), 7.86 (s, 1H), 7.78 (s, 1H), 7.50-7.39 (m, 3H), 6.98-6.88
(m, 3H), 3.80 (s, 3H), 3.21-3.08 (m, 6H), 2.90 (t, J = 7.2 Hz, 2H),
272- 2.61 (m, 4H), 2.51 (q, J = 7.1 Hz, 2H), 1.14 (t, J = 7.1 Hz,
3H). 6 ##STR00067## 503.1 .sup.1H NMR (400 MHz, CD.sub.3OD) .delta.
8.00 (s, 2H), 7.35 (d, J = 9.0 Hz, 2H), 7.00 (d, J = 2.4 Hz, 1H),
6.89-6.84 (m, 3H), 4.42 (t, J = 8.7 Hz, 2H), 3.68 (s, 3H),
3.08-3.06 (m, 4H), 2.96 (t, J = 8.7 Hz, 2H), 2.79-2.69 (m, 4H),
2.59-2.56 (m, 4H), 2.42 (q, J = 7.2 Hz, 2H), 1.06 (t, J = 7.2 Hz,
3H). 7 ##STR00068## 511.2 .sup.1H NMR (400 MHz, CD.sub.3OD) .delta.
8.05 (s, 2H), 7.85-7.83 (m, 2H), 7.53- 7.50 (m, 1H), 7.42 (d, J =
7.2 Hz, 2H), 6.94 (d, J = 7.2 Hz, 2H), 6.91- 6.89 (m, 1H),
3.18-3.14 (m, 6H), 2.90 (t, J = 7.5 Hz, 2H), 2.88-2.83 (m, 1H),
2.66-2.64 (m, 4H), 2.50 (q, J = 7.2 Hz, 2H), 1.14 (t, J = 7.2 Hz,
3H), 0.81-0.78 (m, 2H), 0.65- 0.63 (m, 2H). 8 ##STR00069## 525.3
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.56 (s, 2H), 7.57 (d, J
= 6.5 Hz, 1H), 7.47 (d, J = 8.8 Hz, 2H), 7.13 (s, 1H), 7.11 (s,
2H), 6.94 (d, J = 8.8 Hz, 2H), 6.78 (d, J = 7.8 Hz, 1H), 3.96 (s,
3H), 3.51-3.44 (m, 2H), 3.12-3.07 (m, 2H), 3.06 (d, J = 4.7 Hz,
3H), 2.31 (t, J = 11.0 Hz, 2H), 1.16 (d, J = 6.3 Hz, 6H).
##STR00070##
Example 2
Synthesis of Compounds 9-13
Compound 9
3-(2-(2-((3-(4-ethylpiperazin-1-yl)phenyl)amino)pyrimidin-5-yl)ethyl)-5-me-
thoxy-N-methylbenzamide
##STR00071##
[0189] (A) (E)-methyl
3-(2-(2-((3-(4-ethylpiperazin-1-yl)phenyl)amino)pyrimidin-5-yl)vinyl)-5-m-
ethoxybenzoate
[0190] A mixture of
5-bromo-N-(3-(4-ethylpiperazin-1-yl)phenyl)pyrimidin-2-amine (113
mg, 0.31 mmol), (E)-methyl
3-methoxy-4-(2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)vinyl)benzoat-
e (100 mg, 0.31 mmol), K.sub.2CO.sub.3 (87 mg, 0.63 mmol),
Pd(dffp).sub.2Cl.sub.2CH.sub.2Cl.sub.2 (20 mg, 0.022 mmol) and
water (1 mL) in dioxane (5 mL) was heated at 100.degree. C. for 1 h
under microwave. The resulting mixture was cooled and concentrated
in vacuo. The residue was dissolved in DCM (10 mL) and washed with
water and brine. The organic layer was concentrated, purified via
ISCO (eluted with MeOH in DCM 0-10%) to give a yellow solid (70 mg,
47.4% yield). MS (m/z): 462.2 (M+H).sup.+.
(B)
(E)-3-(2-(2-((3-(4-ethylpiperazin-1-yl)phenyl)amino)pyrimidin-5-yl)vin-
yl)-5-methoxy-N-methylbenzamide
[0191] A mixture of (E)-methyl
3-(2-(2-((3-(4-ethylpiperazin-1-yl)phenyl)amino)pyrimidin-5-yl)vinyl)-5-m-
ethoxybenzoate (70 mg, 0.15 mmol) in methylamine (5 mL, 35%
solution in ethanol) was heated at 120.degree. C. for 30 min under
microwave. The resulting mixture was cooled and concentrated in
vacuo to give a yellow solid (70 mg, quantative yield). MS (m/z):
473.2 (M+H).sup.+.
(C)
3-(2-(2-((3-(4-ethylpiperazin-1-yl)phenyl)amino)pyrimidin-5-yl)ethyl)--
5-methoxy-N-methylbenzamide
[0192] A mixture of
(E)-3-(2-(2-((3-(4-ethylpiperazin-1-yl)phenyl)amino)pyrimidin-5-yl)vinyl)-
-5-methoxy-N-methylbenzamide (70 mg, 0.15 mmol) and Pd/C (5%, 25
mg) in MeOH (15 mL) was stirred under 1 atm of H.sub.2 at
40.degree. C. for 12 h. The resulting mixture was filtered and the
filtrate was concentrated in vacuo. The residue was purified via
PTLC (DCM/MeOH=10:1) to give the title compound as a white solid
(23.0 mg, 32.8% yield). MS (m/z): 475.2 (M+H).sup.+. .sup.1H NMR
(400 MHz, CD.sub.3OD) .delta. 8.18 (s, 2H), 7.37 (s, 1H), 7.24-7.21
(m, 2H), 7.18-7.11 (m, 2H), 6.89 (s, 1H), 6.65 (d, J=8.1 Hz) 3.83
(s, 3H), 3.31-3.26 (m, 4H), 2.95-2.82 (m, 1H), 2.75-2.67 (m, 2H),
1.23 (t, J=7.2 Hz, 3H).
[0193] The following compounds were prepared according to the
procedures of Compound 9 using the corresponding intermediates and
reagents under appropriate conditions that could be recognized by
one skilled in the art.
TABLE-US-00010 LC-MS Com- (m/z) pound Structure (M + H).sup.+
.sup.1H NMR 10 ##STR00072## 425.0 .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. 8.15 (s, 2H), 7.91 (s, 1H), 7.44 (s, 1H), 7.32 (d, J = 6.0
Hz, 1H), 7.21 (s, 1H), 7.00 (d, J = 4.3 Hz, 1H), 4.77-4.69 (m, 1H),
3.90 (s, 3H), 2.97 (d, J = 4.6 Hz, 3H), 2.91 (t, J = 7.4 Hz, 2H),
2.79 (t, J = 7.3 Hz, 2H), 2.62-2.41 (m, 4H), 1.92- 1.83 (m, 2H). 11
##STR00073## 465.9 .sup.1H NMR (400 MHz, DMSO-d6) .delta. 9.20 (s,
1H), 8.38 (d, J = 4.6 Hz, 1H), 8.20 (s, 2H), 7.53 (d, J = 9.1 Hz,
2H), 7.42 (d, J = 7.8 Hz, 1H), 7.37 (d, J = 4.3 Hz, 1H), 6.85 (d, J
= 9.1 Hz, 2H), 3.83 (s, 3H), 3.75-3.67 (m, 4H), 3.03- 2.96 (m, 4H),
2.88 (t, J = 7.3 Hz, 2H), 2.76-2.72 (m, 5H). 12 ##STR00074## 475.1
.sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 8.17 (s, 2H), 7.29 (s,
1H), 7.22 (s, 1H), 7.20 (s, 1H), 7.15-7.08 (m, 2H), 6.88 (s, 1H),
6.62 (d, J = 7.7 Hz, 1H), 3.79 (s, 3H), 3.56-3.50 (m, 2H),
3.02-2.96 (m, 2H), 2.93-2.90 (m, 2H), 2.89 (s, 3H), 2.87-2.82 (m,
2H), 2.27 (t, J = 11.2 Hz, 2H), 1.14 (d, J = 6.4 Hz, 6H). 13
##STR00075## 483.9 .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 8.14
(s, 2H), 7.95 (s, 1H), 7.53 (s, 1H), 7.41 (dd, J = 7.8 Hz, 2.1 Hz,
1H), 7.27 (dd, J = 6.0 Hz, 2.1 Hz, 1H), 4.15-4.09 (m, 2H), 3.88 (s,
3H), 2.94 (t, J = 7.6 Hz, 2H), 2.89 (s, 3H), 2.81 (t, J = 7.6 Hz,
2H), 2.55 (q, J = 7.2 Hz, 4H), 2.50- 2.43 (m, 2H), 2.02-1.99 (m,
2H), 1.01 (t, J = 7.2 Hz, 6H). ##STR00076##
Example 3
Synthesis of Compounds 14-18
Compound 14
3-(2-(2-((3-(4-ethylpiperazin-1-yl)phenyl)amino)pyrimidin-5-yl)ethyl)-N,5--
dimethoxybenzamide
##STR00077##
[0194] (A)
(E)-3-(2-(2-((3-(4-ethylpiperazin-1-yl)phenyl)amino)pyrimidin-5-
-yl)vinyl)-N,5-dimethoxybenzamide
[0195] A mixture of
(E)-N,3-dimethoxy-5-(2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)vinyl-
)benzamide (0.10 g, 0.30 mmol),
5-bromo-N-(3-(4-ethylpiperazin-1-yl)phenyl)pyrimidin-2-amine (0.11
g, 0.30 mmol), Na.sub.2CO.sub.3 (0.07 g, 0.66 mmol) and
Pd(dffp).sub.2Cl.sub.2CH.sub.2Cl.sub.2 (0.025 g, 0.034 mmol) in
dioxane (5 mL) and water (1 mL) was heated at 100.degree. C. for 30
min under microwave. Then the mixture was filtered and the filtrate
was purified via ISCO (eluted with MeOH in H.sub.2O 0.about.100%)
directly to afford the title compound as a yellow solid (0.036 g,
24.6% yield). MS (m/z): 489.7 (M+H).sup.+.
(B)
3-(2-(2-((3-(4-ethylpiperazin-1-yl)phenyl)amino)pyrimidin-5-yl)ethyl)--
N,5-dimethoxybenzamide
[0196] A solution of
(E)-3-(2-(2-((3-(4-ethylpiperazin-1-yl)phenyl)amino)pyrimidin-5-yl)
vinyl)-N,5-dimethoxybenzamide (0.036 g, 0.078 mmol) in MeOH (15 mL)
was added Pd/C (10%, 0.04 g) and the mixture was stirred at
35.degree. C. for 40 h under hydrogen atmosphere. The mixture was
filtered and the filtrate was concentrated. The residue was
purified via PTLC (DCM/MeOH) to afford the title compound as a
yellow solid (0.020 g, 55.3% yield). MS (m/z): 491.7 (M+H).sup.+.
.sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 8.19 (s, 2H), 7.34 (s,
1H), 7.22 (s, 1H), 7.19-7.08 (m, 3H), 6.68-6.59 (m, 2H), 3.76 (s,
3H), 3.71 (s, 3H), 3.23-3.17 (m, 4H), 2.89-2.79 (m, 4H), 2.68-2.61
(m, 4H), 2.49 (q, J=7.3 Hz, 2H), 1.14 (t, J=7.2 Hz, 3H).
[0197] The following compounds were prepared according to the
procedures of Compound 14 using the corresponding intermediates and
reagents under appropriate conditions that could be recognized by
one skilled in the art.
TABLE-US-00011 LC-MS Com- (m/z) pound Structure (M + H).sup.+
.sup.1H NMR 16 ##STR00078## 489.2 .sup.1H NMR (400 MHz, CD.sub.3OD)
.delta. 8.58 (s, 2H), 7.55-7.51 (m, 3H), 7.24 (s, 1H), 7.09-6.96
(m, 5H), 3.83 (s, 3H), 3.72 (s, 3H), 3.18-3.17 (m, 4H), 2.67-2.64
(m, 4H), 2.50 (q, J = 7.1 Hz, 2H), 1.14 (t, J = 7.1 Hz, 3H). 17
##STR00079## 491.2 .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 8.12
(s, 2H), 7.49 (d, J = 9.0 Hz, 2H), 7.13-7.12 (m, 2H), 6.97 (d, J =
9.0 Hz, 2H), 6.90 (s, 1H), 3.78 (s, 3H), 3.77 (s, 3H), 3.36-3.31
(m, 4H), 3.12 (q, J = 7.3 Hz, 3H), 2.90 (t, J = 7.3 Hz, 2H), 2.81
(t, J = 7.3 Hz, 2H), 1.33 (t, J = 7.3 Hz, 3H). 18 ##STR00080##
491.4 .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 8.17 (s, 2H), 7.29
(s, 1H), 7.24-7.06 (m, 4H), 6.75 (s, 1H), 6.61 (s, 1H), 3.76 (s,
3H), 3.73 (s, 3H), 3.57-3.48 (m, 2H), 3.03-2.92 (m, 2H), 2.92-2.76
(m, 4H), 2.25 (t, J = 10.6 Hz, 2H), 1.13 (d, J = 6.0 Hz, 6H).
##STR00081##
Example 4
Synthesis of Compound 19
Compound 19
3-(2-(2-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)pyrimidin-5-yl)-
ethyl)-N,5-dimethoxybenzamide
##STR00082##
[0198] (A) (E)-methyl
3-methoxy-5-(2-(2-(4-(piperazin-1-yl)phenylamino)pyrimidin-5-yl)vinyl)ben-
zoate
[0199] A mixture of 4-(piperazin-1-yl)aniline (348 mg, 1.968 mmol),
(E)-methyl 3-(2-(2-chloropyrimidin-5-yl)vinyl)-5-methoxybenzoate
(600 mg, 1.968 mmol) and TFA (672 mg, 5.904 mmol) in propan-2-ol
(30 mL) was stirred at 150.degree. C. for 40 min under microwave.
The resulting mixture was concentrated, basified with ammonia
water, purified via ISCO (DCM/MeOH) to afford the title compound as
a yellow solid (320 mg, 36.6% yield). MS (m/z): 446.3
(M+H).sup.+.
(B) (E)-methyl
3-(2-(2-(4-(4-(2-hydroxyethyl)piperazin-1-yl)phenylamino)pyrimidin-5-yl)v-
inyl)-5-methoxybenzoate
[0200] A mixture of (E)-methyl
3-methoxy-5-(2-(2-(4-(piperazin-1-yl)phenylamino)pyrimidin-5-yl)vinyl)ben-
zoate (260 mg, 0.584 mmol), 2-bromoethanol (146 mg, 1.167 mmol) and
K.sub.2CO.sub.3 (242 mg, 1.752 mmol) in DMF (5 mL) was stirred at
65.degree. C. for overnight. The resulting mixture was partitioned
between water (30 mL) and EA (30 mL). The organic phase was
concentrated to afford the title compound as a brown oil (200 mg,
70.0% yield). MS (m/z): 490.2 (M+H).sup.+.
(C) Methyl
3-(2-(2-(4-(4-(2-hydroxyethyl)piperazin-1-yl)phenylamino)pyrimi-
din-5-yl)ethyl)-5-methoxybenzoate
[0201] To a mixture of (E)-methyl
3-(2-(2-(4-(4-(2-hydroxyethyl)piperazin-1-yl)phenylamino)pyrimidin-5-yl)v-
inyl)-5-methoxybenzoate (200 mg, 0.409 mmol) in MeOH (8 mL) and THF
(2 mL) was added Pd/C (10%, 100 mg). The resulting mixture was
stirred at ambient temperature for 20 h and 50.degree. C. for 6 h
under hydrogen atmosphere. The resulting mixture was filtered
through celite. The filtrate was concentrated and the residue was
purified via ISCO (eluted with MeOH in H.sub.2O 0.about.100%) to
afford the title compound as a yellow solid (85 mg, 42.3% yield).
MS (m/z): 492.2 (M+H).sup.+.
(D)
3-(2-(2-(4-(4-(2-hydroxyethyl)piperazin-1-yl)phenylamino)pyrimidin-5-y-
l)ethyl)-5-methoxybenzoic acid
[0202] A mixture of methyl
3-(2-(2-(4-(4-(2-hydroxyethyl)piperazin-1-yl)phenylamino)pyrimidin-5-yl)e-
thyl)-5-methoxybenzoate (85 mg, 0.173 mmol) and a solution of 30%
sodium hydroxide (0.8 mL, 6.00 mmol) in MeOH (10 mL) was stirred at
40.degree. C. for 3 h. The resulting mixture was concentrated,
adjusted to pH=7 with 2N HCl, concentrated, purified via ISCO
(eluted with MeOH in H.sub.2O 0.about.100%) to afford the title
compound as a brown oil (70 mg, 84.8% yield). MS (m/z): 478.2
(M+H).sup.+.
(E)
3-(2-(2-(4-(4-(2-hydroxyethyl)piperazin-1-yl)phenylamino)pyrimidin-5-y-
l)ethyl)-N,5-dimethoxybenzamide
[0203] A mixture of
3-(2-(2-(4-(4-(2-hydroxyethyl)piperazin-1-yl)phenylamino)pyrimidin-5-yl)e-
thyl)-5-methoxybenzoic acid (70 mg, 0.173 mmol),
O-methylhydroxylamine (18 mg, 0.220 mmol), HATU (168 mg, 0.441
mmol) and DIPEA (57 mg, 0.441 mmol) in DMF (3 mL) was stirred at
ambient temperature for 20 min. The resulting mixture was
concentrated, purified via ISCO (eluted with MeOH in H.sub.2O
0.about.100%) to afford the title compound as a yellow solid (60
mg, 80.8% yield). MS (m/z): 507.2 (M+H).sup.+. .sup.1H NMR (400
MHz, CD.sub.3OD) .delta. 8.11 (s, 2H), 7.47 (d, J=9.0 Hz, 2H),
7.12-7.11 (m, 2H), 6.96 (d, J=9.0 Hz, 2H), 6.90 (s, 1H), 3.85 (t,
J=5.6 Hz, 2H), 3.78 (s, 3H), 3.76 (s, 3H), 3.32-3.30 (m, 2H), 3.11
(t, J=5.6 Hz, 2H), 2.89 (t, J=7.3 Hz, 2H), 2.81 (t, J=7.3 Hz,
2H).
Example 5
Synthesis of Compound 20
Compound 20
3-(2-(2-((4-(4-ethylpiperazin-1-yl)phenyl)amino)pyrimidin-5-yl)ethyl)-N-(2-
-hydroxyethoxy)-5-methoxybenzamide
##STR00083##
[0204] (A) Methyl
3-(2-(2-((4-(4-ethylpiperazin-1-yl)phenyl)amino)pyrimidin-5-yl)ethyl)-5-m-
ethoxybenzoate
[0205] To a solution of (E)-methyl
3-(2-(2-((4-(4-ethylpiperazin-1-yl)phenyl)amino)pyrimidin-5-yl)vinyl)-5-m-
ethoxybenzoate (0.91 g, 1.9 mmol) in THF (30 mL) was added Pd/C
(10%, 0.5 g) and the mixture was stirred at 40.degree. C. for 24 h
under hydrogen (1 atm). The mixture was filtered and the filtrate
was concentrated to afford the title compound as a yellow solid
(0.68 g, 74.4% yield). MS (m/z): 476.3 (M+H).sup.+.
(B)
3-(2-(2-((4-(4-ethylpiperazin-1-yl)phenyl)amino)pyrimidin-5-yl)ethyl)--
5-methoxybenzoic acid
[0206] To a solution of methyl
3-(2-(2-((4-(4-ethylpiperazin-1-yl)phenyl)amino)pyrimidin-5-yl)ethyl)-5-m-
ethoxybenzoate (0.68 g, 1.4 mmol) in THF (20 mL) was added aqueous
LiOH solution (0.20 g LiOH in 5 mL H.sub.2O). The mixture was
stirred at 40.degree. C. for 2 h, then purified via ISCO (eluted
with MeOH in H.sub.2O 0.about.100%) directly to afford the title
compound as a yellow solid (0.503 g, 76.2% yield). MS (m/z): 462.2
(M+H).sup.+.
(C)
3-(2-(2-(4-(4-ethylpiperazin-1-yl)phenylamino)pyrimidin-5-yl)ethyl)-5--
methoxy-N-(2-(vinyloxy)ethoxy)benzamide
[0207] A mixture of
3-(2-(2-(4-(4-ethylpiperazin-1-yl)phenylamino)pyrimidin-5-yl)ethyl)-5-met-
hoxybenzoic acid (100 mg, 0.210 mmol),
O-(2-(vinyloxy)ethyl)hydroxylamine (32 mg, 0.315 mmol), HATU (240
mg, 0.630 mmol) and DIPEA (81 mg, 0.630 mmol) in DMF (3 mL) was
stirred at ambient temperature for 30 min. The resulting mixture
was partitioned between water (30 mL) and EA (30 mL). The organic
phase was concentrated and the residue was purified via ISCO
(eluted with MeOH in H.sub.2O 0.about.100%) to afford the title
compound as a yellow solid (70 mg, 59.1% yield). MS (m/z): 547.3
(M+H).sup.+.
(D)
3-(2-(2-(4-(4-ethylpiperazin-1-yl)phenylamino)pyrimidin-5-yl)ethyl)-N--
(2-hydroxyethoxy)-5-methoxybenzamide
[0208] To a mixture of
3-(2-(2-(4-(4-ethylpiperazin-1-yl)phenylamino)pyrimidin-5-yl)ethyl)-5-met-
hoxy-N-(2-(vinyloxy)ethoxy)benzamide (70 mg, 0.128 mmol) in MeOH (4
mL) was added 2N HCl (1 mL, 2.0 mmol). The mixture was stirred at
ambient temperature for 1 h. The resulting mixture was
concentrated, basified with ammonia water, concentrated, purified
via ISCO (eluted with MeOH in H.sub.2O 0.about.100%) to afford the
title compound as a yellow solid (35 mg, 52.5% yield). MS (m/z):
521.2 (M+H).sup.+. .sup.1H NMR (400 MHz, CD.sub.3OD) .delta.8.11
(s, 2H), 7.48 (d, J=9.0 Hz, 2H), 7.14 (s, 1H), 7.13 (s, 1H), 6.96
(d, J=9.0 Hz, 2H), 6.91 (s, 1H), 4.00 (t, J=4.5 Hz, 2H), 3.78 (s,
3H), 3.73 (t, J=4.5 Hz, 2H), 3.33-3.31 (m, 4H), 3.25-3.22 (m, 4H),
3.10 (q, J=7.3 Hz, 2H), 2.90 (t, J=7.3 Hz, 2H), 2.81 (t, J=7.3 Hz,
2H), 1.32 (t, J=7.3 Hz, 3H).
Example 6
Synthesis of Compounds 21-59
Compound 21
3-(2-(2-((4-((3R,5S)-3,5-dimethylpiperazin-1-yl)phenyl)amino)pyrimidin-5-y-
l)ethyl)-4-fluoro-5-methoxy-N-methylbenzamide
##STR00084##
[0209] (A) Methyl
3-((E)-2-(2-(4-((3R,5S)-3,5-dimethylpiperazin-1-yl)phenylamino)pyrimidin--
5-yl)vinyl)-4-fluoro-5-methoxybenzoate
[0210] A mixture of (E)-methyl
4-fluoro-3-methoxy-5-(2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)viny-
l)benzoate (278 mg, 0.828 mmol),
5-bromo-N-(4-((3R,5S)-3,5-dimethylpiperazin-1-yl)phenyl)pyrimidin-2-amine
(300 mg, 0.828 mmol), Pd(dffp).sub.2Cl.sub.2.CH.sub.2Cl.sub.2 (34
mg, 0.041 mmol) and Na.sub.2CO.sub.3 (220 mg, 2.07 mmol) in
1,4-dioxane (4 mL) and water (1 mL) was stirred at 110.degree. C.
for 25 min under microwave. The resulting mixture was concentrated,
purified via ISCO (eluted with MeOH in H.sub.2O 0.about.100%) to
afford the title compound as a yellow solid (170 mg, 41.8% yield).
MS (m/z): 492.2 (M+H).sup.+.
(B) Methyl
3-(2-(2-(4-((3R,5S)-3,5-dimethylpiperazin-1-yl)phenylamino)pyri-
midin-5-yl)ethyl)-4-fluoro-5-methoxybenzoate
[0211] To a mixture of methyl
3-((E)-2-(2-(4-((3R,5S)-3,5-dimethylpiperazin-1-yl)phenylamino)pyrimidin--
5-yl)vinyl)-4-fluoro-5-methoxybenzoate (170 mg, 0.346 mmol) in MeOH
(10 mL) and THF (4 mL) was added Pd/C (10%, 50 mg). The mixture was
stirred at 50.degree. C. for 4 h under hydrogen atmosphere. The
resulting mixture was filtered through celite. The filtrate was
concentrated to afford the title compound as a yellow oil (150 mg,
87.9% yield). MS (m/z): 494.2 (M+H).sup.+.
(C)
3-(2-(2-(4-((3R,5S)-3,5-dimethylpiperazin-1-yl)phenylamino)pyrimidin-5-
-yl)ethyl)-4-fluoro-5-methoxybenzoic acid
[0212] A mixture of methyl
3-(2-(2-(4-((3R,5S)-3,5-dimethylpiperazin-1-yl)phenylamino)pyrimidin-5-yl-
)ethyl)-4-fluoro-5-methoxybenzoate (150 mg, 0.304 mmol) and a
solution of 30% sodium hydroxide (1 mL, 7.50 mmol) in MeOH (10 mL)
was stirred at 40.degree. C. for 3 h. The resulting mixture was
cooled to ambient temperature, adjusted to pH=7 with 2N HCl,
concentrated, purified via ISCO (eluted with MeOH in H.sub.2O
0.about.100%) to afford the title compound as a brown oil (60 mg,
41.2% yield). MS (m/z): 480.2 (M+H).sup.+.
(D)
3-(2-(2-(4-((3R,5S)-3,5-dimethylpiperazin-1-yl)phenylamino)pyrimidin-5-
-yl)ethyl)-4-fluoro-5-methoxy-N-methylbenzamide
[0213] A mixture of
3-(2-(2-(4-((3R,5S)-3,5-dimethylpiperazin-1-yl)phenylamino)pyrimidin-5-yl-
)ethyl)-4-fluoro-5-methoxybenzoic acid (40 mg, 0.083 mmol),
methylamine hydrochloride (8.4 mg, 0.125 mmol), HATU (95 mg, 0.250
mmol) and DIPEA (32 mg, 0.250 mmol) in DMF (3 mL) was stirred at
ambient temperature for 30 min. The resulting mixture was purified
via ISCO (eluted with MeOH in H.sub.2O 0.about.100%) and then PTLC
(DCM/MeOH=15:1) to afford the title compound as a yellow solid (29
mg, 70.6% yield). MS (m/z): 493.2 (M+H).sup.+. .sup.1H NMR (400
MHz, CD.sub.3OD) .delta. 8.11 (s, 2H), 7.42 (d, J=9.0 Hz, 2H), 7.41
(dd, J=6.0 Hz, 2.0 Hz, 1H), 7.28 (dd, J=6.0 Hz, 2.0 Hz, 1H), 6.95
(d, J=9.0 Hz, 2H), 3.90 (s, 1H), 3.48-3.43 (m, 2H), 3.05-2.98 (m,
2H), 2.95 (t, J=7.3 Hz, 2H), 2.90 (s, 3H), 2.82 (t, J=7.3 Hz, 2H),
2.28-2.22 (m, 2H), 1.15 (t, J=6.4 Hz, 3H).
[0214] The following compounds were prepared according to the
procedures of Compound 21 using the corresponding intermediates and
reagents under appropriate conditions that could be recognized by
one skilled in the art.
TABLE-US-00012 LC- MS (m/z) Com- (M + pound Structure H).sup.+
.sup.1H NMR 22 ##STR00085## 379.1 .sup.1H NMR (400 MHz, CD.sub.3OD)
.delta. 8.18 (s, 2H), 7.58 (dd, J = 8.6 Hz, 1.0 Hz, 2H), 7.27-7.21
(m, 2H), 7.20 (s, 1H), 7.15 (dd, J = 2.2 Hz, 1.4 Hz, 1H), 6.97-6.91
(m, 1H), 6.72-6.69 (m, 1H), 3.75 (s, 3H), 3.71 (s, 3H), 2.87-2.82
(m, 4H). 23 ##STR00086## 383.5 .sup.1H NMR (400 MHz, CD.sub.3OD)
.delta. 8.16 (s, 2H), 7.89 (s, 1H), 7.51 (s, 1H), 7.14 (d, J = 7.8
Hz, 2H), 6.90 (s, 1H), 3.84 (s, 3H), 3.79 (s, 6H), 2.90 (t, J = 6.8
Hz, 2H), 2.82 (t, J = 6.8 Hz, 2H). 24 ##STR00087## 383.1 .sup.1H
NMR (400 MHz, CD.sub.3OD) .delta. 8.16 (s, 2H), 7.42 (d, J = 2.0
Hz, 1H), 7.15 (s, 1H), 7.12 (s, 1H), 6.90 (s, 1H), 6.48 (d, J = 2.1
Hz, 1H), 3.81-3.76 (m, 9H), 2.89 (t, J = 6.9 Hz, 2H), 2.83 (t, J =
6.8 Hz, 2H). 25 ##STR00088## 385.1 .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. 8.13 (s, 2H), 7.87 (s, 1H), 7.50 (s, 1H), 7.40
(dd, J = 7.8 Hz, 2.1 Hz, 1H), 7.27 (dd, J = 5.9 Hz, 2.1 Hz, 1H),
3.88 (s, 3H), 3.84 (s, 3H), 2.93 (t, J = 7.3 Hz, 2H), 2.89 (s, 3H),
2.81 (t, J = 7.4 Hz, 2H). 26 ##STR00089## 396.0 .sup.1H NMR (400
MHz, CD.sub.3OD) .delta. 8.67 (d, J = 2.1 Hz, 1H), 8.19 (s, 2H),
8.07 (dd, J = 8.5 Hz, 2.7 Hz, 1H), 7.40 (dd, J = 7.8 Hz, 2.1 Hz,
1H), 7.26 (dd, J = 6.0 Hz, 2.2 Hz, 1H), 7.19 (d, J = 8.5 Hz, 1H),
3.87 (s, 3H), 2.95 (t, J = 7.5 Hz, 2H), 2.87 (s, 3H), 2.83 (t, J =
7.5 Hz, 2H), 2.45 (s, 3H). 27 ##STR00090## 398.9 .sup.1H NMR (400
MHz, CD.sub.3OD) .delta. 8.14 (s, 2H), 7.91 (s, 1H), 7.52 (s, 1H),
7.06 (s, 1H), 6.85 (s, 1H), 4.12 (q, J = 6.7 Hz, 2H), 3.74 (s, 3H),
2.99-2.91 (m, 2H), 2.87 (s, 3H), 2.84-2.75 (m, 2H), 1.43 (t, J =
6.6 Hz, 3H). 28 ##STR00091## 399.2 .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. 8.17 (s, 2H), 7.46-7.38 (m, 2H), 7.33- 7.22 (m,
2H), 4.02 (q, J = 6.9 Hz, 2H), 3.88 (s, 3H), 2.96-2.92 (m, 2H),
2.89 (s, 3H), 2.86-2.80 (m, 2H), 1.44 (t, J = 7.2 Hz, 3H). 29
##STR00092## 401.4 .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 8.13
(s, 2H), 7.87 (s, 1H), 7.50 (s, 1H), 7.35 (dd, J = 7.8 Hz, 2.0 Hz,
1H), 7.21 (dd, J = 6.0 Hz, 2.0 Hz, 1H), 3.89 (s, 3H), 3.84 (s, 3H),
3.78 (s, 3H), 2.94 (t, J = 7.3 Hz, 2H), 2.81 (t, J = 7.4 Hz, 2H).
30 ##STR00093## 411.9 .sup.1H NMR (400 MHz, CD.sub.3OD) .delta.
8.33 (d, J = 2.8 Hz, 1H), 8.16 (s, 2H), 7.94 (dd, J = 8.9 Hz, 2.8
Hz, 1H), 7.42 (dd, J = 7.8 Hz, 2.1 Hz, 1H), 7.29 (dd, J = 6.0 Hz,
2.1 Hz, 1H), 6.77 (d, J = 8.9 Hz, 1H), 3.91 (s, 3H), 3.90 (s, 3H),
2.96 (t, J = 7.4 Hz, 2H), 2.92 (s, 3H), 2.84 (t, J = 7.4 Hz, 2H).
31 ##STR00094## 425.1 .sup.1H NMR (400 MHz, CD.sub.3OD) .delta.
8.11 (s, 2H), 7.41 (dd, J = 7.6 Hz, 2.0 Hz, 1H), 7.27 (dd, J = 7.6
Hz, 2.0 Hz, 1H), 7.23 (d, J = 2.1 Hz, 1H), 6.89 (dd, J = 8.3 Hz,
2.0 Hz, 1H), 6.72 (d, J = 8.3 Hz, 1H), 5.90 (s, 2H), 3.89 (s, 3H),
2.95 (t, J = 7.5 Hz, 2H), 2.89 (s, 3H), 2.81 (t, J = 7.5 Hz, 2H).
32 ##STR00095## 429.2 .sup.1H NMR (400 MHz, CD.sub.3OD) .delta.
8.12 (s, 2H), 7.91 (s, 1H), 7.53 (s, 1H), 7.40 (dd, J = 7.8 Hz, 2.1
Hz, 1H), 7.26 (dd, J = 5.9 Hz, 2.1 Hz, 1H), 4.12-4.08 (m, 1H),
4.05-3.95 (m, 2H), 3.88 (s, 3H), 2.94 (t, J = 7.4 Hz, 2H), 2.88 (s,
3H), 2.81 (t, J = 7.3 Hz, 2H), 1.15 (d, J = 6.2 Hz, 3H). 33
##STR00096## 429.2 .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 8.12
(s, 2H), 7.90 (s, 1H), 7.53 (s, 1H), 7.40 (d, J = 7.6 Hz, 1H), 7.26
(d, J = 5.0 Hz, 1H), 4.15-4.06 (m, 1H), 4.05- 3.94 (m, 2H), 3.88
(s, 3H), 2.93 (t, J = 7.0 Hz, 2H), 2.88 (s, 3H), 2.80 (t, J = 7.1
Hz, 2H), 1.15 (d, J = 6.0 Hz, 3H). 34 ##STR00097## 436.1 .sup.1H
NMR (400 MHz, CD.sub.3OD) .delta. 8.22 (d, J = 2.1 Hz, 1H), 8.20
(s, 2H), 7.45 (d, J = 8.6 Hz, 1H), 7.40 (dd, J = 7.6 Hz, 2.1 Hz,
1H), 7.35 (dd, J = 8.6 Hz, 2.1 Hz, 1H), 7.27 (dd, J = 6.0 Hz, 2.1
Hz, 1H), 3.88 (s, 2H), 2.96 (t, J = 7.2 Hz, 2H), 2.87 (s, 3H), 2.84
(t, J = 7.2 Hz, 2H), 2.59 (s, 3H). 35 ##STR00098## 447.0 .sup.1H
NMR (400 MHz, CD.sub.3OD) .delta. 8.19 (s, 2H), 8.11 (d, J = 2.5
Hz, 1H), 7.77 (d, J = 9.2 Hz, 2H), 7.67-7.65 (m, 1H), 7.59 (d, J =
9.2 Hz, 2H), 7.40 (dd, J = 7.8 Hz, 2.1 Hz, 1H), 7.27 (dd, J = 6.0
Hz, 2.1 Hz, 1H), 6.49-6.48 (m, 1H), 3.88 (s, 3H), 2.96 (t, J = 7.3
Hz, 2H), 2.88 (s, 3H), 2.84 (t, J = 7.3 Hz, 2H). 36 ##STR00099##
453.0 .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 8.16 (s, 2H), 8.08
(s, 1H), 7.62 (s, 1H), 7.39 (s, 1H), 7.26 (s, 1H), 4.82-4.80 (m,
2H), 3.86 (s, 3H), 2.96-2.90 (m, 2H), 2.87 (s, 3H), 2.83-2.77 (m,
2H). 37 ##STR00100## 464.2 .sup.1H NMR (400 MHz, CD.sub.3OD)
.delta. 8.09 (s, 2H), 7.45-7.41 (m, 2H), 7.15 (s, 1H), 7.12 (s,
1H), 6.93-6.89 (m, 2H), 6.87 (s, 1H), 3.82-3.79 (m, 4H), 3.77 (s,
3H), 3.76 (s, 3H), 3.07-3.03 (m, 4H), 2.87 (t, J = 6.8 Hz, 3H),
2.78 (t, J = 6.8 Hz, 2H). 38 ##STR00101## 466.2 .sup.1H NMR (400
MHz, CD.sub.3OD) .delta. 8.19 (s, 2H), 7.44 (dd, J = 7.8 Hz, 2.1
Hz, 1H), 7.35 (t, J = 2.1 Hz, 1H), 7.31 (dd, J = 6.0 Hz, 2.1 Hz,
1H), 7.21-7.17 (m, 1H), 7.17-7.14 (m, 1H), 6.67- 6.65 (m, 1H), 3.92
(s, 2H), 3.88-3.85 (m, 4H), 3.17-3.15 (m, 4H), 2.98 (t, J = 7.5 Hz,
2H), 2.92 (s, 3H), 2.85 (t, J = 7.5 Hz, 2H). 39 ##STR00102## 489.3
.sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 8.09 (s, 2H), 7.44 (d, J
= 8.7 Hz, 2H), 7.24 (s, 1H), 7.20 (s, 1H), 6.95 (d, J = 8.9 Hz,
2H), 3.86 (s, 3H), 3.20-3.11 (m, 4H), 2.97-2.91 (m, 2H), 2.89 (s,
3H), 2.78-2.74 (m, 2H), 2.69-2.61 (m, 4H), 2.53-2.45 (m, 2H), 2.14
(s, 3H), 1.14 (t, J = 7.1 Hz, 3H). 40 ##STR00103## 491.2 .sup.1H
NMR (400 MHz, CD.sub.3OD) .delta. 8.12 (s, 2H), 7.45 (d, J = 9.0
Hz, 2H), 7.16- 7.13 (m, 2H), 6.97-6.90 (m, 3H), 3.78 (s, 3H), 3.78
(s, 3H), 3.53-3.46 (m, 2H), 3.14-3.04 (m, 1H), 2.93- 2.84 (m, 3H),
2.84-2.78 (m, 2H), 2.68-2.59 (m, 1H), 2.59-2.50 (m, 2H), 2.48 (s,
3H), 1.22 (d, J = 6.0 Hz, 3H). 41 ##STR00104## 491.2 .sup.1H NMR
(400 MHz, CD.sub.3OD) .delta. 8.13 (s, 2H), 7.50 (d, J = 8.9 Hz,
2H), 7.15 (s, 1H), 7.13 (s, 1H), 6.98 (d, J = 9.0 Hz, 2H), 6.92 (s,
1H), 3.80 (s, 3H), 3.78 (s, 3H), 3.76-3.71 (m, 2H), 3.53- 3.44 (m,
2H), 2.91 (t, J = 7.0 Hz, 2H), 2.85-2.79 (m, 2H), 2.68-2.58 (m,
2H), 1.37 (d, J = 6.6 Hz, 6H). 42 ##STR00105## 492.3 .sup.1H NMR
(400 MHz, CD.sub.3OD) .delta. 8.48 (s, 1H), 8.24 (s, 2H), 8.01 (d,
J = 7.0 Hz, 1H), 7.25 (s, 1H), 7.23 (s, 1H), 7.10-6.89 (m, 2H),
3.91-3.87 (m, 4H), 3.79 (s, 3H), 3.40 (s, 3H), 3.37- 3.24 (m, 4H),
3.17 (q, J = 7.0 Hz, 2H), 3.05-2.97 (m, 2H), 2.97-2.87 (m, 2H),
1.43 (t, J = 7.0 Hz, 3H). 43 ##STR00106## 492.5 .sup.1H NMR (400
MHz, CD.sub.3OD) .delta. 8.13 (s, 2H), 7.51 (d, J = 9.0 Hz, 2H),
7.17- 7.11 (m, 2H), 6.96 (d, J = 9.0 Hz, 2H), 6.93-6.90 (m, 1H),
4.29 (t, J = 8.0 Hz, 2H), 3.79 (s, 3H), 3.74 (s, 3H), 3.61 (t, J =
8.0 Hz, 2H), 3.49-3.39 (m, 4H), 2.91 (t, J = 7.0 Hz, 2H), 2.83 (t,
J = 7.0 Hz, 2H), 2.13-2.09 (m, 4H). 44 ##STR00107## 493.3 .sup.1H
NMR (400 MHz, CD.sub.3OD) .delta. 8.08 (s, 2H), 7.53-7.33 (m, 3H),
7.25 (d, J = 4.3 Hz, 1H), 6.93 (d, J = 8.9 Hz, 2H), 3.87 (s, 3H),
3.18-3.09 (m, 4H), 2.91 (t, J = 7.0 Hz, 2H), 2.87 (s, 3H), 2.78 (t,
J = 7.3 Hz, 2H), 2.69-2.59 (m, 4H), 2.48 (q, J = 7.1 Hz, 2H), 1.12
(t, J = 7.2 Hz, 3H). 45 ##STR00108## 497.3 .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. 8.13 (s, 2H), 7.96 (s, 1H), 7.52 (s, 1H), 7.40
(d, J = 7.7 Hz, 1H), 7.27 (d, J = 5.8 Hz, 1H), 4.21 (t, J = 6.5 Hz,
2H), 3.88 (s, 3H), 2.93 (t, J = 7.2 Hz, 2H), 2.88 (s, 3H),
2.82-2.78 (m, 4H), 2.62- 2.35 (m, 8H), 2.25 (s, 3H). 46
##STR00109## 501.2 .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 8.12
(s, 2H), 7.49 (d, J = 8.8 Hz, 2H), 7.19 (s, 1H), 7.18 (s, 1H), 6.97
(d, J = 8.8 Hz, 2H), 6.87 (s, 1H), 3.78 (s, 3H), 3.37-3.31 (m, 4H),
3.27-3.18 (m, 4H), 3.08 (q, J = 7.1 Hz, 2H), 2.94- 2.85 (m, 2H),
2.86-2.80 (m, 2H), 2.80-2.70 (m, 1H), 1.32 (t, J = 7.3 Hz, 3H),
0.86-0.71 (m, 2H), 0.69- 0.54 (m, 2H). 47 ##STR00110## 504.3
.sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 7.74 (s, 1H), 7.29 (d, J
= 8.3 Hz, 1H), 7.24 (d, J = 8.0 Hz, 2H), 7.15 (s, 1H), 7.13 (s,
1H), 6.93 (d, J = 8.1 Hz, 2H), 6.65 (d, J = 8.1 Hz, 1H), 3.83 (s,
3H), 3.77 (s, 3H), 3.20-3.08 (m, 4H), 2.94- 2.83 (m, 2H), 2.76-2.68
(m, 2H), 2.68-2.56 (m, 4H), 2.48 (q, J = 6.5 Hz, 2H), 2.12 (s, 3H),
1.13 (t, J = 6.6 Hz, 3H). 48 ##STR00111## 505.2 .sup.1H NMR (400
MHz, CD.sub.3OD) .delta. 8.12 (s, 2H), 7.45 (d, J = 8.8 Hz, 2H),
7.16 (s, 1H), 7.15 (s, 1H), 6.94 (d, J = 8.8 Hz, 2H), 6.91 (s, 1H),
3.80 (s, 3H), 3.79 (s, 3H), 3.46-3.38 (m, 2H), 3.04- 2.98 (m, 1H),
2.98-2.87 (m, 4H), 2.86-2.77 (m, 2H), 2.64-2.55 (m, 2H), 2.53-2.43
(m, 2H), 1.16 (d, J = 6.0 Hz, 3H), 1.11 (t, J = 7.2 Hz, 3H). 49
##STR00112## 505.3 .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 8.14
(s, 2H), 7.37-7.35 (m, 2H), 7.17 (s, H), 7.15 (s, 1H), 6.97 (d, J =
9.2 Hz, 1H), 6.91 (s, 1H), 3.80 (s, 3H), 3.79 (s, 3H), 3.08-2.99
(m, 2H), 2.96-2.87 (m, 4H), 2.86-2.80 (m, 2H), 2.34- 2.25 (m, 5H),
1.12 (d, J = 6.4 Hz, 6H). 50 ##STR00113## 505.3 .sup.1H NMR (400
MHz, CD.sub.3OD) .delta. 8.10 (s, 2H), 7.44 (d, J = 8.8 Hz, 2H),
7.15 (s, 1H), 7.14-7.08 (m, 1H), 6.93 (d, J = 8.9 Hz, 2H), 6.89 (s,
1H), 3.98 (q, J = 7.0 Hz, 2H), 3.78 (s, 3H), 3.19- 3.08 (m, 4H),
2.91-2.84 (m, 2H), 2.82-2.75 (m, 2H), 2.68-2.58 (m, 4H), 2.48 (q, J
= 7.1 Hz, 2H), 1.28 (t, J = 7.0 Hz, 3H), 1.13 (t, J = 7.2 Hz, 3H).
51 ##STR00114## 505.3 .sup.1H NMR (400 MHz, CD.sub.3OD) .delta.
8.10 (s, 2H), 7.47 (d, J = 8.8 Hz, 2H), 7.12 (s, 1H), 7.09 (s, 1H),
6.94 (d, J = 8.8 Hz, 2H), 6.86 (s, 1H), 4.00 (q, J = 7.0 Hz, 2H),
3.77 (s, 3H), 3.45-3.29 (m, 6H), 3.25-3.08 (m, 3H), 3.00-2.73 (m,
5H), 1.36-1.34 (m, 3H), 1.33- 1.32 (m, 3H). 52 ##STR00115## 505.4
.sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 8.08 (s, 2H), 7.44 (d, J
= 6.1 Hz, 2H), 7.18 (s, 1H), 7.13 (s, 1H), 6.94 (d, J = 5.5 Hz,
2H), 3.85 (s, 3H), 3.77 (s, 3H), 3.24-3.08 (m, 4H), 2.99-2.86 (m,
2H), 2.82-2.71 (m, 2H), 2.71-2.56 (m, 4H), 2.56-2.42 (m, 2H), 2.14
(s, 3H), 1.13 (t, J = 9.8 Hz, 3H). 53 ##STR00116## 507.2 .sup.1H
NMR (400 MHz, CD.sub.3OD) .delta. 8.09 (s, 2H), 7.43 (d, J = 8.8
Hz, 2H), 7.39 (s, 1H), 7.26 (d, J = 4.6 Hz, 1H), 6.93 (d, J = 8.8
Hz, 2H), 3.88 (s, 3H), 3.48- 3.36 (m, 2H), 3.06-2.91 (m, 4H), 2.88
(s, 3H), 2.86-2.73 (m, 3H), 2.67- 2.38 (m, 4H), 1.15 (d, J = 5.4
Hz, 3H), 1.10 (t, J = 6.8 Hz, 3H). 54 ##STR00117## 509.2 .sup.1H
NMR (400 MHz, CD.sub.3OD) .delta. 8.16 (s, 2H), 7.58 (dd, J = 15.0
Hz, 2.5 Hz, 1H), 7.22-7.18 (m, 1H), 7.16-7.15 (m, 1H), 7.13-7.12
(m, 1H), 6.97- 6.91 (t, J = 8.0 Hz, 1H), 6.89 (s, 1H), 3.78 (s,
3H), 3.77 (s, 3H), 3.24-3.16 (m, 2H), 3.07-2.98 (m, 2H), 2.92- 2.86
(m, 2H), 2.86-2.78 (m, 2H), 2.28 (t, J = 11.0 Hz, 2H), 1.10 (d, J =
6.5 Hz, 6H). 55 ##STR00118## 509.3 .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. 8.09 (s, 2H), 7.42 (d, J = 8.5 Hz, 2H), 7.33
(d, J = 7.2 Hz, 1H), 7.20 (d, J = 4.5 Hz, 1H), 6.92 (d, J = 8.5 Hz,
2H), 3.86 (s, 3H), 3.76 (s, 3H), 3.18-3.08 (m, 4H), 2.90 (t, J =
6.9 Hz, 2H), 2.78 (t, J = 7.2 Hz, 2H), 2.68-2.59 (m, 4H), 2.48 (q,
J = 6.9 Hz, 2H), 1.12 (t, J = 7.1 Hz, 3H). 56 ##STR00119## 509.2
.sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 8.09 (s, 2H), 7.58-7.20
(m, 4H), 6.93 (d, J = 8.5 Hz, 2H), 3.90 (s, 3H), 3.20- 3.09 (m,
4H), 3.02 (t, J = 7.3 Hz, 2H), 2.88 (s, 3H), 2.80 (t, J = 7.3 Hz,
2H), 2.69-2.59 (m, 4H), 2.48 (q, J = 7.1 Hz, 2H), 1.13 (t, J = 7.0
Hz, 3H). 57 ##STR00120## 519.3 .sup.1H NMR (400 MHz, CD.sub.3OD)
.delta. 8.08 (s, 2H), 7.42 (d, J = 8.9 Hz, 2H), 7.38 (d, J = 7.8
Hz, 1H), 7.24 (d, J = 4.1 Hz, 1H), 6.93 (d, J = 8.9 Hz, 2H), 3.86
(s, 3H), 3.18-3.09 (m, 4H), 3.06- 2.98 (m, 1H), 2.91 (t, J = 7.0
Hz, 2H), 2.80-2.75 (m, 2H), 2.67-2.59 (m, 4H), 2.47 (q, J = 7.2 Hz,
2H), 1.12 (t, J = 7.2 Hz, 3H), 0.81-0.72 (m, 2H), 0.64-0.57 (m,
2H). 58 ##STR00121## 519.3 .sup.1H NMR (400 MHz, CD.sub.3OD)
.delta. 8.10 (s, 2H), 7.44 (d, J = 6.5 Hz, 2H), 7.13 (s, 2H),
7.05-6.73 (m, 3H), 4.26- 4.08 (m, 1H), 3.78 (s, 3H), 3.23-3.04 (m,
4H), 2.95-2.75 (m, 4H), 2.74- 2.57 (m, 4H), 2.57-2.42 (m, 2H), 1.25
(d, J = 4.1 Hz, 6H), 1.13 (t, J = 12.3 Hz, 3H). 59 ##STR00122##
525.2 .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 8.10 (s, 2H), 7.43
(d, J = 8.1 Hz, 2H), 7.30 (s, 1H), 7.22 (s, 1H), 6.93 (d, J = 8.1
Hz, 2H), 3.90 (s, 3H), 3.76 (s, 3H), 3.20-3.09 (m, 4H), 3.09-2.96
(m, 2H), 2.86-2.73 (m, 2H), 2.71-2.58 (m, 4H), 2.48 (q, J = 6.8 Hz,
2H), 1.13 (t, J = 6.7 Hz, 3H). ##STR00123##
Example 7
Synthesis of Compounds 60-77
Compound 60
4-fluoro-3-methoxy-N-methyl-5-(2-(2-((2-methylpyridin-4-yl)amino)pyrimidin-
-5-yl)ethyl)benzamide
##STR00124##
[0215] (A) (E)-methyl
4-fluoro-3-methoxy-5-(2-(2-((2-methylpyridin-4-yl)amino)pyrimidin-5-yl)vi-
nyl)benzoate
[0216] To a solution of (E)-methyl
3-(2-(2-chloropyrimidin-5-yl)vinyl)-4-fluoro-5-methoxybenzoate (232
mg, 0.72 mmol) in 1,4-dioxane (12 mL) were added
2-methylpyridin-4-amine (93 mg, 0.86 mmol),
palladium(.quadrature.)acetate (16 mg, 0.072 mmol), Xantphos (83
mg, 0.14 mmol) and Cs.sub.2CO.sub.3 (703 mg, 2.16 mmol). Then the
mixture was stirred under microwave at 150.degree. C. for 20 min.
The mixture was then concentrated and purified via ISCO (eluted
with MeOH in DCM 0%.about.15%) directly to give a yellow solid (143
mg, 50.4% yield). MS (m/z): 395.1 (M+H).sup.+.
(B) Methyl
4-fluoro-3-methoxy-5-(2-(2-((2-methylpyridin-4-yl)amino)pyrimid-
in-5-yl)ethyl)benzoate
[0217] To a solution of (E)-methyl
4-fluoro-3-methoxy-5-(2-(2-((2-methylpyridin-4-yl)amino)pyrimidin-5-yl)vi-
nyl)benzoate (143 mg, 0.36 mmol) in a mixed solvent of MeOH/THF (10
mL/10 mL) was added Pd/C (10%, 50 mg). Then the mixture was purged
with hydrogen and stirred overnight at 35.degree. C. under hydrogen
atmosphere. After filtration, the filtrate was concentrated and the
residue (119 mg, 82.8% yield) was used directly in the next step
without further purification. MS (m/z): 397.1 (M+H).sup.+.
(C)
4-fluoro-3-methoxy-5-(2-(2-((2-methylpyridin-4-yl)amino)pyrimidin-5-yl-
)ethyl)benzoic acid
[0218] To a solution of methyl
4-fluoro-3-methoxy-5-(2-(2-((2-methylpyridin-4-yl)amino)pyrimidin-5-yl)et-
hyl)benzoate (119 mg, 0.30 mmol) in MeOH (10 mL) was added aqueous
NaOH (2 N, 4 mL, 8 mmol). Then the mixture was stirred overnight at
room temperature. After concentration, the residue was purified via
ISCO (eluted with MeOH in H.sub.2O 0%.about.100%) to give a yellow
solid (110 mg, 95.8% yield). MS (m/z): 383.1 (M+H).sup.+.
(D)
4-fluoro-3-methoxy-N-methyl-5-(2-(2-((2-methylpyridin-4-yl)amino)pyrim-
idin-5-yl)ethyl)benzamide
[0219] To a solution of
4-fluoro-3-methoxy-5-(2-(2-((2-methylpyridin-4-yl)amino)pyrimidin-5-yl)et-
hyl)benzoic acid (55 mg, 0.14 mmol) in DMF (5 mL) were added
methanamine hydrochloride (19 mg, 0.29 mmol), HATU (164 mg, 0.43
mmol) and DIPEA (74 mg, 0.58 mmol). The mixture was stirred for 2 h
at room temperature. Then the mixture was purified with ISCO
(eluted with MeOH in H.sub.2O 0.about.100%) directly to afford the
title compound as a yellow solid (17.5 mg, 30.8% yield). MS (m/z):
396.1 (M+H).sup.+. .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 8.29
(s, 2H), 8.13 (d, J=5.9 Hz, 1H), 7.61 (d, J=2.1 Hz, 1H), 7.59 (dd,
J=5.8 Hz, 2.3 Hz, 1H), 7.41 (dd, J=7.8 Hz, 2.1 Hz, 1H), 7.28 (dd,
J=6.0 Hz, 2.1 Hz, 1H), 3.88 (s, 3H), 2.98 (t, J=7.5 Hz, 3H),
2.91-2.86 (m, 5H), 2.45 (s, 3H).
[0220] The following compounds were prepared according to the
procedures of Compound 60 using the corresponding intermediates and
reagents under appropriate conditions that could be recognized by
one skilled in the art.
TABLE-US-00013 LC-MS Com- (m/z) pound Structure (M + H).sup.+
.sup.1H NMR 61 ##STR00125## 383.1 .sup.1H NMR (400 MHz, CD.sub.3OD)
.delta. 9.51 (s, 1H), 9.05-8.90 (m, 1H), 8.56 (s, 2H), 8.52-8.45
(m, 1H), 7.60 (dd, J = 7.8 Hz, 2.1 Hz, 1H), 7.48 (dd, J = 6.0 Hz,
2.1 Hz, 1H), 4.08 (s, 3H), 3.19 (t, J = 7.4 Hz, 2H), 3.11 (t, J =
7.4 Hz, 2H), 3.08 (s, 3H). 62 ##STR00126## 412.0 .sup.1H NMR (400
MHz, CD.sub.3OD) .delta. 8.28 (s, 2H), 7.86 (d, J = 5.9 Hz, 1H),
7.40 (dd, J = 7.7 Hz, 2.1 Hz, 1H), 7.38 (d, J = 1.9 Hz, 1H), 7.27
(dd, J = 5.9 Hz, 2.1 Hz, 1H), 7.15 (dd, J = 5.9 Hz, 2.1 Hz, 1H),
3.88 (s, 3H), 3.86 (s, 3H), 2.97 (t, J = 7.5 Hz, 2H), 2.99-2.85 (m,
5H). 63 ##STR00127## 411.9 .sup.1H NMR (400 MHz, CD.sub.3OD)
.delta. 8.63 (dd, J = 7.8 Hz, 1.6 Hz, 1H), 8.24 (s, 2H), 7.71 (dd,
J = 5.0 Hz, 1.7 Hz, 1H), 7.40 (dd, J = 7.8 Hz, 2.0 Hz, 1H), 7.27
(dd, J = 6.0 Hz, 2.0 Hz, 1H), 6.92 (dd, J = 7.8 Hz, 5.0 Hz, 1H),
4.01 (s, 3H), 3.88 (s, 3H), 2.97 (t, J = 7.4 Hz, 2H), 2.88 (s, 3H),
2.86 (t, J = 7.4 Hz, 2H). 65 ##STR00128## 419.1 .sup.1H NMR (400
MHz, CD.sub.3OD) .delta. 9.19 (s, 1H), 8.16 (s, 2H), 7.70 (s, 1H),
7.40 (s, 1H), 7.36 (d, J = 9.6 Hz, 1H), 7.22 (dd, J = 9.6 Hz, 2.0
Hz, 1H), 7.11 (s, 1H), 7.07 (dd, J = 2.4 Hz, 1.4 Hz, 1H), 6.68 (dd,
J = 2.2 Hz, 1.4 Hz, 1H), 3.68 (s, 3H), 3.64 (s, 3H), 2.83-2.76 (m,
4H). 66 ##STR00129## 421.1 .sup.1H NMR (400 MHz, CD.sub.3OD)
.delta. 8.73-8.62 (m, 1H), 8.53- 8.43 (m, 1H), 8.36 (s, 2H),
7.94-7.80 (m, 1H), 7.75- 7.59 (m, 1H), 7.41 (dd, J = 7.8 Hz, 2.1
Hz, 1H), 7.33 (d, J = 7.2 Hz, 1H), 7.29 (dd, J = 5.9 Hz, 2.0 Hz,
1H), 3.88 (s, 3H), 3.01 (t, J = 6.7 Hz, 2H), 2.95-2.90 (t, J = 6.7
Hz, 2H), 2.89 (s, 3H). 67 ##STR00130## 422 .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. 9.72 (dd, J = 1.9 Hz, 0.8 Hz, 1H), 8.29 (s,
1H), 8.28 (s, 2H), 7.70 (dd, J = 9.5 Hz, 2.0 Hz, 1H), 7.66 (dd, J =
9.5 Hz, 0.7 Hz, 1H), 7.40 (dd, J = 7.8 Hz, 2.1 Hz, 1H), 7.28 (dd, J
= 6.0 Hz, 2.1 Hz, 1H), 3.87 (s, 3H), 2.97 (t, J = 7.4 Hz, 2H),
2.89-2.85 (m, 5H). 68 ##STR00131## 422.1 .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. 8.93 (d, J = 0.7 Hz, 1H), 8.51-8.47 (m, 1H),
8.32 (s, 2H), 8.30-8.28 (m, 1H), 7.40 (dd, J = 7.7 Hz, 2.0 Hz, 1H),
7.28 (dd, J = 6.0 Hz, 2.0 Hz, 1H), 7.08 (dd, J = 7.5 Hz, 2.0 Hz,
1H), 3.87 (s, 3H), 2.98 (t, J = 7.3 Hz, 2H), 2.91-2.86 (m, 5H). 69
##STR00132## 436.1 .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 9.59
(dd, J = 2.0 Hz, 0.7 Hz, 1H), 8.26 (s, 2H), 7.65 (dd, J = 9.5 Hz,
2.1 Hz, 1H), 7.54 (dd, J = 9.5 Hz, 0.6 Hz, 1H), 7.40 (dd, J = 7.8
Hz, 2.1 Hz, 1H), 7.27 (dd, J = 6.0 Hz, 2.1 Hz, 1H), 3.87 (s, 3H),
2.97 (t, J = 7.1 Hz, 2H), 2.89-2.84 (m, 5H), 2.49 (s, 3H). 70
##STR00133## 436.1 .sup.1H NMR (400 MHz, CD.sub.3OD) .delta.
8.37-8.34 (m, 1H), 8.24 (s, 2H), 8.03 (d, J = 7.5 Hz, 1H), 7.32
(dd, J = 7.8 Hz, 2.0 Hz, 1H), 7.20 (dd, J = 5.9 Hz, 2.0 Hz, 1H),
7.01 (dd, J = 7.5 Hz, 2.0 Hz, 1H), 3.79 (s, 3H), 2.90 (t, J = 7.3
Hz, 2H), 2.83-2.79 (m, 5H), 2.59 (s, 3H). 71 ##STR00134## 444.2
.sup.1H NMR (400 MHz, DMSO- d6) .delta. 11.39 (br s, 1H), 8.45 (br
s, 1H), 8.42 (s, 2H), 7.44 (s, 1H), 7.42 (s, 1H), 6.62 (s, 1H),
3.89 (s, 3H), 3.03 (t, J = 7.5 Hz, 2H), 2.85 (t, J = 7.6 Hz, 2H),
2.79 (d, J = 3.4 Hz, 3H), 2.01-1.89 (m, 1H), 0.86- 0.73 (m, 4H). 72
##STR00135## 466.1 .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 9.68
(d, J = 1.3 Hz, 1H), 8.22 (s, 2H), 7.61 (d, J = 9.4 Hz, 1H), 7.36
(dd, J = 9.5 Hz, 2.1 Hz, 1H), 7.33 (dd, J = 7.7 Hz, 1.9 Hz, 1H),
7.08 (dd, J = 5.8 Hz, 1.9 Hz, 1H), 4.74 (s, 2H), 3.91 (s, 3H), 3.54
(s, 3H), 2.98 (s, 3H), 2.97-2.93 (t, J = 7.3 Hz, 2H), 2.87-2.82 (t,
J = 7.3 Hz, 2H). 73 ##STR00136## 466.1 .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. 8.44 (dd, J = 2.0 Hz, 0.8 Hz, 1H), 8.25 (s,
2H), 8.18 (dd, J = 7.5 Hz, 0.8 Hz, 1H), 7.33 (dd, J = 7.8 Hz, 2.1
Hz, 1H), 7.20 (dd, J = 6.0 Hz, 2.2 Hz, 1H), 7.05 (dd, J = 7.5 Hz,
2.1 Hz, 1H), 4.84 (s, 2H), 3.80 (s, 3H), 3.31 (s, 3H), 2.94-2.89
(t, J = 7.0 Hz, 2H), 2.83 (t, J = 7.0 Hz, 2H), 2.80 (s, 3H). 74
##STR00137## 490.3 .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 7.74
(s, 1H), 7.31 (dd, J = 8.5 Hz, 2.0 Hz, 1H), 7.25 (d, J = 8.7 Hz,
2H), 7.16- 7.09 (m, 2H), 6.92 (d, J = 8.2 Hz, 2H), 6.86 (s, 1H),
6.65 (d, J = 8.5 Hz, 1H), 3.77 (s, 3H), 3.76 (s, 3H), 3.19-3.08 (m,
4H), 2.90- 2.83 (m, 2H), 2.82-2.74 (m, 2H), 2.69-2.60 (m, 4H), 2.50
(q, J = 7.2 Hz, 2H), 1.13 (t, J = 7.2 Hz, 3H). 75 ##STR00138##
491.3 .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 8.27 (s, 1H),
7.86-7.68 (m, 2H), 7.38 (d, J = 8.4 Hz, 1H), 7.13 (s, 1H), 7.10 (s,
1H), 6.92-6.83 (m, 2H), 6.76-6.59 (m, 1H), 3.77 (s, 3H), 3.76 (s,
3H), 3.76-3.64 (m, 4H), 3.38-3.29 (m, 4H), 3.20 (q, J = 7.1 Hz,
2H), 2.89-2.76 (m, 4H), 1.34 (t, J = 7.0 Hz, 3H). 76 ##STR00139##
492.3 .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 8.28 (s, 2H), 7.86
(d, J = 5.9 Hz, 1H), 7.35 (d, J = 1.7 Hz, 1H), 7.20 (t, J = 1.4 Hz,
1H), 7.15 (dd, J = 2.5 Hz, 1.3 Hz, 1H), 7.01 (dd, J = 5.9 Hz, 1.8
Hz, 1H), 6.62 (dd, J = 2.4 Hz, 1.6 Hz, 1H), 3.74 (s, 3H), 3.69 (s,
3H), 3.50-3.46 (m, 4H), 2.86 (m, 4H), 2.61-2.57 (m, 4H), 2.48 (q, J
= 7.3 Hz, 2H), 1.14 (t, J = 7.2 Hz, 3H). 77 ##STR00140## 509.2
.sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 8.20 (s, 2H), 7.19 (s,
1H), 7.16-7.09 (m, 2H), 6.96 (s, 1H), 6.70 (s, 1H), 6.29 (dt, J =
11.9 Hz, 2.0 Hz, 1H), 3.75 (s, 3H), 3.71 (s, 3H), 3.22-3.17 (t, J =
4.9 Hz, 4H), 2.84 (m, 4H), 2.62-2.58 (t, J = 4.9 Hz, 4H), 2.47 (q,
J = 7.2 Hz, 2H), 1.12 (t, J = 7.2 Hz, 3H).
Example 8
Synthesis of Compounds 78
Compound 78
4-((5-(2-fluoro-3-methoxy-5-(methylcarbamoyl)phenethyl)pyrimidin-2-yl)amin-
o)-2-methylpyridine 1-oxide
##STR00141##
[0221]
4-((5-(2-fluoro-3-methoxy-5-(methylcarbamoyl)phenethyl)pyrimidin-2--
yl)amino)-2-methylpyridine 1-oxide
[0222] To a solution of
4-fluoro-3-methoxy-N-methyl-5-(2-(2-((2-methylpyridin-4-yl)amino)pyrimidi-
n-5-yl)ethyl)benzamide (18 mg, 0.046 mmol) in DCM (6 mL) was added
3-chlorobenzoperoxoic acid (8 mg, 0.046 mmol) in one portion. The
resulting mixture was stirred for 2 h at 0.degree. C. Then the
reaction mixture was diluted with DCM and washed with 10% aqueous
K.sub.2CO.sub.3 solution. After removal of the solvent, the residue
was purified via PTLC (DCM/MeOH=20:1) to afford the title compound
as a yellow solid (6.7 mg, 35.8% yield). MS (m/z): 412.1
(M+H).sup.+. .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 8.30 (s,
2H), 8.12 (d, J=7.3 Hz, 1H), 7.89 (d, J=3.1 Hz, 1H), 7.80 (dd,
J=7.3 Hz, 3.1 Hz, 1H), 7.40 (dd, J=7.8 Hz, 2.1 Hz, 1H), 7.27 (dd,
J=6.0 Hz, 2.1 Hz, 1H), 3.87 (s, 3H), 2.97 (t, J=7.3 Hz, 2H),
2.91-2.85 (m, 5H), 2.49 (s, 3H).
Example 9
Synthesis of Compounds 79-91, 146-155
Compound 79
4-chloro-3-(2-(2-((4-((3S,5R)-3,5-dimethylpiperazin-1-yl)phenyl)amino)pyri-
midin-5-yl)ethyl)-5-methoxy-N-methylbenzamide
##STR00142##
[0223] (A) Methyl
4-chloro-3-((E)-2-(2-(4-((3S,5R)-3,5-dimethylpiperazin-1-yl)phenylamino)p-
yrimidin-5-yl)vinyl)-5-methoxybenzoate
[0224] A mixture of (E)-methyl
4-chloro-3-(2-(2-chloropyrimidin-5-yl)vinyl)-5-methoxybenzoate (150
mg, 0.442 mmol), 4-((3S,5R)-3,5-dimethylpiperazin-1-yl)aniline (109
mg, 0.531 mmol) and TFA (0.1 mL, 1.326 mmol) in propan-2-ol (5 mL)
was stirred at 150.degree. C. for 1 h under microwave. The
resulting mixture was concentrated, basified with ammonia water,
purified via ISCO (DCM/MeOH) to afford the title compound as a
yellow solid (130 mg, 57.9% yield). MS (m/z): 508.2
(M+H).sup.+.
(B)
4-chloro-3-((E)-2-(2-(4-((3S,5R)-3,5-dimethylpiperazin-1-yl)phenylamin-
o)pyrimidin-5-yl)vinyl)-5-methoxy-N-methylbenzamide
[0225] A mixture of methyl
4-chloro-3-((E)-2-(2-(4-((3S,5R)-3,5-dimethylpiperazin-1-yl)phenylamino)p-
yrimidin-5-yl)vinyl)-5-methoxybenzoate (250 mg, 0.492 mmol) and
methylamine (6 mL, 35% solution in ethanol) was stirred at
145.degree. C. for 22 min under microwave. The resulting mixture
was concentrated, purified via ISCO (DCM/MeOH) to afford the title
compound as a yellow solid (145 mg, 58.1% yield). MS (m/z): 506.9
(M+H).sup.+.
(C)
4-chloro-3-(2-(2-(4-((3S,5R)-3,5-dimethylpiperazin-1-yl)phenylamino)py-
rimidin-5-yl)ethyl)-5-methoxy-N-methylbenzamide
[0226] A mixture of
4-chloro-3-((E)-2-(2-(4-((3S,5R)-3,5-dimethylpiperazin-1-yl)phenylamino)p-
yrimidin-5-yl)vinyl)-5-methoxy-N-methylbenzamide (120 mg, 0.237
mmol), 4-methylbenzenesulfonohydrazide (528 mg, 2.84 mmol) and
sodium acetate (233 mg, 2.84 mmol) in THF (6 mL) and water (6 mL)
was stirred overnight at 100.degree. C. under nitrogen atmosphere.
The resulting mixture was concentrated. The residue was partitioned
between 2N HCl (15 mL) and EA (15 mL). The aqueous layer was then
adjusted to pH=8 with 30% NaOH and extracted with DCM (2*15 mL).
The combined extracts were concentrated and the residue was
purified via ISCO (eluted with MeOH in H.sub.2O 0.about.100%) to
afford the title compound as a yellow solid (50 mg, 41.5% yield).
MS (m/z): 509.0 (M+H).sup.+. .sup.1H NMR (400 MHz, CD.sub.3OD)
.delta. 8.11 (s, 2H), 7.44 (d, J=9.1 Hz, 2H), 7.37 (d, J=2.0 Hz,
1H), 7.30 (d, J=2.0 Hz, 1H), 6.95 (d, J=9.1 Hz, 2H), 3.93 (s, 3H),
3.53-3.44 (m, 2H), 3.10-2.99 (m, 4H), 2.90 (s, 3H), 2.82 (t, J=7.6
Hz, 2H), 2.25 (t, J=7.5 Hz, 2H), 1.16 (d, J=6.4 Hz, 6H).
[0227] The following compounds were prepared according to the
procedures of Compound 79 using the corresponding intermediates and
reagents under appropriate conditions that could be recognized by
one skilled in the art.
TABLE-US-00014 LC-MS Com- (m/z) pound Structure (M + H).sup.+
.sup.1H NMR 80 ##STR00143## 433.2 .sup.1H NMR (400 MHz, CD.sub.3OD)
.delta. 8.13 (s, 2H), 7.90 (s, 1H), 7.52 (s, 1H), 7.26 (d, J = 5.5
Hz, 1H), 4.13 (q, J = 7.2 Hz, 2H), 3.88 (s, 3H), 3.10 (t, J = 6.9
Hz, 2H), 2.90 (s, 3H), 2.79 (t, J = 7.0 Hz, 2H), 1.43 (t, J = 7.3
Hz, 3H). 81 ##STR00144## 441.0 .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. 8.16 (s, 2H), 7.91 (s, 1H), 7.43 (s, 1H), 7.28 (s, 1H),
7.23 (s, 1H), 7.03 (s, 1H), 4.77-4.69 (m, 1H), 3.95 (s, 3H), 3.01
(t, J = 7.6 Hz, 2H), 2.97 (d, J = 4.7 Hz, 3H), 2.79 (t, J = 7.6 Hz,
2H), 2.62-2.40 (m, 4H), 1.92-1.83 (m, 2H). 82 ##STR00145## 445.3
.sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 8.13 (s, 2H), 7.91 (s,
1H), 7.54 (s, 1H), 7.36 (d, J = 1.9 Hz, 1H), 7.30 (d, J = 1.9 Hz,
1H), 4.14-4.06 (m, 1H), 4.05-3.96 (m, 2H), 3.92 (s, 3H), 3.05 (t, J
= 7.6 Hz, 2H), 2.89 (s, 3H), 2.82 (t, J = 7.6 Hz, 2H), 1.15 (d, J =
6.2 Hz, 3H). 83 ##STR00146## 458.9 460.9 .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. 8.15 (s, 2H), 7.91 (s, 1H), 7.52 (s, 1H), 7.30
(s, 1H), 7.29 (s, 1H), 4.12 (q, J = 6.8 Hz, 2H), 3.91 (s, 3H),
3.12- 3.02 (m, 2H), 2.89 (s, 3H), 2.81 (t, J = 9.1 Hz, 2H), 1.43
(t, J = 6.9 Hz, 3H). 84 ##STR00147## 464.9 .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. 8.22 (s, 2H), 8.09 (s, 1H), 7.51 (d, J = 9.0
Hz, 1H), 7.38 (d, J = 1.9 Hz, 1H), 7.32 (d, J = 1.9 Hz, 1H), 7.06
(dd, J = 9.0 Hz, 1.8 Hz, 1H), 4.02 (s, 3H), 3.93 (s, 3H), 3.08 (t,
J = 7.2 Hz, 2H), 2.89 (s, 3H), 2.86 (t, J = 7.2 Hz, 2H), 2.59 (s,
3H). 85 ##STR00148## 481.8 .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. 8.09 (s, 2H), 7.39 (d, J = 7.5 Hz, 2H), 7.22 (d, J = 1.8
Hz, 1H), 6.99 (s, 1H), 6.93 (d, J = 1.8 Hz, 1H), 6.85 (s, 2H), 5.95
(s, 1H), 3.89 (s, 3H), 3.82-3.78 (m, 4H), 3.07-3.03 (m, 4H), 2.97-
2.92 (m, 2H), 2.90 (d, J = 4.8 Hz, 3H), 2.78-2.72 (m, 2H). 86
##STR00149## 485.9 .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 8.15
(s, 2H), 7.97 (s, 1H), 7.54 (s, 1H), 7.37 (d, J = 1.8 Hz, 1H), 7.31
(d, J = 1.8 Hz, 1H), 4.19 (t, J = 7.0 Hz, 2H), 3.92 (s, 3H), 3.06
(t, J = 7.6 Hz, 2H), 2.93-2.87 (m, 5H), 2.83 (t, J = 7.5 Hz, 2H),
2.58 (q, J = 7.1 Hz, 4H), 1.04 (t, J = 7.1 Hz, 6H). 87 ##STR00150##
491.2 .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.55 (s, 2H), 7.47
(d, J = 8.9 Hz, 2H), 7.34 (dd, J = 7.9 Hz, 1.9 Hz, 1H), 7.14 (d, J
= 16.6 Hz, 1H), 7.08 (s, 1H), 7.02 (d, J = 16.5 Hz, 1H), 6.95 (d, J
= 8.7 Hz, 2H), 6.14 (s, 1H), 3.95 (s, 3H), 3.24-3.16 (m, 4H), 3.04
(d, J = 4.9 Hz, 3H), 2.66-2.59 (m, 4H), 2.49 (q, J = 7.1 Hz, 2H),
1.14 (t, J = 7.2 Hz, 3H). 88 ##STR00151## 500.0 .sup.1H NMR (400
MHz, CD.sub.3OD) .delta. 8.15 (s, 2H), 7.95 (s, 1H), 7.53 (s, 1H),
7.37 (d, J = 1.9 Hz, 1H), 7.31 (d, J = 1.9 Hz, 1H), 4.12 (t, J =
6.7 Hz, 2H), 3.92 (s, 3H), 3.05 (t, J = 7.6 Hz, 2H), 2.90 (s, 3H),
2.82 (t, J = 7.6 Hz, 2H), 2.55 (q, J = 7.2 Hz, 4H), 2.51-2.42 (m,
2H), 2.06-1.93 (m, 2H), 1.01 (t, J = 7.2 Hz, 6H). 89 ##STR00152##
513.0 .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 8.15 (s, 2H), 7.97
(s, 1H), 7.53 (s, 1H), 7.36 (s, 1H), 7.30 (s, 1H), 4.21 (t, J = 6.6
Hz, 2H), 3.92 (s, 3H), 3.05 (t, J = 7.6 Hz, 2H), 2.89 (s, 3H),
2.89-2.78 (m, 4H), 2.62-2.40 (m, 8H), 2.26 (s, 3H). 90 ##STR00153##
523.3 .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 8.23 (s, 2H), 7.77
(d, J = 8.8 Hz, 2H), 7.38-7.35 (m, 3H), 7.31 (d, J = 2.0 Hz, 1H),
3.93 (s, 3H), 3.79-3.54 (m, 4H), 3.08 (t, J = 7.6 Hz, 2H), 2.89-
2.85 (m, 5H), 2.53-2.41 (m, 4H), 2.32 (s, 3H). 91 ##STR00154##
527.3 .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 8.01 (s, 2H), 7.34
(d, J = 8.5 Hz, 2H), 7.18 (d, J = 6.2 Hz, 1H), 6.85 (d, J = 8.6 Hz,
2H), 3.80 (s, 3H), 3.43-3.32 (m, 2H), 3.02 (t, J = 7.2 Hz, 2H),
2.96-2.87 (m, 2H), 2.81 (s, 3H), 2.70 (t, J = 7.4 Hz, 2H), 2.15 (t,
J = 11.0 Hz, 2H), 1.05 (d, J = 6.4 Hz, 6H). 146 ##STR00155## 401.1
.sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 8.17 (s, 2H), 7.87 (s,
1H), 7.52 (s, 1H), 7.37 (s, 1H), 7.31 (s, 1H), 3.94 (s, 3H), 3.86
(s, 3H), 3.09-3.02 (m, 2H), 2.92 (s, 3H), 3.86-2.80 (m, 2H). 147
##STR00156## 414.9 .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 8.15
(s, 2H), 7.88 (s, 1H), 7.50 (s, 1H), 7.37 (s, 1H), 7.30 (s, 1H),
3.93 (s, 3H), 3.84 (s, 3H), 3.38 (q, J = 6.5 Hz, 2H), 3.10-3.01 (m,
2H), 2.87-2.77 (m, 2H), 1.20 (t, J = 6.8 Hz, 3H). 148 ##STR00157##
431.0 .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 8.13 (s, 2H), 7.93
(s, 1H), 7.54 (s, 1H), 7.36 (d, J = 1.8 Hz, 1H), 7.29 (d, J = 1.9
Hz, 1H), 4.16 (t, J = 5.4 Hz, 2H), 3.91 (s, 3H), 3.86 (t, J = 5.2
Hz, 2H), 3.04 (t, J = 7.6 Hz, 2H), 2.89 (s, 3H), 2.81 (t, J = 7.6
Hz, 2H). 149 ##STR00158## 436.9 .sup.1H NMR (400 MHz, CD.sub.3OD)
.delta. 8.33 (s, 1H), 8.22 (s, 2H), 7.76 (s, 1H), 7.38 (t, J = 59.8
Hz, 1H), 7.37 (d, J = 2.0 Hz, 1H), 7.31 (d, J = 1.6 Hz, 1H), 3.93
(s, 3H), 3.07 (t, J = 7.6 Hz, 2H), 2.89 (s, 3H), 2.85 (t, J = 7.6
Hz, 2H). 150 ##STR00159## 445.2 .sup.1H NMR (400 MHz, CD.sub.3OD)
.delta. 8.13 (s, 2H), 7.93 (s, 1H), 7.54 (s, 1H), 7.36 (s, 1H),
7.30 (s, 1H), 4.19-3.97 (m, 3H), 3.91 (s, 3H), 3.04 (t, J = 7.0 Hz,
2H), 2.89 (s, 3H), 2.81 (d, J = 7.0 Hz, 2H), 1.15 (d, J = 5.2 Hz,
3H). 151 ##STR00160## 463.9 .sup.1H NMR (400 MHz, CD.sub.3OD)
.delta. 8.86 (s, 1H), 8.38 (s, 1H), 8.21 (s, 2H), 7.93-7.80 (m,
3H), 7.33 (s, 1H), 7.29 (s, 1H), 7.23-7.16 (m, 1H), 3.91 (s, 3H),
3.09-2.98 (m, 2H), 2.89 (s, 3H), 2.87-2.77 (m, 2H). 152
##STR00161## 477.9 .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 8.82
(s, 1H), 8.55 (s, 1H), 8.24 (s, 2H), 8.05 (d, J = 6.9 Hz, 1H), 7.85
(s, 1H), 7.40 (d, J = 7.2 Hz, 1H), 7.38 (s, 1H), 7.33 (s, 1H), 3.94
(s, 3H), 3.08 (t, J = 7.8 Hz, 2H), 2.92 (s, 3H), 2.89-2.83 (m, 2H),
2.58 (s, 3H). 153 ##STR00162## 492.9 .sup.1H NMR (400 MHz, DMSO-
d6) .delta. 9.33 (s, 1H), 8.47 (s, 1H), 8.23 (s, 2H), 7.97 (s, 1H),
7.51 (s, 1H), 7.42 (s, 1H), 7.40 (s, 1H), 4.47 (t, J = 6.9 Hz, 2H),
3.87 (s, 3H), 3.64 (t, J = 6.5 Hz, 2H), 2.97 (t, J = 7.4 Hz, 2H),
2.83 (s, 3H), 2.78- 2.71 (m, 5H). 154 ##STR00163## 498.0 .sup.1H
NMR (400 MHz, CD.sub.3OD) .delta. 8.15 (s, 2H), 7.98 (s, 1H), 7.55
(s, 1H), 7.37 (d, J = 1.9 Hz, 1H), 7.30 (d, J = 1.9 Hz, 1H), 4.07
(d, J = 6.9 Hz, 2H), 3.93 (s, 3H), 3.06 (t, J = 7.5 Hz, 2H), 2.90
(s, 3H), 2.84 (t, J = 7.5 Hz, 2H), 2.79 (s, 3H), 2.20-2.16 (m, 2H),
2.08- 1.99 (m, 1H), 1.86-1.82 (m, 2H), 1.60-1.46 (m, 4H). 155
##STR00164## 511.9 .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 8.16
(s, 2H), 7.92 (s, 1H), 7.54 (s, 1H), 7.37 (d, J = 1.9 Hz, 1H), 7.31
(d, J = 1.9 Hz, 1H), 3.98 (d, J = 7.2 Hz, 2H), 3.93 (s, 3H), 3.06
(t, J = 7.6 Hz, 2H), 2.98-2.92 (m, 2H), 2.90 (s, 3H), 2.83 (t, J =
7.6 Hz, 2H), 2.42 (q, J = 7.4 Hz, 2H), 2.02-1.90 (m, 3H), 1.64-1.56
(m, 2H), 1.37-1.34 (m, 2H), 1.08 (t, J = 7.4 Hz, 3H).
##STR00165##
Example 10
Synthesis of Compounds 92-99
Compound 92
4-fluoro-3-methoxy-N-methyl-5-(2-(2-((5-(morpholinomethyl)pyridin-2-yl)ami-
no)pyrimidin-5-yl)ethyl)benzamide
##STR00166##
[0228] (A) Methyl
3-(2-(2-aminopyrimidin-5-yl)ethyl)-4-fluoro-5-methoxybenzoate
[0229] To a solution of (E)-methyl
3-(2-(2-aminopyrimidin-5-yl)vinyl)-4-fluoro-5-methoxybenzoate (0.26
g, 0.86 mmol) in THF (40 mL) was added Pd/C (10%, 0.14 g). The
mixture was stirred at 35.degree. C. for 48 h under hydrogen (1
atm). The mixture was filtered and the filtrate was concentrated.
The residue was then purified via ISCO (eluted with MeOH in
H.sub.2O 0.about.100%) to afford the title compound as a yellow
solid (0.11 g, 42.0% yield). MS (m/z): 306.1 (M+H).sup.+.
(B) Methyl
4-fluoro-3-methoxy-5-(2-(2-((5-(morpholinomethyl)pyridin-2-yl)a-
mino)pyrimidin-5-yl)ethyl)benzoate
[0230] A mixture of methyl
3-(2-(2-aminopyrimidin-5-yl)ethyl)-4-fluoro-5-methoxybenzoate (0.09
g, 0.30 mmol), 4-((6-bromopyridin-3-yl)methyl)morpholine (0.12 g,
0.47 mmol), Cs.sub.2CO.sub.3 (0.20 g, 0.62 mmol),
palladium(0)acetate (0.02 g, 0.089 mmol) and Xantphos (0.02 g,
0.035 mmol) in dioxane (6 mL) was heated at 130.degree. C. under
microwave for 15 min. Then the mixture was concentrated and the
residue was purified via ISCO (eluted with MeOH in H.sub.2O
0.about.100%) to afford the title compound as a yellow solid (0.06
g, 42.3% yield). MS (m/z): 482.3 (M+H).sup.+.
(C)
4-fluoro-3-methoxy-5-(2-(2-((5-(morpholinomethyl)pyridin-2-yl)amino)py-
rimidin-5-yl)ethyl)benzoic acid
[0231] A mixture of methyl
4-fluoro-3-methoxy-5-(2-(2-((5-(morpholinomethyl)pyridin-2-yl)amino)pyrim-
idin-5-yl)ethyl)benzoate (0.06 g, 0.12 mmol) in THF (4 mL) and
aqueous LiOH solution (0.02 g in 1 mL H.sub.2O) was stirred at
40.degree. C. for 2 h. Then the reaction mixture was purified via
ISCO (eluted with MeOH in H.sub.2O 0.about.100%) directly to afford
the title compound as a yellow solid (0.042 g, 72.1% yield). MS
(m/z): 468.2 (M+H).sup.+.
(D)
4-fluoro-3-methoxy-N-methyl-5-(2-(2-((5-(morpholinomethyl)pyridin-2-yl-
)amino)pyrimidin-5-yl)ethyl)benzamide
[0232] A mixture of
4-fluoro-3-methoxy-5-(2-(2-((5-(morpholinomethyl)pyridin-2-yl)amino)pyrim-
idin-5-yl)ethyl)benzoic acid (0.042 g, 0.090 mmol), methylamine
hydrochloride (0.010 g, 0.15 mmol), DIPEA (0.032 g, 0.25 mmol) and
HATU (0.070 g, 0.18 mmol) in DMF (8 mL) was stirred at room
temperature for 0.5 h. Then the reaction mixture was purified via
ISCO (eluted with MeOH in H.sub.2O 0.about.100%) directly to afford
the title compound as a yellow solid (0.015 g, 34.7% yield). MS
(m/z): 481.2 (M+H).sup.+. .sup.1H NMR (400 MHz, CD.sub.3OD) .delta.
8.30 (s, 2H), 8.17 (s, 1H), 7.73 (s, 1H), 7.72 (s, 1H), 7.42 (d,
J=7.2 Hz, 1H), 7.30 (d, J=7.1 Hz, 1H), 3.91 (s, 3H), 3.80-3.66 (m,
4H), 3.54-3.47 (m, 2H), 3.00 (t, J=9.1 Hz, 2H), 2.92 (s, 3H),
2.91-2.82 (m, 2H), 2.57-2.40 (m, 4H).
[0233] The following compounds were prepared according to the
procedures of Compound 92 using the corresponding intermediates and
reagents under appropriate conditions that could be recognized by
one skilled in the art.
TABLE-US-00015 LC- MS (m/z) Com- (M + pound Structure H).sup.+
.sup.1H NMR 93 ##STR00167## 412.0 .sup.1H NMR (400 MHz, CD.sub.3OD)
.delta. 8.29 (s, 2H), 7.46 (d, J = 7.5 Hz, 1H), 7.40 (dd, J = 7.8
Hz, 2.0 Hz, 1H), 7.30 (d, J = 2.4 Hz, 1H), 7.27 (dd, J = 5.9 Hz,
2.0 Hz, 1H), 6.64 (dd, J = 7.5 Hz, 2.4 Hz, 1H), 3.88 (s, 3H), 3.48
(s, 3H), 2.97 (t, J = 7.2 Hz, 2H), 2.88 (s, 3H), 2.87 (t, J = 7.2
Hz, 2H). 94 ##STR00168## 422.0 .sup.1H NMR (400 MHz, CD.sub.3OD)
.delta. 9.74 (s, 1H), 8.60 (s, 1H), 8.27 (s, 2H), 8.03 (s, 1H),
7.41 (d, J = 7.7 Hz, 1H), 7.29 (d, J = 4.3 Hz, 1H), 6.63 (s, 1H),
3.89 (s, 3H), 2.98 (t, J = 7.3 Hz, 2H), 2.92- 2.84 (m, 5H). 95
##STR00169## 421.9 .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 9.72
(s, 1H), 8.30 (s, 1H), 8.25 (s, 2H), 7.69 (d, J = 9.4 Hz, 1H), 7.36
(dd, J = 9.4 Hz, 2.0 Hz, 1H), 7.32 (dd, J = 7.7 Hz, 2.0 Hz, 1H),
7.16 (s, 1H), 7.06 (dd, J = 5.9 Hz, 2.0 Hz, 1H), 6.06 (s, 1H), 3.92
(s, 3H), 2.98 (d, J = 4.8 Hz, 3H), 2.96- 2.93 (m, 2H), 2.86 (t, J =
7.4 Hz, 2H). 96 ##STR00170## 422.9 .sup.1H NMR (400 MHz, DMSO-d6)
.delta. 10.24 (s, 1H), 9.91 (s, 1H), 8.45 (s, 2H), 8.38 (d, J = 4.4
Hz, 1H), 8.13 (d, J = 9.6 Hz, 1H), 7.89 (dd, J = 9.6 Hz, 1.8 Hz,
1H), 7.42 (dd, J = 7.9 Hz, 2.0 Hz, 1H), 7.38 (dd, J = 7.9 Hz, 2.0
Hz, 1H), 3.82 (s, 3H), 2.93 (t, J = 7.4 Hz, 2H), 2.84 (t, J = 7.5
Hz, 2H), 2.74 (d, J = 4.5 Hz, 3H). 97 ##STR00171## 480.0 .sup.1H
NMR (400 MHz, CD.sub.3OD) .delta. 8.17 (s, 2H), 7.58 (d, J = 8.6
Hz, 2H), 7.42 (dd, J = 7.7 Hz, 2.2 Hz, 1H), 7.28 (dd, J = 5.9 Hz,
2.2 Hz, 1H), 7.25 (d, J = 8.6 Hz, 2H), 3.90 (s, 3H), 3.69 (t, J =
4.5 Hz, 4H), 3.48 (s, 2H), 2.97 (t, J = 7.4 Hz, 2H), 2.90 (s, 3H),
2.84 (t, J = 7.4 Hz, 2H), 2.46 (t, J = 4.5 Hz, 4H). 98 ##STR00172##
481.0 .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 8.80 (d, J = 2.6
Hz, 1H), 8.23-8.21 (m, 3H), 7.43-7.39 (m, 2H), 7.27 (dd, J = 6.0
Hz, 2.1 Hz, 1H), 3.88 (s, 3H), 3.77 (s, 2H), 3.75-3.72 (m, 4H),
2.97 (t, J = 7.3 Hz, 2H), 2.88 (s, 3H), 2.85 (t, J = 7.3 Hz, 2H),
2.70-2.65 (m, 4H). 99 ##STR00173## 493.0 .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. 8.18 (s, 2H), 7.63 (d, J = 8.3 Hz, 2H), 7.43-
7.41 (m, 1H), 7.30-7.26 (m, 3H), 3.89 (s, 3H), 3.69 (s, 2H),
3.14-3.06 (m, 4H), 2.97 (t, J = 7.8 Hz, 2H), 2.90 (s, 3H),
2.86-2.78 (m, 6H), 2.73 (s, 3H).
Example 11
Synthesis of Compounds 100-139, 206, 212, 216, 218
Compound 100
3-(2-(2-(1-ethyl-1H-pyrazol-4-ylamino)pyrimidin-5-yl)ethyl)-4-fluoro-5-met-
hoxy-N-methylbenzamide
##STR00174##
[0234] (A) (E)-Methyl
3-(2-(2-((1-ethyl-1H-pyrazol-4-yl)amino)pyrimidin-5-yl)vinyl)-4-fluoro-5--
methoxybenzoate
[0235] A mixture of (E)-methyl
3-(2-(2-chloropyrimidin-5-yl)vinyl)-4-fluoro-5-methoxybenzoate (150
mg, 0.46 mmol), 1-Ethyl-1H-pyrazol-4-amine (103 mg, 0.93 mmol) and
p-toluenesulfonic acid (79 mg, 0.46 mmol) in propan-2-ol (20 mL)
was stirred at 150.degree. C. under microwave for 40 min. The
volatiles were removed under reduced pressure and the residue was
partitioned between saturated aqueous NaHCO.sub.3 (20 mL) and DCM
(60 mL). The organic layer was concentrated and purified via ISCO
(DCM/MeOH) to afford the title compound as a yellow solid (130 mg,
70.4% yield).
(B) Methyl
3-(2-(2-((1-ethyl-1H-pyrazol-4-yl)amino)pyrimidin-5-yl)ethyl)-4-
-fluoro-5-methoxybenzoate
[0236] To a solution of (E)-methyl
3-(2-(2-((1-ethyl-1H-pyrazol-4-yl)amino)pyrimidin-5-yl)
vinyl)-4-fluoro-5-methoxybenzoate (130 mg, 0.33 mmol) in THF (30
mL) and MeOH (20 mL) was added Pd/C (10%, 100 mg). The mixture was
stirred at 40.degree. C. under hydrogen atmosphere for 16 h. The
catalyst was filtered off and the filtrate was concentrated to
afford the title compound as a yellow solid (130 mg, quantative
yield). MS (m/z): 400.0 (M+H).sup.+.
(C)
3-(2-(2-((1-Ethyl-1H-pyrazol-4-yl)amino)pyrimidin-5-yl)ethyl)-4-fluoro-
-5-methoxybenzoic acid
[0237] To a solution of Methyl
3-(2-(2-((1-ethyl-1H-pyrazol-4-yl)amino)pyrimidin-5-yl)ethyl)-4-fluoro-5--
methoxybenzoate (130 mg, 0.33 mmol) in MeOH (10 mL) was added aq
NaOH (66 mg, 1.65 mmol in 4 mL H.sub.2O). The reaction was stirred
at 40.quadrature. for 3 h. The volatiles were removed under reduced
pressure and the residue was purified via ISCO (eluted with MeOH in
H.sub.2O 0.about.100%) to afford the title compound as a white
solid (100 mg, 79.7% yield). MS (m/z): 386.0 (M+H).sup.+.
(D)
3-(2-(2-((1-Ethyl-1H-pyrazol-4-yl)amino)pyrimidin-5-yl)ethyl)-4-fluoro-
-5-methoxy-N-methylbenzamide
[0238] To a solution of
3-(2-(2-((1-ethyl-1H-pyrazol-4-yl)amino)pyrimidin-5-yl)ethyl)-4-fluoro-5--
methoxybenzoic acid (100 mg, 0.26 mmol) in dry DMF (4 mL) was added
DIPEA (10 drops), HATU (296 mg, 0.78 mmol) and methylamine
hydrochloride (52 mg, 0.78 mmol). The reaction was stirred at
ambient temperature for 30 min and then purified via ISCO (eluted
with MeOH in H.sub.2O 0.about.100%) directly to afford the title
compound as a white solid (78 mg, 75.4% yield). MS (m/z): 399.1
(M+H).sup.+. .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 8.12 (s,
2H), 7.89 (s, 1H), 7.50 (s, 1H), 7.39 (dd, J=7.7 Hz, 1.9 Hz, 1H),
7.25 (dd, J=5.9 Hz, 2.0 Hz, 1H), 4.11 (q, J=7.3 Hz, 2H), 3.87 (s,
3H), 2.92 (t, J=7.4 Hz, 2H), 2.87 (s, 3H), 2.79 (t, J=7.5 Hz, 2H),
1.42 (t, J=7.3 Hz, 3H).
[0239] The following compounds were prepared according to the
procedures of Compound 100 using the corresponding intermediates
and reagents under appropriate conditions that could be recognized
by one skilled in the art.
TABLE-US-00016 LC- MS (m/z) Com- (M + pound Structure H).sup.+
.sup.1H NMR 101 ##STR00175## 369.1 .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. 8.14 (s, 2H), 7.77 (s, 2H), 7.16-7.13 (m, 2H),
6.91 (s, 1H), 3.79-3.78 (m, 6H), 2.89- 2.88 (m, 2H), 2.83-2.82 (m,
2H). 102 ##STR00176## 371.1 .sup.1H NMR (400 MHz, CD.sub.3OD)
.delta. 8.13 (s, 2H), 7.75 (s, 2H), 7.40 (dd, J = 7.7 Hz, 2.0 Hz,
1H), 7.26 (dd, J = 5.9 Hz, 2.0 Hz, 1H), 3.87 (s, 3H), 2.93 (t, J =
7.4 Hz, 2H), 2.88 (s, 3H), 2.80 (t, J = 7.4 Hz, 2H). 103
##STR00177## 384.1 .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 7.76
(d, J = 3.1 Hz, 2H), 7.39 (d, J = 0.7 Hz, 1H), 7.37 (dd, J = 7.8
Hz, 2.2 Hz, 1H), 7.30 (dd, J = 8.6 Hz, 2.4 Hz, 1H), 7.24 (dd, J =
6.0 Hz, 2.1 Hz, 1H), 6.56 (dd, J = 8.5 Hz, 0.6 Hz, 1H), 3.87 (s,
3H), 3.83 (s, 3H), 2.93-2.88 (t, J = 7.5 Hz, 2H), 2.87 (s, 3H),
2.78 (t, J = 7.5 Hz, 2H). 104 ##STR00178## 397.2 .sup.1H NMR (400
MHz, CD.sub.3OD) .delta. 8.16 (s, 2H), 7.58 (dd, J = 9.0 Hz, 4.8
Hz, 2H), 7.16 (s, 1H), 7.13 (s, 1H), 7.05-6.95 (m, 2H), 6.91 (s,
1H), 3.79 (s, 3H), 3.78 (s, 3H), 2.94-2.87 (m, 2H), 2.86-2.79 (m,
2H). 105 ##STR00179## 399.1 .sup.1H NMR (400 MHz, CD.sub.3OD)
.delta. 8.02 (s, 2H), 7.40 (s, 1H), 7.38 (d, J = 2.0 Hz, 1H), 7.24
(dd, J = 5.9 Hz, 2.0 Hz, 1H), 3.86 (s, 3H), 3.75 (s, 3H), 2.91 (t,
J = 7.4 Hz, 2H), 2.88 (s, 3H), 2.77 (t, J = 7.3 Hz, 2H), 2.11 (s,
3H). 106 ##STR00180## 409.2 .sup.1H NMR (400 MHz, CD.sub.3OD)
.delta. 8.06 (s, 2H), 7.38 (d, J = 7.8 Hz, 2H), 7.11 (s, 1H), 7.09
(s, 1H), 6.86 (s, 1H), 6.81 (d, J = 7.9 Hz, 2H), 3.84-3.62 (m, 9H),
2.84 (t, J = 6.2 Hz, 2H), 2.77 (t, J = 6.2 Hz, 2H). 107
##STR00181## 411.0 .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 8.13
(s, 2H), 7.92 (s, 1H), 7.49 (s, 1H), 7.40 (dd, J = 7.7 Hz, 2.1 Hz,
1H), 7.26 (dd, J = 6.0 Hz, 2.1 Hz, 1H), 3.88 (s, 3H), 3.57-3.54 (m,
1H), 2.94 (t, J = 7.3 Hz, 2H), 2.88 (s, 3H), 2.81 (t, J = 7.3 Hz,
2H), 1.07-0.97 (m, 4H). 108 ##STR00182## 413.1 .sup.1H NMR (400
MHz, CD.sub.3OD) .delta. 8.13 (s, 2H), 8.13 (s, 2H), 7.93 (s, 1H),
7.93 (s, 1H), 7.54 (s, 1H), 7.54 (s, 1H), 7.15- 7.13 (m, 2H), 6.89
(s, 1H), 4.17 (t, J = 5.4 Hz, 2H), 3.86 (t, J = 5.3 Hz, 2H), 3.78
(s, 6H), 2.89-2.87 (m, 2H), 2.83- 2.81 (m, 2H). 109 ##STR00183##
413.1 .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 7.99 (s, 2H), 7.39
(dd, J = 7.8 Hz, 2.0 Hz, 1H), 7.23 (dd, J = 5.9 Hz, 2.0 Hz, 1H),
3.87 (s, 3H), 3.69 (s, 3H), 2.91 (t, J = 7.4 Hz, 2H), 2.88 (s, 3H),
2.78 (t, J = 7.3 Hz, 2H), 2.06 (s, 3H), 2.00 (s, 3H). 110
##STR00184## 413 .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 8.03 (s,
2H), 7.44 (s, 1H), 7.40 (dd, J = 7.8 Hz, 1.9 Hz, 1H), 7.26 (dd, J =
5.9 Hz, 1.9 Hz, 1H), 4.10 (q, J = 7.2 Hz, 2H), 3.88 (s, 3H), 2.93
(t, J = 7.4 Hz, 2H), 2.89 (s, 3H), 2.79 (t, J = 7.3 Hz, 2H), 2.14
(s, 3H), 1.38 (t, J = 7.2 Hz, 3H). 111 ##STR00185## 413 .sup.1H NMR
(400 MHz, CD.sub.3OD) .delta. 8.07 (s, 2H), 7.72 (s, 1H), 7.40 (dd,
J = 7.8 Hz, 2.0 Hz, 1H), 7.26 (dd, J = 5.9 Hz, 2.1 Hz, 1H), 4.07
(q, J = 7.3 Hz, 2H), 3.88 (s, 3H), 2.94 (t, J = 7.2 Hz, 2H), 2.89
(s, 3H), 2.80 (t, J = 7.4 Hz, 2H), 2.12 (s, 3H), 1.42 (t, J = 7.3
Hz, 3H). 112 ##STR00186## 413.0 .sup.1H NMR (400 MHz, CD.sub.3OD)
.delta. 8.11 (s, 2H), 7.89 (s, 1H), 7.51 (s, 1H), 7.39 (d, J = 7.2
Hz, 1H), 7.25 (d, J = 4.7 Hz, 1H), 4.50-4.36 (m, 1H), 3.86 (s, 3H),
2.92 (t, J = 7.2 Hz, 2H), 2.87 (s, 3H), 2.78 (t, J = 7.1 Hz, 2H),
1.45 (d, J = 6.5 Hz, 6H). 113 ##STR00187## 413.2 .sup.1H NMR (400
MHz, CD.sub.3OD) .delta. 8.15 (s, 2H), 7.56 (d, J = 8.9 Hz, 2H),
7.21 (d, J = 8.9 Hz, 2H), 7.16 (s, 1H), 7.13 (s, 1H), 6.81 (s, 1H),
3.79 (s, 3H), 3.77 (s, 3H), 2.92-2.85 (m, 2H), 2.85-2.78 (m, 2H).
114 ##STR00188## 415.1 .sup.1H NMR (400 MHz, CD.sub.3OD) .delta.
8.15 (s, 2H), 7.95 (s, 1H), 7.58 (s, 1H), 7.43 (d, J = 7.4 Hz, 1H),
7.30 (d, J = 4.4 Hz, 1H), 4.20 (t, J = 5.2 Hz, 2H), 3.91 (s, 3H),
3.90-3.88 (m, 2H), 2.97-2.95 (m, 2H), 2.92 (s, 3H), 2.84 (t, J =
7.2 Hz, 2H). 115 ##STR00189## 414.9 .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. 8.15 (s, 2H), 7.89 (s, 1H), 7.53 (s, 1H), 7.36
(s, 1H), 7.30 (s, 1H), 4.13 (q, J = 7.2 Hz, 2H), 3.92 (s, 3H), 3.04
(t, J = 7.4 Hz, 2H), 2.90 (s, 3H), 2.81 (t, J = 7.6 Hz, 2H), 1.45
(t, J = 7.2 Hz, 3H). 116 ##STR00190## 421.3 .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. 8.33 (s, 1H), 8.21 (s, 2H), 7.76 (s, 1H), 7.41
(dd, J = 7.6 Hz, 2.0 Hz, 1H), 7.38 (t, J = 60.0 Hz, 1H), 7.28 (dd,
J = 6.0 Hz, 2.0 Hz, 1H), 3.89 (s, 3H), 2.96 (t, J = 7.3 Hz, 2H),
2.90 (s, 3H), 2.84 (t, J = 7.3 Hz, 2H). 117 ##STR00191## 426.9
.sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 8.14 (s, 2H), 8.09 (s,
1H), 7.63 (s, 1H), 7.40 (dd, J = 7.7 Hz, 2.1 Hz, 1H), 7.26 (dd, J =
6.0 Hz, 2.0 Hz, 1H), 5.53-5.44 (m, 1H), 5.05-4.98 (m, 4H), 3.88 (s,
3H), 2.94 (t, J = 7.4 Hz, 2H), 2.88 (s, 3H), 2.80 (d, J = 7.3 Hz,
2H). 118 ##STR00192## 427.0 .sup.1H NMR (400 MHz, CD.sub.3OD)
.delta. 8.13 (s, 2H), 7.88 (s, 1H), 7.52 (s, 1H), 7.39 (dd, J = 7.8
Hz, 2.1 Hz, 1H), 7.26 (dd, J = 6.0 Hz, 2.0 Hz, 1H), 3.87 (s, 3H),
3.87 (d, J = 7.2 Hz, 2H), 2.93 (t, J = 7.4 Hz, 2H), 2.88 (s, 3H),
2.80 (t, J = 7.4 Hz, 2H), 2.19-2.09 (m, 1H), 0.89 (d, J = 6.8 Hz,
6H). 119 ##STR00193## 426.9 .sup.1H NMR (400 MHz, CD.sub.3OD)
.delta. 8.14 (s, 2H), 7.92 (s, 1H), 7.50 (s, 1H), 7.36 (d, J = 1.9
Hz, 1H), 7.29 (d, J = 1.9 Hz, 1H), 3.91 (s, 3H), 3.57-3.55 (m, 1H),
3.04 (t, J = 7.6 Hz, 2H), 2.89 (s, 3H), 2.81 (t, J = 7.6 Hz, 2H),
1.07-0.97 (m, 4H). 120 ##STR00194## 429.0 .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. 8.12 (s, 2H), 7.91 (s, 1H), 7.53 (s, 1H), 7.39
(dd, J = 7.8 Hz, 1.9 Hz, 1H), 7.25 (dd, J = 5.9 Hz, 1.9 Hz, 1H),
4.22 (t, J = 5.3 Hz, 2H), 3.87 (s, 3H), 3.70 (t, J = 5.3 Hz, 2H),
2.92 (t, J = 7.3 Hz, 2H), 2.87 (s, 3H), 2.79 (t, J = 7.4 Hz, 2H).
121 ##STR00195## 429.1 .sup.1H NMR (400 MHz, CD.sub.3OD) .delta.
8.14 (s, 2H), 7.90 (s, 1H), 7.52 (s, 1H), 7.36 (s, 1H), 7.29 (s,
1H), 4.49-4.41 (m, 1H), 3.91 (s, 3H), 3.05 (t, J = 7.6 Hz, 2H),
2.89 (s, 3H), 2.81 (t, J = 7.7 Hz, 2H), 1.47 (d, J = 6.7 Hz, 6H).
122 ##STR00196## 439.0 .sup.1H NMR (400 MHz, CD.sub.3OD) .delta.
8.12 (s, 2H), 7.90 (s, 1H), 7.52 (s, 1H), 7.39 (d, J = 7.8 Hz, 1H),
7.26 (d, J = 4.0 Hz, 1H), 4.67-4.60 (m, 1H), 3.88 (s, 3H), 2.93 (t,
J = 7.4 Hz, 2H), 2.88 (s, 3H), 2.80 (t, J = 7.3 Hz, 2H), 2.21-2.09
(m, 2H), 2.02-1.80 (m, 4H), 1.73-1.70 (m, 2H). 123 ##STR00197##
441.0 .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 8.13 (s, 2H), 7.96
(s, 1H), 7.54 (s, 1H), 7.40 (dd, J = 7.8 Hz, 2.1 Hz, 1H), 7.26 (dd,
J = 6.0 Hz, 2.1 Hz, 1H), 5.00-4.93 (m, 1H), 4.14-4.05 (m, 1H), 4.00
(d, J = 4.8 Hz, 2H), 3.92-3.85 (m, 4H), 2.94 (t, J = 7.3 Hz, 2H),
2.88 (s, 3H), 2.81 (t, J = 7.4 Hz, 2H), 2.51-2.40 (m, 1H), 2.35-
2.23 (m, 1H). 124 ##STR00198## 440.9 .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. 8.13 (s, 2H), 7.96 (s, 1H), 7.54 (s, 1H), 7.40
(dd, J = 7.8 Hz, 2.1 Hz, 1H), 7.26 (dd, J = 5.9 Hz, 2.1 Hz, 1H),
5.02-4.94 (m, 1H), 4.15-4.07 (m, 1H), 4.00 (d, J = 4.8 Hz, 2H),
3.94-3.84 (m, 4H), 2.94 (t, J = 7.3 Hz, 2H), 2.88 (s, 3H), 2.81 (t,
J = 7.4 Hz, 2H), 2.50-2.41 (m, 1H), 2.35- 2.26 (m, 1H). 125
##STR00199## 442.0 .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 8.13
(s, 2H), 7.96 (s, 1H), 7.54 (s, 1H), 7.40 (dd, J = 7.8 Hz, 2.1 Hz,
1H), 7.26 (dd, J = 6.0 Hz, 2.1 Hz, 1H), 4.24 (t, J = 6.8 Hz, 2H),
3.87 (s, 3H), 2.93 (t, J = 7.4 Hz, 2H), 2.90-2.85 (m, 5H), 2.81 (t,
J = 7.4 Hz, 2H), 2.34 (s, 6H). 126 ##STR00200## 443.1 .sup.1H NMR
(400 MHz, CD.sub.3OD) .delta. 8.12 (s, 2H), 7.89 (s, 1H), 7.51 (s,
1H), 7.39 (s, 1H), 7.26 (s, 1H), 4.18-4.12 (m, 2H), 3.86 (s, 3H),
3.33-3.31 (m, 5H), 2.92- 2.90 (m, 2H), 2.87 (s, 3H), 2.82-2.74 (m,
2H), 2.07-2.01 (m, 2H). 127 ##STR00201## 444.9 .sup.1H NMR (400
MHz, CD.sub.3OD) .delta. 8.15 (s, 2H), 7.93 (s, 1H), 7.54 (s, 1H),
7.36 (d, J = 1.8 Hz, 1H), 7.30 (d, J = 1.8 Hz, 1H), 4.23 (t, J =
5.3 Hz, 2H), 3.92 (s, 3H), 3.71 (t, J = 5.2 Hz, 2H), 3.31 (s, 3H),
3.05 (t, J = 7.6 Hz, 2H), 2.89 (s, 3H), 2.82 (t, J = 7.7 Hz, 2H).
128 ##STR00202## 448.1 .sup.1H NMR (400 MHz, CD.sub.3OD) .delta.
8.95 (s, 1H), 8.56 (s, 1H), 8.42 (d, J = 4.3 Hz, 1H), 8.21 (s, 2H),
8.13 (d, J = 7.1 Hz, 1H), 7.84 (s, 1H), 7.51 (dd, J = 8.3 Hz, 4.8
Hz, 1H), 7.38 (dd, J = 7.7 Hz, 1.9 Hz, 1H), 7.27 (dd, J = 5.9 Hz,
2.0 Hz, 1H), 3.88 (s, 3H), 2.98-2.91 (m, 2H), 2.89 (s, 3H), 2.83
(t, J = 7.4 Hz, 2H). 129 ##STR00203## 448.9 .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. 8.81 (d, J = 2.4 Hz, 1H), 8.28 (dd, J = 8.6 Hz,
2.7 Hz, 1H), 8.24 (s, 2H), 7.51 (d, J = 8.8 Hz, 1H), 7.42 (dd, J =
7.9 Hz, 1.9 Hz, 1H), 7.28 (dd, J = 6.0 Hz, 1.9 Hz, 1H), 3.89 (s,
3H), 3.01-2.95 (m, 2H), 2.89 (s, 3H), 2.89-2.84 (m, 2H), 1.74 (s,
6H). 130 ##STR00204## 448.9 .sup.1H NMR (400 MHz, CD.sub.3OD)
.delta. 8.20 (s, 2H), 8.09 (s, 1H), 7.51 (d, J = 8.9 Hz, 1H), 7.41
(dd, J = 7.6 Hz, 2.0 Hz, 1H), 7.28 (dd, J = 6.0 Hz, 2.0 Hz, 1H),
7.05 (dd, J = 9.0 Hz, 1.7 Hz, 1H), 4.02 (s, 3H), 3.89 (s, 3H), 2.97
(t, J = 7.1 Hz, 2H), 2.89 (s, 3H), 2.85 (t, J = 7.1 Hz, 3H), 2.59
(s, 3H). 131 ##STR00205## 455.0 .sup.1H NMR (400 MHz, CD.sub.3OD)
.delta. 8.13 (s, 2H), 7.94 (s, 1H), 7.54 (s, 1H), 7.40 (dd, J = 7.7
Hz, 2.0 Hz, 1H), 7.26 (dd, J = 5.9 Hz, 2.0 Hz, 1H), 4.70 (d, J =
6.1 Hz, 2H), 4.34 (d, J = 6.1 Hz, 2H), 4.29 (s, 2H), 3.88 (s, 3H),
2.94 (t, J = 7.4 Hz, 2H), 2.88 (s, 3H), 2.81 (t, J = 7.4 Hz, 2H),
1.23 (s, 3H). 132 ##STR00206## 454.9 .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. 8.15 (s, 2H), 7.98 (s, 1H), 7.56 (s, 1H), 7.41
(dd, J = 7.8 Hz, 2.1 Hz, 1H), 7.28 (dd, J = 6.0 Hz, 2.1 Hz, 1H),
4.40-4.30 (m, 1H), 4.12-4.02 (m, 2H), 3.89 (s, 3H), 3.62-3.52 (m,
2H), 2.95 (t, J = 7.5 Hz, 2H), 2.90 (s, 3H), 2.82 (t, J = 7.4 Hz,
3H), 2.08-1.98 (m, 4H). 133 ##STR00207## 456.0 .sup.1H NMR (400
MHz, CD.sub.3OD) .delta. 8.13 (s, 2H), 7.99 (s, 1H), 7.56 (s, 1H),
7.40 (dd, J = 7.8 Hz, 2.1 Hz, 1H), 7.27 (dd, J = 6.0 Hz, 2.1 Hz,
1H), 4.23 (t, J = 6.4 Hz, 2H), 3.88 (s, 3H), 3.13-3.06 (m, 2H),
2.94 (t, J = 7.2 Hz, 2H), 2.88 (s, 3H), 2.85-2.83 (m, 6H),
2.82-2.79 (m, 2H), 2.28-2.20 (m, 2H). 134 ##STR00208## 462.4
.sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 8.82 (s, 1H), 8.55 (s,
1H), 8.21 (s, 2H), 8.06 (s, J = 7.2 Hz, 1H), 7.83 (s, 1H), 7.42 (s,
1H), 7.40 (s, 1H), 7.28 (s, 1H), 3.89 (s, 3H), 3.01-2.94 (m, 2H),
2.89 (s, 3H), 2.87-2.79 (m, 2H), 2.57 (s, 3H). 135 ##STR00209##
468.0 .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 8.12 (s, 2H), 7.95
(s, 1H), 7.53 (s, 1H), 7.39 (d, J = 7.2 Hz, 1H), 7.26 (d, J = 4.8
Hz, 1H), 4.23 (t, J = 6.9 Hz, 2H), 3.87 (s, 3H), 2.98-2.88 (m, 4H),
2.87 (s, 3H), 2.80 (t, J = 7.1 Hz, 2H), 2.60-2.50 (m, 4H),
1.84-1.72 (m, 4H). 136 ##STR00210## 469.9 .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. 8.14 (s, 2H), 7.96 (s, 1H), 7.54 (s, 1H), 7.41
(dd, J = 7.8 Hz, 2.1 Hz, 1H), 7.27 (dd, J = 5.9 Hz, 2.1 Hz, 1H),
4.24-4.13 (m, 2H), 3.89 (s, 3H), 2.97-2.89 (m, 4H), 2.89 (s, 3H),
2.82 (t, J = 7.4 Hz, 2H), 2.58 (q, J = 7.2 Hz, 4H), 1.04 (t, J =
7.2 Hz, 6H). 137 ##STR00211## 482.0 .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. 8.14 (s, 2H), 7.92 (s, 1H), 7.53 (s, 1H), 7.41
(dd, J = 7.8 Hz, 2.1 Hz, 1H), 7.27 (dd, J = 5.9 Hz, 2.1 Hz, 1H),
3.98 (d, J = 7.2 Hz, 2H), 3.89 (s, 3H), 2.95 (t, J = 7.5 Hz, 2H),
2.89 (s, 3H), 2.81 (t, J = 7.5 Hz, 2H), 2.25 (s, 3H), 2.02-1.93 (m,
2H), 1.93-1.82 (m, 1H), 1.60-1.53 (m, 2H), 1.37-1.28 (m, 4H). 138
##STR00212## 482.1 .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 8.05
(s, 2H), 7.86 (s, 1H), 7.44 (s, 1H), 7.31 (d, J = 7.7 Hz, 1H), 7.18
(d, J = 4.1 Hz, 1H), 4.07 (t, J = 6.7 Hz, 2H), 3.79 (s, 3H), 2.86
(t, J = 7.5 Hz, 2H), 2.80 (s, 3H), 2.73 (t, J = 7.2 Hz, 2H), 2.66-
2.54 (m, 4H), 2.54-2.45 (m, 2H), 2.05- 1.95 (m, 2H), 1.83-1.69 (m,
4H). 139 ##STR00213## 484.0 .sup.1H NMR (400 MHz, CD.sub.3OD)
.delta. 8.11 (s, 2H), 7.96 (s, 1H), 7.51 (s, 1H), 7.39 (dd, J = 7.8
Hz, 2.1 Hz, 1H), 7.26 (dd, J = 6.0 Hz, 2.1 Hz, 1H), 4.21 (t, J =
6.6 Hz, 2H), 3.87 (s, 3H), 3.68-3.58 (m, 4H), 2.93 (t, J = 7.4 Hz,
2H), 2.87 (s, 3H), 2.82-2.78 (m, 2H), 2.77-2.75 (m, 2H), 2.49-2.43
(m, 4H). 206 ##STR00214## 439.2 .sup.1H NMR (400 MHz, DMSO-d6)
.delta. 9.34 (s, 1H), 8.38-8.32 (m, 1H), 8.23 (s, 2H), 7.58 (d, J =
8.4 Hz, 2H), 7.41 (d, J = 6.6 Hz, 1H), 7.37 (d, J = 6.0 Hz, 1H),
7.09 (d, J = 8.4 Hz, 2H), 3.82 (s, 3H), 3.36 (s, 2H), 2.88 (t, J =
7.5 Hz, 2H), 2.78-2.72 (m, 5H). 212 ##STR00215## 494.0 .sup.1H NMR
(400 MHz, CD.sub.3OD) .delta. 8.30 (d, J = 2.7 Hz, 1H), 8.10 (s,
2H), 7.82 (dd, J = 9.1 Hz, 2.7 Hz, 1H), 7.40 (dd, J = 7.8 Hz, 2.1
Hz, 1H), 7.26 (dd, J = 5.9 Hz, 2.0 Hz, 1H), 6.82 (d, J = 9.1 Hz,
1H), 4.12-4.02 (m, 2H), 3.88 (s, 3H), 3.02-2.95 (m, 2H), 2.93 (t, J
= 7.4 Hz, 2H), 2.88 (s, 3H), 2.80 (t, J = 7.4 Hz, 2H), 2.43 (dd, J
= 12.6 Hz, 11.0 Hz, 2H), 1.18 (d, J = 6.4 Hz, 6H). 216 ##STR00216##
510.9 .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 8.15 (s, 2H), 7.57
(dd, J = 15.0 Hz, 2.4 Hz, 1H), 7.40 (dd, J = 7.7 Hz, 2.0 Hz, 1H),
7.26 (dd, J = 5.9 Hz, 2.0 Hz, 1H), 7.20 (dd, J = 8.7 Hz, 2.4 Hz,
1H), 6.93 (t, J = 9.2 Hz, 1H), 3.87 (s, 3H), 3.24-3.16 (m, 2H),
3.08-2.98 (m, 2H), 2.94 (t, J = 7.3 Hz, 2H), 2.88 (s, 3H), 2.81 (t,
J = 7.4 Hz, 2H), 2.29 (t, J = 10.9 Hz, 2H), 1.10 (d, J = 6.4 Hz,
6H). 218 ##STR00217## 506.9 .sup.1H NMR (400 MHz, CD.sub.3OD)
.delta. 8.11 (s, 2H), 7.40 (dd, J = 7.7 Hz, 2.1 Hz, 1H), 7.37-7.32
(m, 2H), 7.26 (dd, J = 6.0 Hz, 2.0 Hz, 1H), 6.95 (d, J = 9.3 Hz,
1H), 3.88 (s, 3H), 3.07-2.98 (m, 2H), 2.97-2.89 (m, 4H), 2.88 (s,
3H), 2.81 (t, J = 7.4 Hz,
2H), 2.28 (t, J = 11.0 Hz, 2H), 2.26 (s, 3H), 1.10 (d, J = 6.4 Hz,
6H). ##STR00218##
Example 12
Synthesis of Compound 140
Compound 140
3-(2-(2-(1-(ethylsulfonyl)-1H-pyrazol-4-ylamino)pyrimidin-5-yl)ethyl)-4-fl-
uoro-5-methoxy-N-methylbenzamide
##STR00219##
[0240] (A)
3-(2-(2-((1-(ethylsulfonyl)-1H-pyrazol-4-yl)amino)pyrimidin-5-y-
l)ethyl)-4-fluoro-5-methoxy-N-methylbenzamide
[0241] To a solution of
3-(2-(2-((1H-pyrazol-4-yl)amino)pyrimidin-5-yl)ethyl)-4-fluoro-5-methoxy--
N-methylbenzamide (80.0 mg, 0.22 mmol) in THF/DMF (1 mL, 1:1 vol.)
was added KHMDS (0.43 mL, 0.22 mmol, 0.5 M in Toluene) dropwise
with ice-water bath cooling. After the addition, the mixture was
stirred for further 2 min. Then, to the mixture was added
ethanesulfonyl chloride (28 mg, 0.22 mmol) dropwise at the same
temperature. After the addition, the mixture was stirred for
further 2 min and then quenched with water (0.5 mL). The resulting
mixture was extracted with DCM (5 mL). The organic layer was
concentrated in vacuo and the residue was purified via ISCO (eluted
with MeOH in H.sub.2O 0.about.100%) to give the tilted compound as
a white solid (7.8 mg, 7.8% yield). MS (m/z): 426.9 (M+H).sup.+.
.sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 8.47 (s, 1H), 8.23 (s,
2H), 7.95 (s, 1H), 7.41 (dd, J=7.8 Hz, 2.1 Hz, 1H), 7.28 (dd, J=6.0
Hz, 2.1 Hz, 1H), 3.89 (s, 3H), 3.51 (q, J=7.4 Hz, 2H), 2.97 (t,
J=7.4 Hz, 2H), 2.89 (s, 3H), 2.85 (t, J=7.4 Hz, 2H), 1.20 (t, J=7.4
Hz, 3H).
Example 13
Synthesis of Compounds 141-144
Compound 141
3-(2-(2-(1-(cyclopropylmethyl)-1H-pyrazol-4-ylamino)pyrimidin-5-yl)ethyl)--
4-fluoro-5-methoxy-N-methylbenzamide
##STR00220##
[0242] (A)
3-(2-(2-((1-(cyclopropylmethyl)-1H-pyrazol-4-yl)amino)pyrimidin-
-5-yl)ethyl)-4-fluoro-5-methoxy-N-methylbenzamide
[0243] To a solution of
3-(2-(2-((1H-pyrazol-4-yl)amino)pyrimidin-5-yl)ethyl)-4-fluoro-5-methoxy--
N-methylbenzamide (106 mg, 0.29 mmol) and (bromomethyl)cyclopropane
(77 mg, 0.57 mmol) in DMF (10 mL) was added Cs.sub.2CO.sub.3 (280
mg, 0.86 mmol). The mixture was stirred at 80.degree. C. for
overnight. The mixture was then partitioned between EA and water.
The organic layer was washed with water and brine, dried over
anhydrous sodium sulfate and concentrated. The residue was purified
via ISCO (eluted with MeOH in DCM 0.about.10%) to afford the title
compound as an off-white solid (34 mg, 28.0% yield). MS (m/z):
425.1 (M+H).sup.+. .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 8.13
(s, 2H), 7.95 (s, 1H), 7.52 (s, 1H), 7.40 (dd, J=7.8 Hz, 2.1 Hz,
1H), 7.26 (dd, J=5.9 Hz, 2.0 Hz, 1H), 3.93 (d, J=7.1 Hz, 2H), 3.88
(s, 3H), 2.94 (t, J=7.4 Hz, 2H), 2.88 (s, 3H), 2.80 (t, J=7.4 Hz,
2H), 1.28-1.26 (m, 1H), 0.62-0.56 (m, 2H), 0.41-0.34 (m, 2H).
[0244] The following compounds were prepared according to the
procedures of Compound 141 using the corresponding intermediates
and reagents under appropriate conditions that could be recognized
by one skilled in the art.
TABLE-US-00017 LC-MS Com- (m/z) pound Structure (M + H).sup.+
.sup.1H NMR 142 ##STR00221## 462.1 .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. 8.50 (d, J = 4.9 Hz, 1H), 8.13 (s, 2H), 8.07
(s, 1H), 7.77 (td, J = 7.8 Hz, 1.7 Hz, 1H), 7.61 (s, 1H), 7.39 (dd,
J = 7.8 Hz, 2.1 Hz, 1H), 7.32 (dd, J = 6.9 Hz, 5.3 Hz, 1H), 7.26
(dd, J = 5.9 Hz, 2.1 Hz, 1H), 7.05 (d, J = 7.9 Hz, 1H), 5.39 (s,
2H), 3.87 (s, 3H), 2.93 (t, J = 7.4 Hz, 2H), 2.87 (s, 3H), 2.80 (t,
J = 7.4 Hz, 2H). 143 ##STR00222## 482.2 .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 8.15 (s, 2H), 7.60 (s, 1H), 7.34 (d, J = 7.5
Hz, 1H), 6.98 (s, 1H), 6.22 (s, 1H), 4.86 (s, 2H), 3.91 (s, 3H),
3.58-3.43 (m, 4H), 2.95 (s, 3H), 2.93-2.87 (m, 2H), 2.85-2.77 (m,
2H), 2.04-1.98 (m, 2H), 1.90-1.84 (m, 2H). 144 ##STR00223## 511.2
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.29-7.95 (m, 2H), 7.66-
7.45 (m, 1H), 7.33 (d, J = 6.8 Hz, 1H), 7.04-6.96 (m, 1H),
6.32-6.09 (m, 1H), 5.30 (s, 2H), 3.92 (s, 3H), 3.70-3.63 (m, 2H),
3.61-3.55 (m, 2H), 2.97 (d, J = 3.7 Hz, 3H), 2.92 (t, J = 7.0 Hz,
2H), 2.85-2.75 (t, J = 7.0 Hz, 2H), 2.48-2.37 (m, 4H), 2.35-2.29
(m, 3H).
Example 14
Synthesis of Compound 145
Compound 145
4-fluoro-3-methoxy-N-methyl-5-(2-(2-(4-(2-oxopiperidin-1-yl)phenylamino)py-
rimidin-5-yl)ethyl)benzamide
##STR00224##
[0245] (A) (E)-methyl
4-fluoro-3-methoxy-5-(2-(2-((4-(2-oxopyridin-1(2H)-yl)phenyl)amino)pyrimi-
din-5-yl)vinyl)benzoate
[0246] A mixture of 1-(4-aminophenyl)pyridin-2(1H)-one (138 mg,
0.74 mmol), (E)-methyl
3-(2-(2-chloropyrimidin-5-yl)vinyl)-4-fluoro-5-methoxybenzoate (120
mg, 0.37 mmol) and 4-methylbenzenesulfonic acid hydrate (71 mg,
0.37 mmol) in propan-2-ol (4 mL) was stirred at 140.degree. C. for
1 h under microwave. The mixture was filtered and the filter cake
was washed with propan-2-ol (3*10 mL). The solid was dried under
reduced pressure at 50.degree. C. for 20 min to give the desired
compound as a grey solid (150 mg, 85.4% yield). MS (m/z): 473.1
(M+H).sup.+.
(B) Methyl
4-fluoro-3-methoxy-5-(2-(2-((4-(2-oxopiperidin-1-yl)phenyl)amin-
o)pyrimidin-5-yl)ethyl)benzoate
[0247] To a solution of (E)-methyl
4-fluoro-3-methoxy-5-(2-(2-((4-(2-oxopyridin-1(2H)-yl)phenyl)amino)pyrimi-
din-5-yl)vinyl)benzoate (150 mg, 0.32 mmol) in a mixed solvent of
THF/MeOH (20 mL/20 mL) was added Pd/C (10%, 100 mg). The mixture
was purged with hydrogen and stirred overnight at room temperature
under hydrogen atmosphere. The catalyst was filtered off through
celite and the filtrate was concentrated to give a light yellow oil
(152 mg, quantative yield). MS (m/z): 479.1 (M+H).sup.+.
(C)
4-fluoro-3-methoxy-N-methyl-5-(2-(2-((4-(2-oxopiperidin-1-yl)phenyl)am-
ino)pyrimidin-5-yl)ethyl)benzamide
[0248] To a solution of methyl
4-fluoro-3-methoxy-5-(2-(2-((4-(2-oxopiperidin-1-yl)phenyl)amino)pyrimidi-
n-5-yl)ethyl)benzoate (152 mg, 0.32 mmol) in MeOH (20 mL) was added
aqueous NaOH (2 N, 3 mL, 6 mmol). Then the mixture was stirred
overnight at room temperature. After concentration, the residue was
adjusted to PH<2 with cone HCl. Then the mixture was
concentrated to give a brown solid which was suspended in DMF (10
mL) and then methanamine hydrochloride (43 mg, 0.64 mmol), HATU
(183 mg, 0.48 mmol) and DIPEA (165 ing, 1.28 mmol) were added. The
resulting mixture was stirred for 2 h at room temperature and then
partitioned between EA and water. The organic layer was washed with
water and brine, dried over anhydrous sodium sulfate and
concentrated. The residue was purified via ISCO (eluted with MeOH
in H.sub.2O 0.about.100%) to give the title compound as a slight
yellow solid (29.1 mg, 19.2% yield). MS (m/z): 478.2 (M+H).sup.+.
.sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 8.17 (s, 2H), 7.68 (d,
J=8.5 Hz, 2H), 7.42-7.37 (m, 1H), 7.29-7.24 (m, 1H), 7.14 (d, J=8.7
Hz, 2H), 3.87 (s, 3H), 3.65-3.62 (m, 2H), 2.97-2.93 (m, 2H), 2.88
(s, 3H), 2.85-2.80 (m, 2H), 2.51-2.46 (m, 2H), 1.97-1.92 (m,
4H).
Example 15
Synthesis of Compounds 156-157, 196, 200, 204, 208, 214
Compound 156
4-chloro-3-methoxy-N-methyl-5-(2-(2-(1-methyl-1H-pyrazol-4-ylamino)pyrimid-
in-5-yl)ethyl)benzamide
##STR00225##
[0249] (A) Methyl
4-chloro-3-methoxy-5-(2-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-5-y-
l)ethyl)benzoate
[0250] A mixture of (E)-methyl
4-chloro-3-methoxy-5-(2-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-5-y-
l)vinyl)benzoate (0.25 g, 0.63 mmol),
4-methylbenzenesulfonohydrazide (1.2 g, 6.4 mmol) and sodium
acetate (0.53 g, 6.5 mmol) in THF (15 mL) and H.sub.2O (10 mL) was
heated at 100.degree. C. for 20 h under nitrogen. Then the
volatiles were removed under reduced pressure and the residue was
purified via ISCO (eluted with MeOH in H.sub.2O 0.about.100%) to
afford the title compound as a yellow solid (0.12 g, 47.8% yield).
MS (m/z): 402.3 (M+H).sup.+.
(B)
4-chloro-3-methoxy-5-(2-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin--
5-yl)ethyl)benzoic acid
[0251] A solution of methyl
4-chloro-3-methoxy-5-(2-(2-(2-(1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-5-
-yl)ethyl)benzoate (0.12 g, 0.30 mmol) in THF (3 mL) and MeOH (2
mL) was mixed with aqueous NaOH solution (0.20 g NaOH in 1 mL
H.sub.2O). The resulting mixture was stirred at room temperature
for 2 h, and then purified via ISCO (eluted with MeOH in H.sub.2O
0.about.100%) directly to afford the title compound as a white
solid (0.075 g, 64.8% yield). MS (m/z): 388.3 (M+H).sup.+.
(C) (E)-methyl
4-chloro-3-methoxy-5-(2-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-5-y-
l)vinyl)benzoate
[0252] A mixture of
4-chloro-3-methoxy-5-(2-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-5-y-
l)ethyl)benzoic acid (0.025 g, 0.065 mmol), methoxylamine
hydrochloride (0.012 g, 0.14 mmol), DIPEA (0.030 g, 0.23 mmol) and
HATU (0.035 g, 0.092 mmol) in DMF (4 mL) was stirred at room
temperature for 30 min. Then the reaction mixture was purified via
ISCO (eluted with MeOH in H.sub.2O 0.about.100%) directly to afford
the title compound as a yellow solid (0.022 g, 81.9% yield). MS
(m/z): 417.4 (M+H).sup.+. .sup.1H NMR (400 MHz, CD.sub.3OD) .delta.
8.17 (s, 2H), 7.87 (s, 1H), 7.53 (s, 1H), 7.31 (d, J=1.6 Hz, 1H),
7.26 (d, J=1.6 Hz, 1H), 3.95 (s, 3H), 3.87 (s, 3H), 3.82 (s, 3H),
3.06 (t, J=7.7 Hz, 2H), 2.83 (t, J=7.7 Hz, 2H).
[0253] The following compound was prepared according to the
procedures of Compound 156 using the corresponding intermediates
and reagents under appropriate conditions that could be recognized
by one skilled in the art.
TABLE-US-00018 LC-MS Com- (m/z) pound Structure (M + H).sup.+
.sup.1H NMR 157 ##STR00226## 427.0 .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. 8.13 (s, 2H), 7.87 (s, 1H), 7.50 (s, 1H), 7.35
(s, 1H), 7.28 (s, 1H), 3.91 (s, 3H), 3.84 (s, 3H), 3.03 (t, J = 9.4
Hz, 2H), 2.91- 2.83 (m, 1H), 2.83-2.75 (m, 2H), 0.86- 0.70 (m, 2H),
0.70-0.51 (m, 2H). 196 ##STR00227## 480.8 .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. 8.10 (s, 2H), 7.43 (d, J = 7.3 Hz, 2H), 7.37-
7.34 (m, 1H), 7.30-7.26 (m, 1H), 6.93 (d, J = 7.3 Hz, 2H), 3.91 (s,
3H), 3.09- 3.01 (m, 6H), 3.00-2.94 (m, 4H), 2.88 (s, 3H), 2.81 (t,
J = 7.4 Hz, 2H). 200 ##STR00228## 508.8 .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. 8.09 (s, 2H), 7.39 (d, J = 8.8 Hz, 2H), 7.35
(s, 1H), 7.28 (s, 1H), 6.87 (d, J = 8.8 Hz, 2H), 3.91 (s, 3H),
3.06-2.95 (m, 6H), 2.88 (s, 3H), 2.84-2.76 (m, 4H), 1.21 (s, 6H).
204 ##STR00229## 527.3 .sup.1H NMR (400 MHz, CD.sub.3OD) .delta.
8.16 (s, 2H), 7.57 (d, J = 14.2 Hz, 1H), 7.36 (s, 1H), 7.29 (s,
1H), 7.19 (d, J = 8.3 Hz, 1H), 6.93 (t, J = 9.1 Hz, 1H), 3.91 (s,
3H), 3.20 (d, J = 11.0 Hz, 2H), 3.09- 2.95 (m, 4H), 2.88 (s, 3H),
2.82 (t, J = 7.1 Hz, 2H), 2.28 (t, J = 10.7 Hz, 2H), 1.10 (d, J =
6.1 Hz, 6H). 208 ##STR00230## 523.3 .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. 8.12 (s, 2H), 7.37-7.32 (m, 3H), 7.30-7.28 (m,
1H), 6.95 (d, J = 9.3 Hz, 1H), 3.91 (s, 3H), 3.07-3.01 (m, 4H),
2.94-2.89 (m, 2H), 2.88 (s, 3H), 2.81 (t, J = 7.6 Hz, 2H), 2.28 (t,
J = 10.9 Hz, 2H), 2.26 (s, 3H), 1.09 (d, J = 6.5 Hz, 6H). 214
##STR00231## 510.3 .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 8.38
(d, J = 2.6 Hz, 1H), 8.13 (s, 2H), 7.91 (dd, J = 9.0 Hz, 2.7 Hz,
1H), 7.36 (d, J = 1.8 Hz, 1H), 7.29 (d, J = 1.9 Hz, 1H), 6.92 (d, J
= 9.1 Hz, 1H), 4.36 (dd, J = 14.0 Hz, 2.4 Hz, 2H), 3.92 (s, 3H),
3.45- 3.36 (m, 2H), 3.05 (t, J = 7.6 Hz, 2H), 2.89 (s, 3H), 2.83
(t, J = 7.6 Hz, 2H), 2.75 (dd, J = 13.9 Hz, 11.4 Hz, 2H), 1.37 (d,
J = 6.6 Hz, 6H). ##STR00232##
Example 16
Synthesis of Compound 158
Compound 158
4-chloro-3-methoxy-N-methyl-5-(2-(2-(1-(piperidin-4-yl)-1H-pyrazol-4-ylami-
no)pyrimidin-5-yl)ethyl)benzamide
##STR00233##
[0254] (A) tert-butyl
4-(4-((5-(2-chloro-3-methoxy-5-(methylcarbamoyl)phenethyl)-pyrimidin-2-yl-
)amino)-1H-pyrazol-1-yl)piperidine-1-carboxylate
[0255] The title compound was prepared according to the procedures
of Example 9 using the corresponding intermediates and
reagents.
(B)
4-chloro-3-methoxy-N-methyl-5-(2-(2-((1-(piperidin-4-yl)-1H-pyrazol-4--
yl)amino)pyrimidin-5-yl)ethyl)benzamide
[0256] A mixture of tert-butyl
4-(4-((5-(2-chloro-3-methoxy-5-(methylcarbamoyl)-phenethyl)-pyrimidin-2-y-
l)amino)-1H-pyrazol-1-yl)piperidine-1-carboxylate (80 mg, 0.15
mmol) in MeOH (2 mL) was treated with 5 drops of conc. hydrochloric
acid. The mixture was concentrated in vacuo (45.degree. C. water
bath) and the residue was taken in aq. NaHCO.sub.3 (5 mL) and
extracted with DCM (2*10 mL). The organic layers were combined and
concentrated in vacuo. The residue was purified via ISCO (eluted
with MeOH in H.sub.2O 0.about.100%) to afford the title compound
(46 mg, 69.7% yield). MS (m/z): 470.0 (M+H).sup.+. .sup.1H NMR (400
MHz, CD.sub.3OD) .delta. 8.14 (s, 2H), 8.01 (s, 1H), 7.57 (s, 1H),
7.36 (d, J=1.9 Hz, 1H), 7.30 (d, J=1.9 Hz, 1H), 4.52-4.43 (m, 1H),
3.92 (s, 3H), 3.59-3.50 (m, 2H), 3.23-3.13 (m, 2H), 3.05 (t, J=7.6
Hz, 2H), 2.89 (s, 3H), 2.83 (t, J=7.6 Hz, 2H), 2.33-2.17 (m,
4H).
Example 17
Synthesis of Compounds 159-164
Compound 159
(R)-4-fluoro-3-methoxy-N-methyl-5-(2-(2-(1-(piperidin-3-yl)-1H-pyrazol-4-y-
lamino)pyrimidin-5-yl)ethyl)benzamide
##STR00234##
[0257] (A) (R)-tert-butyl
3-(4-(5-(2-fluoro-3-methoxy-5-(methylcarbamoyl)phenethyl)pyrimidin-2-ylam-
ino)-1H-pyrazol-1-yl)piperidine-1-carboxylate
[0258] The title compound was prepared according to the procedures
of Example 11 using the corresponding intermediates and
reagents.
(B)
(R)-4-fluoro-3-methoxy-N-methyl-5-(2-(2-(1-(piperidin-3-yl)-1H-pyrazol-
-4-ylamino)pyrimidin-5-yl)ethyl)benzamide
[0259] A mixture of (R)-tert-butyl
3-(4-((5-(2-fluoro-3-methoxy-5-(methylcarbamoyl)
phenethyl)py-rimidin-2-yl)amino)-1H-pyrazol-1-yl)piperidine-1-carboxylate
(160 mg, 0.29 mmol) in MeOH (2 mL) was treated with 6 drops of
conc. hydrochloric acid. The mixture was concentrated in vacuo
(40.degree. C. water bath) and the residue was taken in aq.
NaHCO.sub.3 (5 mL) and extracted with DCM (2*10 mL). The organic
layers were combined and concentrated in vacuo. The residue was
purified via ISCO (eluted with MeOH in H.sub.2O 0.about.100%) to
afford the title compound (87.0 mg, 66.4% yield). MS (m/z): 454.0
(M+H).sup.+. .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 8.12 (s,
2H), 7.93 (s, 1H), 7.52 (s, 1H), 7.39 (dd, J=7.8 Hz, 2.2 Hz, 1H),
7.26 (dd, J=6.0 Hz, 2.1 Hz, 1H), 4.17-4.10 (m, 1H), 3.87 (s, 3H),
3.25-3.18 (m, 1H), 2.95-2.90 (m, 3H), 2.87 (s, 3H), 2.83-2.78 (m,
3H), 2.62-2.57 (m, 1H), 2.17-2.16 (m, 1H), 1.95-1.88 (m, 1H),
1.84-1.79 (m, 1H), 1.64-1.59 (m, 1H).
[0260] The following compounds were prepared according to the
procedures of Compound 159 using the corresponding intermediates
and reagents under appropriate conditions that could be recognized
by one skilled in the art.
TABLE-US-00019 LC-MS Com- (m/z) pound Structure (M + H).sup.+
.sup.1H NMR 160 ##STR00235## 426.1 .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. 8.13 (s, 2H), 8.06 (s, 1H), 7.58 (s, 1H), 7.39
(dd, J = 7.7 Hz, 2.1 Hz, 1H), 7.26 (dd, J = 5.9 Hz, 2.0 Hz, 1H),
5.28-5.08 (m, 1H), 4.10-3.99 (m, 2H), 3.92-3.87 (m, 2H), 3.87 (s,
3H), 2.93 (t, J = 7.4 Hz, 2H), 2.87 (s, 3H), 2.80 (t, J = 7.4 Hz,
2H). 161 ##STR00236## 439.9 .sup.1H NMR (400 MHz, CD.sub.3OD)
.delta. 8.13 (s, 2H), 7.96 (s, 1H), 7.54 (s, 1H), 7.40 (dd, J = 7.8
Hz, 2.1 Hz, 1H), 7.27 (dd, J = 6.0 Hz, 2.1 Hz, 1H), 3.88 (s, 3H),
3.24-3.09 (m, 4H), 2.99-2.95 (m, 1H), 2.95 (t, J = 7.4 Hz, 2H),
2.89 (s, 3H), 2.81 (t, J = 7.4 Hz, 2H), 2.36-2.26 (m, 1H),
2.22-2.11 (m, 1H). 162 ##STR00237## 439.9 .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. 8.12 (s, 2H), 7.95 (s, 1H), 7.53 (s, 1H), 7.39
(dd, J = 7.8 Hz, 2.1 Hz, 1H), 7.26 (dd, J = 6.0 Hz, 2.1 Hz, 1H),
3.87 (s, 3H), 3.25-3.11 (m, 4H), 3.00-2.95 (m, 1H), 2.93 (t, J =
7.4 Hz, 2H), 2.88 (s, 3H), 2.80 (t, J = 7.4 Hz, 2H), 2.35-2.25 (m,
1H), 2.21-2.10 (m, 1H). 163 ##STR00238## 454.0 .sup.1H NMR (400
MHz, CD.sub.3OD) .delta. 8.12 (s, 2H), 7.93 (s, 1H), 7.52 (s, 1H),
7.39 (dd, J = 7.6 Hz, 2.0 Hz, 1H), 7.26 (dd, J = 7.6 Hz, 2.0 Hz,
1H), 4.19-4.12 (m, 1H), 3.87 (s, 3H), 3.25-3.20 (m, 1H), 2.93- 2.91
(m, 3H), 2.87 (s, 3H), 2.82-2.80 (m, 3H), 2.61-2.58 (m, 1H),
2.18-2.16 (m, 1H), 2.00-1.90 (m, 1H), 1.90-1.79 (m, 1H), 1.65-1.59
(m, 1H). 164 ##STR00239## 454.0 .sup.1H NMR (400 MHz, CD.sub.3OD)
.delta. 8.12 (s, 2H), 7.93 (s, 1H), 7.52 (s, 1H), 7.39 (d, J = 6.4
Hz, 1H), 7.26 (d, J = 4.1 Hz, 1H), 4.26-4.12 (m, 1H), 3.87 (s, 3H),
3.18- 3.09 (m, 2H), 2.92 (t, J = 7.2 Hz, 2H), 2.87 (s, 3H), 2.79
(t, J = 7.4 Hz, 2H), 2.75- 2.64 (m, 2H), 2.11-1.99 (m, 2H), 1.94-
1.80 (m, 2H). ##STR00240##
Example 18
Synthesis of Compounds 165-178
Compound 165
(R)-4-fluoro-3-methoxy-N-methyl-5-(2-(2-(1-(1-methylpiperidin-3-yl)-1H-pyr-
azol-4-ylamino)pyrimidin-5-yl)ethyl)benzamide
##STR00241##
[0261] (A)
(R)-4-fluoro-3-methoxy-N-methyl-5-(2-(2-((1-(1-methylpiperidin--
3-yl)-1H-pyrazol-4-yl)amino)pyrimidin-5-yl)ethyl)benzamide
[0262] To a mixture of
(R)-4-fluoro-3-methoxy-N-methyl-5-(2-(2-((1-(piperidin-3-yl)-1H-pyrazol-4-
-yl)amino)pyrimidin-5-yl)ethyl)benzamide (37.0 mg, 0.082 mmol) and
formaldehyde (37%, 0.01 mL) in THF (5 mL) was added sodium
triacetoxyborohydride (52 mg, 0.25 mmol) in portions under
ice-water bath cooling. The mixture was then stirred at room
temperature for 2 h. The resulting mixture was concentrated in
vacuo. The residue was taken in aq. Na.sub.2CO.sub.3 (10 mL) and
extracted with DCM (2*10 mL). The organic layers were combined and
concentrated in vacuo. The residue was purified via PTLC
(DCM/MeOH=7:1) to afford the title compound as a yellow solid (31.2
mg, 81.8% yield). MS (m/z): 468.0 (M+H).sup.+. .sup.1H NMR (400
MHz, CD.sub.3OD) .delta. 8.13 (s, 2H), 8.00 (s, 1H), 7.55 (s, 1H),
7.40 (dd, J=7.8 Hz, 2.2 Hz, 1H), 7.27 (dd, J=5.9 Hz, 2.1 Hz, 1H),
4.47-4.36 (m, 1H), 3.87 (s, 3H), 3.36-3.33 (m, 1H), 3.25-3.20 (m,
1H), 3.20-3.10 (m, 1H), 3.07-3.00 (m, 1H), 2.94 (t, J=7.3 Hz, 2H),
2.88 (s, 3H), 2.81 (t, J=7.3 Hz, 2H), 2.55 (s, 3H), 2.17-2.06 (m,
1H), 2.00-1.87 (m, 2H), 1.83-1.74 (m, 1H).
[0263] The following compounds were prepared according to the
procedures of Compound 165 using the corresponding intermediates
and reagents under appropriate conditions that could be recognized
by one skilled in the art.
TABLE-US-00020 LC- MS (m/z) Com- (M + pound Structure H).sup.+
.sup.1H NMR 166 ##STR00242## 440.1 .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. 8.13 (s, 2H), 8.03 (s, 1H), 7.58 (s, 1H), 7.39
(dd, J = 7.8 Hz, 2.0 Hz, 1H), 7.26 (dd, J = 5.9 Hz, 2.0 Hz, 1H),
4.95-4.89 (m, 1H), 3.87 (s, 3H), 3.84-3.78 (m, 2H), 3.59-3.50 (m,
2H), 2.92 (t, J = 7.3 Hz, 2H), 2.87 (s, 3H), 2.80 (t, J = 7.4 Hz,
2H), 2.43 (s, 3H). 167 ##STR00243## 454.2 .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. 8.13 (s, 2H), 8.03 (s, 1H), 7.58 (s, 1H), 7.39
(dd, J = 7.8 Hz, 2.1 Hz, 1H), 7.26 (dd, J = 5.9 Hz, 2.1 Hz, 1H),
4.98-4.90 (m, 1H), 3.86 (s, 3H), 3.82-3.75 (m, 2H), 3.52-3.45 (m,
2H), 2.92 (t, J = 7.4 Hz, 2H), 2.87 (s, 3H), 2.79 (t, J = 7.4 Hz,
2H), 2.63 (q, J = 7.2 Hz, 2H), 1.01 (t, J = 7.2 Hz, 3H). 168
##STR00244## 454.0 .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 8.14
(s, 2H), 8.01 (s, 1H), 7.55 (s, 1H), 7.41 (dd, J = 7.8 Hz, 2.1 Hz,
1H), 7.28 (dd, J = 6.0 Hz, 2.1 Hz, 1H), 4.90-4.89 (m, 1H), 3.89 (s,
3H), 3.11-3.04 (m, 1H), 2.95 (t, J = 7.4 Hz, 2H), 2.92- 2.86 (m,
5H), 2.82 (t, J = 7.3 Hz, 2H), 2.77-2.71 (m, 1H), 2.52-2.45 (m,
1H), 2.44 (s, 3H), 2.27-2.16 (m, 1H). 169 ##STR00245## 454.0
.sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 8.14 (s, 2H), 8.01 (s,
1H), 7.54 (s, 1H), 7.41 (dd, J = 7.8 Hz, 2.2 Hz, 1H), 7.27 (dd, J =
6.0 Hz, 2.1 Hz, 1H), 4.90-4.87 (m, 1H), 3.89 (s, 3H), 3.09-3.03 (m,
1H), 2.95 (t, J = 7.4 Hz, 2H), 2.92- 2.85 (m, 5H), 2.82 (t, J = 7.4
Hz, 2H), 2.76-2.69 (m, 1H), 2.52-2.44 (m, 1H), 2.43 (s, 3H),
2.25-2.15 (m, 1H). 170 ##STR00246## 468.0 .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. 8.15 (s, 2H), 8.04 (s, 1H), 7.57 (s, 1H), 7.42
(dd, J = 7.8 Hz, 2.1 Hz, 1H), 7.29 (dd, J = 7.8 Hz, 2.1 Hz, 1H),
5.01-4.98 (m, 1H), 3.89 (s, 3H), 3.49-3.48 (m, 2H), 3.36-3.35 (m,
2H), 3.15-3.12 (m, 2H), 2.96 (t, J = 7.2 Hz, 2H), 2.90 (s, 3H),
2.83 (t, J = 7.2 Hz, 2H), 2.54- 2.45 (m, 1H), 2.31-2.19 (m, 1H),
1.23 (t, J = 7.0 Hz, 3H). 171 ##STR00247## 468.0 .sup.1H NMR (400
MHz, CD.sub.3OD) .delta. 8.15 (s, 2H), 8.06 (s, 1H), 7.60 (s, 1H),
7.42 (dd, J = 7.7 Hz, 2.1 Hz, 1H), 7.30 (dd, J = 7.7 Hz, 2.1 Hz,
1H), 5.15-5.08 (m, 1H), 3.89 (s, 3H), 3.56-3.42 (m, 2H), 3.40-3.33
(m, 2H), 3.12-3.04 (m, 2H), 2.96 (t, J = 7.3 Hz, 2H), 2.90 (s, 3H),
2.84 (d, J = 7.5 Hz, 2H), 2.64- 2.54 (m, 1H), 2.36-2.27 (m, 1H),
1.30 (t, J = 7.4 Hz, 3H). 172 ##STR00248## 468.0 .sup.1H NMR (400
MHz, CD.sub.3OD) .delta. 8.13 (s, 2H), 8.02 (s, 1H), 7.57 (s, 1H),
7.40 (dd, J = 7.8 Hz, 2.1 Hz, 1H), 7.27 (dd, J = 6.0 Hz, 2.2 Hz,
1H), 4.54-4.48 (m, 1H), 3.87 (s, 3H), 3.48-3.42 (m, 1H), 3.35-3.33
(m, 2H), 3.21-3.16 (m, 1H), 2.94 (t, J = 7.4 Hz, 2H), 2.88 (s, 3H),
2.81 (t, J = 7.4 Hz, 2H), 2.74 (s, 3H), 2.16-2.06 (m, 1H), 2.04-
1.92 (m, 2H), 1.87-1.75 (m, 1H). 173 ##STR00249## 468.1 .sup.1H NMR
(400 MHz, CD.sub.3OD) .delta. 8.12 (s, 2H), 7.93 (s, 1H), 7.52 (s,
1H), 7.39 (d, J = 6.9 Hz, 1H), 7.26 (d, J = 4.3 Hz, 1H), 4.15-4.03
(m, 1H), 3.87 (s, 3H), 3.01-2.90 (m, 4H), 2.87 (s, 3H), 2.83-2.72
(m, 2H), 2.30 (s, 3H), 2.25- 2.15 (m, 2H), 2.12-1.98 (m, 4H). 174
##STR00250## 482.0 .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 8.13
(s, 2H), 8.02 (s, 1H), 7.56 (s, 1H), 7.40 (dd, J = 7.7 Hz, 2.1 Hz,
1H), 7.26 (dd, J = 6.0 Hz, 2.1 Hz, 1H), 4.55-4.51 (m, 1H), 3.87 (s,
3H), 3.47-3.36 (m, 2H), 3.35-3.32 (m, 2H), 3.25-3.20 (m, 1H),
3.20-3.12 (m, 1H), 2.94 (t, J = 7.4 Hz, 2H), 2.88 (s, 3H), 2.81 (t,
J = 7.4 Hz, 2H), 2.21-2.08 (m, 1H), 2.07-1.93 (m, 2H), 1.89-1.80
(m, 1H), 1.33-1.21 (m, 3H). 175 ##STR00251## 482.0 .sup.1H NMR (400
MHz, CD.sub.3OD) .delta. 8.13 (s, 2H), 8.03 (s, 1H), 7.57 (s, 1H),
7.40 (dd, J = 7.8 Hz, 2.1 Hz, 1H), 7.27 (dd, J = 5.9 Hz, 2.1 Hz,
1H), 4.53-4.52 (m, 1H), 3.87 (s, 3H), 3.48-3.43 (m, 1H), 3.35-3.33
(m, 2H), 3.23-3.20 (m, 1H), 3.05-2.94 (m, 4H), 2.88 (s, 3H), 2.81
(t, J = 7.4 Hz, 2H), 2.17- 2.10 (m, 1H), 2.06-1.90 (m, 2H),
1.89-1.80 (m, 1H), 1.27 (t, J = 8.0 Hz, 3H). 176 ##STR00252## 482.2
.sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 8.12 (s, 2H), 7.93 (s,
1H), 7.52 (s, 1H), 7.39 (dd, J = 7.7 Hz, 1.7 Hz, 1H), 7.26 (dd, J =
5.8 Hz, 1.7 Hz, 1H), 4.18-4.04 (m, 1H), 3.87 (s, 3H), 3.12-3.01 (m,
2H), 2.93 (t, J = 7.2 Hz, 2H), 2.87 (s, 3H), 2.80 (t, J = 7.4 Hz,
2H), 2.47 (q, J = 7.2 Hz, 2H), 2.20-1.97 (m, 6H), 1.11 (t, J = 7.2
Hz, 3H). 177 ##STR00253## 484.0 .sup.1H NMR (400 MHz, CD.sub.3OD)
.delta. 8.14 (s, 2H), 7.95 (s, 1H), 7.53 (s, 1H), 7.36 (d, J = 2.0
Hz, 1H), 7.30 (d, J = 2.0 Hz, 1H), 4.15-4.06 (m, 1H), 3.92 (s, 3H),
3.05 (t, J = 7.6 Hz, 2H), 3.01- 2.95 (m, 2H), 2.89 (s, 3H), 2.82
(t, J = 7.6 Hz, 2H), 2.31 (s, 3H), 2.26-2.17 (m, 2H), 2.11-2.01 (m,
4H). 178 ##STR00254## 498.0 .sup.1H NMR (400 MHz, CD.sub.3OD)
.delta. 8.15 (s, 2H), 8.01 (s, 1H), 7.57 (s, 1H), 7.37 (s, 1H),
7.30 (s, 1H), 4.51-4.39 (m, 1H), 3.92 (s, 3H), 3.67-3.57 (m, 2H),
3.23-3.08 (m, 4H), 3.05 (t, J = 7.5 Hz, 2H), 2.89 (s, 3H), 2.83 (t,
J = 7.6 Hz, 2H), 2.37-2.26 (m, 4H), 1.35 (t, J = 7.3 Hz, 3H).
##STR00255##
Example 19
Synthesis of Compound 179
Compound 179
4-cyano-3-(2-(2-((1-ethyl-1H-pyrazol-4-yl)amino)pyrimidin-5-yl)ethyl)-5-me-
thoxy-N-methylbenzamide
##STR00256##
[0264] (A)
(E)-4-cyano-3-(2-((1-ethyl-1H-pyrazol-4-yl)amino)pyrimidin-5-yl-
)vinyl)-5-methoxy-N-methylbenzamide
[0265] A mixture of
(E)-4-bromo-3-(2-(2-((1-ethyl-1H-pyrazol-4-yl)amino)pyrimidin-5-yl)
vinyl)-5-methoxy-N-methylbenzamide (0.060 g, 0.13 mmol), zinc
cyanide (0.030 g, 0.26 mmol) and Pd(PPh.sub.3).sub.4 (0.015 g,
0.013 mmol) in DMF (5 mL) was heated at 100.degree. C. for 30 min
under microwave. Then the mixture was purified via ISCO (eluted
with MeOH in H.sub.2O 0.about.100%) directly to afford the title
compound as a white solid (0.045 g, 85.0% yield). MS (m/z): 404.1
(M+H).sup.+.
(B)
4-cyano-3-(2-(2-((1-ethyl-1H-pyrazol-4-yl)amino)pyrimidin-5-yl)ethyl)--
5-methoxy-N-methylbenzamide
[0266] To a solution of
(E)-4-cyano-3-(2-(2-((1-ethyl-1H-pyrazol-4-yl)amino)pyrimidin-5-yl)
vinyl)-5-methoxy-N-methylbenzamide (0.045 g, 0.11 mmol) in MeOH (10
mL) was added Pd/C (10%, 0.012 g) and the resulting mixture was
stirred at 40.degree. C. for 16 h under hydrogen atmosphere. The
catalyst was filtered off through celite and the filtrate was
concentrated. The residue was purified via PTLC (DCM/MeOH) to
afford the title compound as a yellow solid (0.023 g, 50.9% yield).
MS (m/z): 406.1 (M+H).sup.+. .sup.1H NMR (400 MHz, CD.sub.3OD)
.delta. 8.15 (s, 2H), 7.91 (s, 1H), 7.51 (s, 1H), 7.40 (s, 1H),
7.37 (s, 1H), 4.12 (q, J=6.6 Hz, 2H), 3.97 (s, 3H), 3.08 (t, J=7.1
Hz, 2H), 2.91 (s, 3H), 2.89-2.83 (m, 2H), 1.43 (t, J=6.6 Hz,
3H).
Example 20
Synthesis of Compounds 181-185
Compound 181
3-(((2-((1-ethyl-1H-pyrazol-4-yl)amino)pyrimidin-5-yl)oxy)methyl)-4-fluoro-
-5-methoxy-N-methylbenzamide
##STR00257##
[0267] (A) Methyl
3-(((2-((1-ethyl-1H-pyrazol-4-yl)amino)pyrimidin-5-yl)oxy)methyl)-4-fluor-
o-5-methoxybenzoate
[0268] To a solution of
2-((1-ethyl-1H-pyrazol-4-yl)amino)pyrimidin-5-ol (150 mg, 0.73
mmol) and methyl 3-(bromomethyl)-4-fluoro-5-methoxybenzoate (203
mg, 0.73 mmol) in DMF (10 mL) were added K.sub.2CO.sub.3 (203 mg,
1.47 mmol) and Bu.sub.4NI (54 mg, 0.15 mmol). Then the mixture was
stirred overnight at 60.degree. C. After cooled to room
temperature, the mixture was partitioned between EA and water and
the organic layer was washed with water and brine, dried over
anhydrous sodium sulfate and concentrated. The residue was purified
via ISCO (eluted with EA in PE 0.about.100%) to afford the title
compound as a yellow solid (160 mg, 54.5% of yield). MS (m/z):
402.1 (M+H).sup.+.
(B)
3-(((2-((1-ethyl-1H-pyrazol-4-yl)amino)pyrimidin-5-yl)oxy)methyl)-4-fl-
uoro-5-methoxy-N-methylbenzamide
[0269] To a solution of methyl
3-(((2-((1-ethyl-1H-pyrazol-4-yl)amino)pyrimidin-5-yl)oxy)methyl)-4-fluor-
o-5-methoxybenzoate (160 mg, 0.40 mmol) in MeOH (20 mL) was added
aqueous NaOH solution (2 N, 5 mL, 10 mmol). Then the mixture was
stirred at room temperature for overnight. The volatiles were
removed under reduced pressure and the residue was adjusted to
pH<2 with conc HCl and concentrated to give a brown solid which
was suspended in DMF (10 mL). Then methanamine hydrochloride (32
mg, 0.48 mmol), HATU (228 mg, 0.60 mmol) and DIPEA (155 mg, 1.20
mmol) were added. The resulting mixture was stirred for 2 h at room
temperature and then partitioned between EA and water. The organic
layer was washed with water and brine, dried over anhydrous sodium
sulfate and concentrated. The residue was purified via ISCO (eluted
with MeOH in DCM 0.about.10%) to afford the title compound as a
yellow solid (94.3 mg, 59.1% of yield). MS (m/z): 401.1
(M+H).sup.+. .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 8.22 (s,
2H), 7.92 (s, 1H), 7.58 (s, 1H), 7.56 (s, 1H), 7.51 (s, 1H), 5.16
(s, 2H), 4.12 (q, J=7.3 Hz, 2H), 3.94 (s, 3H), 2.91 (s, 3H), 1.43
(t, J=7.3 Hz, 3H).
[0270] The following compounds were prepared according to the
procedures of Compound 181 using the corresponding intermediates
and reagents under appropriate conditions that could be recognized
by one skilled in the art.
TABLE-US-00021 LC-MS Com- (m/z) pound Structure (M + H).sup.+
.sup.1H NMR 182 ##STR00258## 387.1 .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. 8.22 (s, 2H), 7.89 (s, 1H), 7.57 (s, 1H), 7.56
(s, 1H), 7.50 (s, 1H), 5.16 (s, 2H), 3.94 (s, 3H), 3.84 (s, 3H),
2.91 (s, 3H). 183 ##STR00259## 403.1 .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. 8.23 (s, 2H), 7.89 (s, 1H), 7.64 (d, J = 1.8
Hz, 1H), 7.51 (d, J = 1.9 Hz, 1H), 7.50 (s, 1H), 5.20 (s, 2H), 3.97
(s, 3H), 3.84 (s, 3H), 2.92 (s, 3H). 184 ##STR00260## 416.9 .sup.1H
NMR (400 MHz, CD.sub.3OD) .delta. 8.22 (s, 2H), 7.92 (s, 1H), 7.64
(s, 1H), 7.51 (s, 2H), 5.20 (s, 2H), 4.11 (q, J = 7.2 Hz, 2H), 3.96
(s, 3H), 2.91 (s, 3H), 1.42 (t, J = 7.3 Hz, 3H). 185 ##STR00261##
419.1 .sup.1H NMR (400 MHz, DMSO-d6) .delta. 11.99 (s, 1H), 9.27
(s, 1H), 8.37 (s, 2H), 7.90 (s, 1H), 7.67 (d, J = 1.6 Hz, 1H), 7.55
(d, J = 1.6 Hz, 1H), 7.49 (s, 1H), 5.27 (s, 2H), 4.00 (s, 3H), 3.85
(s, 3H), 3.79 (s, 3H).
Example 21
Synthesis of Compounds 186-195, 197, 199, 201-203, 205, 207,
209-211, 220
Compound 186
4-chloro-3-(((2-((4-((3S,5R)-3,5-dimethylpiperazin-1-yl)phenyl)amino)pyrim-
idin-5-yl)oxy)methyl)-5-methoxy-N-methylbenzamide
##STR00262##
[0271] (A) Methyl
4-chloro-3-((2-chloropyrimidin-5-yloxy)methyl)-5-methoxybenzoate
[0272] A mixture of 3-(bromomethyl)-4-chloro-5-methoxybenzoate (600
mg, 2.04 mmol), 2-chloropyrimidin-5-ol (320 mg, 2.45 mmol),
Bu.sub.4NI (151 mg, 0.408 mmol) and K.sub.2CO.sub.3 (564 mg, 4.08
mmol) in DMF (15 mL) was stirred at 60.degree. C. for 2 h. The
resulting mixture was partitioned between water (100 mL) and DCM
(100 mL). Then the organic layer was concentrated to afford the
title compound as a yellow solid (700 mg, quantative yield). MS
(m/z): 343.0 (M+H).sup.+.
(B) Methyl
4-chloro-3-((2-(4-((3S,5R)-3,5-dimethylpiperazin-1-yl)phenylami-
no)pyrimidin-5-yloxy)methyl)-5-methoxybenzoate
[0273] A mixture of methyl
4-chloro-3-((2-chloropyrimidin-5-yloxy)methyl)-5-methoxybenzoate
(500 mg, 1.460 mmol), 4-((3S,5R)-3,5-dimethylpiperazin-1-yl)
aniline (359 mg, 1.750 mmol), Palladium(II) acetate (33 mg, 0.146
mmol), Xantphos (169 mg, 0.292 mmol) and Cs.sub.2CO.sub.3 (1.43 g,
4.38 mmol) in 1,4-dioxane (10 mL) was stirred at 80.degree. C. for
overnight. The resulting mixture was concentrated and the residue
was partitioned between water (50 mL) and EA (50 mL). The aqueous
layer was extracted with EA (2*50 mL). The combined organic layers
were concentrated and the residue was purified via ISCO (eluted
with MeOH in H.sub.2O 0.about.100%) to afford the title compound as
a brown solid (480 mg, 64.3% yield). MS (m/z): 511.9
(M+H).sup.+.
(C)
4-chloro-3-((2-(4-((3S,5R)-3,5-dimethylpiperazin-1-yl)phenylamino)pyri-
midin-5-yloxy)methyl)-5-methoxybenzoic acid
[0274] A mixture of methyl
4-chloro-3-((2-(4-((3S,5R)-3,5-dimethylpiperazin-1-yl)phenylamino)pyrimid-
in-5-yloxy)methyl)-5-methoxybenzoate (288 mg, 0.562 mmol) and a
solution of 30% sodium hydroxide (3 mL, 22.5 mmol) in MeOH (10 mL)
was stirred at 50.degree. C. for 2 h. The resulting mixture was
cooled to ambient temperature, adjusted to pH=7 with 2N HCl,
concentrated to afford the title compound as a white solid (280 mg,
quantitative yield). MS (m/z): 497.9 (M+H).sup.+.
(D)
4-chloro-3-((2-(4-((3S,5R)-3,5-dimethylpiperazin-1-yl)phenylamino)pyri-
midin-5-yloxy)methyl)-5-methoxy-N-methylbenzamide
[0275] A mixture of
4-chloro-3-((2-(4-((3S,5R)-3,5-dimethylpiperazin-1-yl)phenylamino)pyrimid-
in-5-yloxy)methyl)-5-methoxybenzoic acid (280 mg, 0.562 mmol),
methylamine hydrochloride (75 mg, 1.124 mmol), HATU (641 mg, 1.686
mmol) and DIPEA (217 mg, 1.686 mmol) in DMF (10 mL) was stirred at
ambient temperature for 1 h. The resulting mixture was
concentrated, purified via ISCO (eluted with MeOH in H.sub.2O
0.about.100%) to afford the title compound as a yellow solid (184
mg, 64.0% yield). MS (m/z): 510.9 (M+H).sup.+. .sup.1H NMR (400
MHz, CD.sub.3OD) .delta. 8.21 (s, 2H), 7.65 (d, J=1.9 Hz, 1H), 7.52
(d, J=1.9 Hz, 1H), 7.47 (d, J=9.0 Hz, 2H), 6.94 (d, J=9.0 Hz, 2H),
5.22 (s, 2H), 3.97 (s, 3H), 3.48-3.45 (m, 2H), 3.06-2.99 (m, 2H),
2.92 (s, 3H), 2.28-2.23 (m, 2H), 1.16 (d, J=6.4 Hz, 6H).
[0276] The following compounds were prepared according to the
procedures of Compound 186 using the corresponding intermediates
and reagents under appropriate conditions that could be recognized
by one skilled in the art.
TABLE-US-00022 LC-MS Com- (m/z) pound Structure (M + H).sup.+
.sup.1H NMR 187 ##STR00263## 400.2 .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. 7.93-7.74 (m, 2H), 7.65-7.50 (m, 2H), 7.42 (s,
1H), 7.33-7.20 (m, 1H), 6.68-6.54 (m, 1H), 5.09 (s, 2H), 4.22-4.04
(m, 2H), 3.92 (s, 3H), 2.90 (s, 3H), 1.58-1.29 (m, 3H). 188
##STR00264## 466.9 .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 8.19
(s, 2H), 7.58-7.54 (m, 2H), 7.46 (d, J = 8.2 Hz, 2H), 6.93 (d, J =
8.3 Hz, 2H), 5.16 (s, 2H), 3.93 (s, 3H), 3.09-3.03 (m, 4H), 3.01-
2.94 (m, 4H), 2.90 (s, 3H). 189 ##STR00265## 472.0 .sup.1H NMR (400
MHz, CD.sub.3OD) .delta. 8.22 (s, 2H), 7.96 (s, 1H), 7.57- 7.55 (m,
2H), 7.53 (s, 1H), 5.16 (s, 2H), 4.17 (t, J = 7.0 Hz, 2H), 3.94 (s,
3H), 2.94-2.86 (m, 5H), 2.57 (q, J = 7.2 Hz, 4H), 1.03 (t, J = 7.2
Hz, 6H). 190 ##STR00266## 487.9 .sup.1H NMR (400 MHz, CD.sub.3OD)
.delta. 8.22 (s, 2H), 7.96 (s, 1H), 7.63 (s, 1H), 7.53 (s, 1H),
7.50 (s, 1H), 5.19 (s, 2H), 4.17 (t, J = 7.0 Hz, 2H), 3.94 (s, 3H),
2.93-2.84 (m, 5H), 2.57 (q, J = 7.2 Hz, 4H), 1.03 (t, J = 7.2 Hz,
6H). 191 ##STR00267## 494.3 .sup.1H NMR (400 MHz, CD.sub.3OD)
.delta. 7.81 (d, J = 2.9 Hz, 1H), 7.61- 7.51 (m, 2H), 7.38-7.20 (m,
3H), 6.93 (d, J = 8.7 Hz, 2H), 6.73 (d, J = 9.0 Hz, 1H), 5.11 (s,
2H), 3.93 (s, 3H), 3.47-3.39 (m, 2H), 3.05-2.96 (m, 2H), 2.90 (s,
3H), 2.23 (t, J = 11.0 Hz, 2H), 1.13 (d, J = 6.4 Hz, 6H). 192
##STR00268## 494.9 .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 8.20
(s, 2H), 7.59-7.55 (m, 2H), 7.47 (d, J = 8.9 Hz, 2H), 6.94 (d, J =
8.9 Hz, 2H), 5.17 (s, 2H), 3.94 (s, 3H), 3.44-3.42 (m, 2H), 3.00-
2.98 (m, 2H), 2.91 (s, 3H), 2.26- 2.20 (m, 2H), 1.14 (d, J = 6.4
Hz, 6H). 193 ##STR00269## 495.0 .sup.1H NMR (400 MHz, CD.sub.3OD)
.delta. 8.18 (s, 2H), 7.58-7.54 (m, 2H), 7.43 (d, J = 8.1 Hz, 2H),
6.88 (d, J = 8.3 Hz, 2H), 5.16 (s, 2H), 3.93 (s, 3H), 3.01-2.97 (m,
4H), 2.90 (s, 3H), 2.83-2.81 (m, 2H), 1.22 (s, 6H). 194
##STR00270## 509.3 .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 8.20
(s, 2H), 7.56 (s, 1H), 7.55- 7.53 (m, 1H), 7.44 (dd, J = 8.6 Hz,
2.5 Hz, 1H), 7.41 (d, J = 1.7 Hz, 1H), 6.99 (d, J = 8.6 Hz, 1H),
5.16 (s, 2H), 3.92 (s, 3H), 3.51- 3.41 (m, 2H), 3.17-3.10 (m, 2H),
2.89 (s, 3H), 2.63 (t, J = 11.8 Hz, 2H), 2.27 (s, 3H), 1.31 (d, J =
6.8 Hz, 6H). 195 ##STR00271## 513.3 .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. 8.25 (s, 2H), 7.70-7.65 (m, 1H), 7.58-7.53 (m,
2H), 7.26 (dd, J = 8.6 Hz, 1.4 Hz, 1H), 7.00 (t, J = 9.1 Hz, 1H),
5.18 (s, 2H), 3.93 (s, 3H), 3.58-3.51 (m, 2H), 3.46 (dd, J = 12.6
Hz, 1.4 Hz, 2H), 2.90 (s, 3H), 2.73 (t, J = 11.9 Hz, 2H), 1.35 (d,
J = 6.8 Hz, 6H). 197 ##STR00272## 511.9 .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. 8.32 (d, J = 2.7 Hz, 1H), 8.20 (s, 2H), 7.84
(dd, J = 9.0 Hz, 2.8 Hz, 1H), 7.63 (d, J = 1.9 Hz, 1H), 7.50 (d, J
= 1.8 Hz, 1H), 6.80 (d, J = 9.1 Hz, 1H), 5.20 (s, 2H), 4.01 (dd, J
= 12.7 Hz, 2.4 Hz, 2H), 3.95 (s, 3H), 2.96-2.91 (m, 2H), 2.90 (s,
3H), 2.40-2.32 (m, 2H), 1.15 (d, J = 6.4 Hz, 6H). 199 ##STR00273##
513.3 .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 8.17 (s, 2H),
7.53-7.47 (m, 1H), 7.45 (d, J = 8.9 Hz, 2H), 6.92 (d, J = 8.8 Hz,
2H), 5.17 (s, 2H), 3.89 (s, 3H), 3.49-3.41 (m, 2H), 3.06- 2.96 (m,
2H), 2.91 (s, 3H), 2.24 (t, J = 11.1 Hz, 2H), 1.14 (d, J = 6.4 Hz,
6H). 201 ##STR00274## 495.9 .sup.1H NMR (400 MHz, CD.sub.3OD)
.delta. 8.24 (d, J = 2.6 Hz, 1H), 8.12 (s, 2H), 7.76 (dd, J = 9.1
Hz, 2.7 Hz, 1H), 7.51-7.46 (m, 2H), 6.72 (d, J = 9.0 Hz, 1H), 5.09
(s, 2H), 3.92 (dd, J = 12.5 Hz, 2.4 Hz, 2H), 3.85 (s, 3H),
2.86-2.78 (m, 2H), 2.83 (s, 3H), 2.31-2.20 (m, 2H), 1.06 (d, J =
6.4 Hz, 6H). 202 ##STR00275## 483.9 .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. 8.20 (s, 2H), 8.00 (s, 1H), 7.57- 7.53 (m, 3H),
5.16 (s, 2H), 3.93 (s, 3H), 3.91-3.85 (m, 1H), 3.64- 3.56 (m, 1H),
3.39-3.36 (m, 1H), 2.90 (s, 3H), 2.32-2.22 (m, 2H), 2.21-2.09 (m,
2H), 1.48 (d, J = 7.2 Hz, 3H), 1.34 (d, J = 6.8 Hz, 3H). 203
##STR00276## 419.4 .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 8.19
(s, 2H), 7.90 (s, 1H), 7.51 (s, 1H), 7.47 (dd, J = 9.4 Hz, 6.8 Hz,
1H), 5.17 (s, 2H), 4.11 (q, J = 7.3 Hz, 2H), 3.89 (s, 3H), 2.91 (s,
3H), 1.42 (t, J = 7.3 Hz, 3H). 205 ##STR00277## 509.3 .sup.1H NMR
(400 MHz, CD.sub.3OD) .delta. 8.18 (s, 2H), 7.59-7.53 (m, 2H), 7.45
(d, J = 9.0 Hz, 2H), 6.91 (d, J = 9.0 Hz, 2H), 5.14 (s, 2H), 3.92
(s, 3H), 3.46 (dd, J = 12.1 Hz, 2.3 Hz, 2H), 3.39 (q, J = 7.3 Hz,
2H), 3.04-2.94 (m, 2H), 2.22 (t, J = 11.1 Hz, 2H), 1.20 (t, J = 7.3
Hz, 3H), 1.13 (d, J = 6.4 Hz, 6H). 207 ##STR00278## 441.2 .sup.1H
NMR (400 MHz, DMSO-d6) .delta. 9.31 (s, 1H), 8.51-8.45 (m, 1H),
8.34 (s, 2H), 7.64-7.60 (m, 2H), 7.58 (d, J = 8.4 Hz, 2H), 7.11 (d,
J = 8.4 Hz, 2H), 5.20 (s, 2H), 3.91 (s, 3H), 3.34 (s, 2H), 2.76 (d,
J = 4.3 Hz, 3H). 209 ##STR00279## 524.9 .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. 8.21 (s, 2H), 7.63 (d, J = 2.0 Hz, 1H), 7.50
(d, J = 1.9 Hz, 1H), 7.39-7.35 (m, 2H), 6.94 (d, J = 8.6 Hz, 1H),
5.20 (s, 2H), 3.95 (s, 3H), 3.07-2.96 (m, 2H), 2.93- 2.88 (m, 2H),
2.90 (s, 3H), 2.30- 2.23 (m, 2H), 2.25 (s, 3H), 1.09 (d, J = 6.5
Hz, 6H). 210 ##STR00280## 406.9 .sup.1H NMR (400 MHz, DMSO-d6)
.delta. 9.66 (s, 1H), 8.46 (s, 1H), 8.37 (s, 2H), 7.71 (d, J = 8.7
Hz, 2H), 7.62- 7.56 (m, 2H), 7.33 (d, J = 8.6 Hz, 2H), 5.20 (s,
2H), 3.92 (s, 1H), 3.88 (s, 3H), 2.76 (d, J = 4.5 Hz, 3H). 211
##STR00281## 398.9 .sup.1H NMR (400 MHz, DMSO-d6) .delta. 9.00 (s,
1H), 8.89 (s, 1H), 8.45 (s, 1H), 8.24 (s, 2H), 7.64-7.52 (m, 2H),
7.39 (d, J = 8.5 Hz, 2H), 6.63 (d, J = 8.6 Hz, 2H), 5.15 (s, 2H),
3.87 (s, 3H), 2.75 (d, J = 3.9 Hz, 3H). 220 ##STR00282## 528.9
.sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 8.25 (s, 2H), 7.64 (d, J
= 1.7 Hz, 1H), 7.60 (dd, J = 15.1 Hz, 2.4 Hz, 1H), 7.51 (d, J = 1.7
Hz, 1H), 7.21 (dd, J = 8.7 Hz, 1.6 Hz, 1H), 6.93 (t, J = 9.2 Hz,
1H), 5.22 (s, 2H), 3.96 (s, 3H), 3.22-3.16 (m, 2H), 3.05-2.98 (m,
2H), 2.91 (s, 3H), 2.27 (t, J = 10.9 Hz, 2H), 1.10 (d, J = 6.4 Hz,
6H). ##STR00283##
Example 22
Synthesis of Compounds 222-223
Compound 222
4-chloro-3-((2-((4-((3S,5R)-3,5-dimethylpiperazin-1-yl)phenyl)amino)pyrimi-
din-5-yl)ethynyl)-5-methoxy-N-methylbenzamide
##STR00284##
[0277] (A) Methyl 4-chloro-3-ethynyl-5-methoxybenzoate
[0278] A mixture of methyl 3-bromo-4-chloro-5-methoxybenzoate (0.81
g, 2.90 mmol), ethynyltriisopropylsilane (0.6 g, 3.29 mmol), CuI
(0.055 g, 0.29 mmol), PdCl.sub.2(PPh.sub.3).sub.2 (0.202 g, 0.29
mmol) and triethylamine (0.6 g, 5.93 mmol) in THF (20 mL) was
stirred at 60.quadrature. for 16 h under nitrogen atmosphere. The
resulting mixture was partitioned between water (100 mL) and EA
(100 mL). The organic layer was then dried over anhydrous
Na.sub.2SO.sub.4 and concentrated under reduced pressure. The
residue was dissolved in tetrabutylammonium fluoride THF solution
(1 M, 10 mL) and the resulting mixture was stirred at ambient
temperature for 4 h. The volatiles were removed under reduced
pressure and the residue was purified via ISCO (eluted with MeOH in
H.sub.2O 0.about.100%) to afford the title compound as a yellow
solid (0.25 g, 38.4% yield). MS (m/z): 225.0 (M+H).sup.+.
(B)
4-chloro-3-((2-((4-((3S,5R)-3,5-dimethylpiperazin-1-yl)phenyl)amino)py-
rimidin-5-yl)ethynyl)-5-methoxybenzoate
[0279] A mixture of methyl 4-chloro-3-ethynyl-5-methoxybenzoate
(0.052 g, 0.231 mmol),
5-bromo-N-(4-((3R,5S)-3,5-dimethylpiperazin-1-yl)phenyl)pyrimidin-2-amine
(0.160 g, 0.442 mmol), CuI (0.005 g, 0.026 mmol) and
PdCl.sub.2(PPh.sub.3).sub.2 (0.018 g, 0.026 mmol) in THF (8 mL) was
stirred at 60.quadrature. for 3 h under nitrogen atmosphere. The
volatiles were removed under reduced pressure and the residue was
purified via ISCO (eluted with MeOH in H.sub.2O 0.about.100%) to
afford the title compound as a yellow solid (0.045 g, 38.4% yield).
MS (m/z): 506.3 (M+H).sup.+.
(C)
4-chloro-3-((2-((4-((3S,5R)-3,5-dimethylpiperazin-1-yl)phenyl)amino)py-
rimidin-5-yl)ethynyl)-5-methoxy-N-methylbenzamide
[0280] A mixture of
4-chloro-3-((2-((4-((3S,5R)-3,5-dimethylpiperazin-1-yl)phenyl)amino)pyrim-
idin-5-yl)ethynyl)-5-methoxybenzoate (0.045 g, 0.089 mmol) and a
solution of sodium hydroxide (0.043 g in 1 mL water, 1.075 mmol) in
MeOH (2 mL) and THF (3 mL) was stirred at ambient temperature for 2
h. Then the reaction mixture was purified via ISCO (eluted with
MeOH in H.sub.2O 0.about.100%) directly to afford the acid as a
white solid (0.031 g, 70.9% yield). MS (m/z): 492.3 (M+H).sup.+. A
mixture of the intermediate acid (0.031 g, 0.063 mmol), methylamine
hydrochloride (0.012 g, 0.179 mmol), HATU (0.080 g, 0.210 mmol) and
DIPEA (0.040 g, 0.310 mmol) in DMF (5 mL) was stirred at ambient
temperature for 30 min. Then the reaction mixture was purified via
ISCO (eluted with MeOH in H.sub.2O 0.about.100%) directly to afford
the title compound as a yellow solid (0.011 g, 34.6% yield). MS
(m/z): 505.3 (M+H).sup.+. .sup.1H NMR (400 MHz, CDCl.sub.3) .delta.
8.53 (s, 2H), 7.53-7.38 (m, 4H), 7.16 (s, 1H), 6.93 (d, J=8.4 Hz,
2H), 6.15 (s, 1H), 3.97 (s, 3H), 3.55-3.38 (m, 2H), 3.13-3.03 (m,
2H), 3.02 (d, J=4.6 Hz, 3H), 2.37-2.20 (m, 2H), 1.14 (d, J=5.8 Hz,
6H).
[0281] The following compounds were prepared according to the
procedures of Compound 222 using the corresponding intermediates
and reagents under appropriate conditions that could be recognized
by one skilled in the art.
TABLE-US-00023 LC-MS Com- (m/z) pound Structure (M + H).sup.+
.sup.1H NMR 223 ##STR00285## 411.2 .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. 8.55 (s, 2H), 8.00 (s, 1H), 7.63 (d, J = 1.7
Hz, 1H), 7.60 (s, 1H), 7.50 (d, J = 1.7 Hz, 1H), 4.16 (q, J = 7.2
Hz, 2H), 3.97 (s, 3H), 2.93 (s, 3H), 1.47 (t, J = 7.2 Hz, 3H).
Example 23
Transcreener Kinase Assay of FGFR1
[0282] Solution Preparation [0283] Transcreenen.TM. KINASE Assay
kit: Bellbrook Labs., 3003-10K; [0284] Recombinant human FGFR1:
Invitrogen, PV3146; [0285] Poly E4Y (substrate): Sigma, P0275; 5
mg/mL, dissolved in MilliQ water; [0286] Assay buffer: 67 mM HEPES,
0.013% Triton X-100, 27 mM MgCl.sub.2, 0.67 mM MnCl.sub.2, 1.25 mM
DTT, PH 7.4; [0287] 10 mM ATP: Invitrogen, PV3227; [0288] 500 mM
EDTA: Invitrogen, 15575-038; [0289] 96 well black Greiner plate:
Greiner, 675076.
[0290] Prepare Solution [0291] Compounds were solved in DMSO and
were diluted with assay buffer to 5 folds of final concentration
keeping the DMSO concentration at 5%. Further dilution are needed
to make final concentrations are at 1, 0.33, 0.11, 0.037, 0.012,
0.004, 0.0014, 0.0005 .mu.M; (the final concentration of DMSO is
1%). [0292] Enzyme/Substrate stock Preparation: Recombinant human
FGFR1 and Poly E4Y are both diluted in assay buffer. The final
concentration is 0.4 ng/.mu.L for FGFR1 and 62.5 ng/.mu.L for Poly
E4Y. The mixture is being kept in ice before use; [0293] ATP
Diluents Preparation: 10 mM ATP is diluted in assay buffer, the
final concentration is 25 .mu.M; [0294] ADP Diluents Preparation:
dilute ADP (500 .mu.M) in assay buffer, the final concentration is
25 .mu.M; [0295] Prepare ATP standard curve stock as following:
TABLE-US-00024 [0295] ADP diluents ATP diluents Column (.mu.L)
(.mu.L) 1 50 0 2 25 25 3 10 40 4 5 45 5 5 95 6 5 195 7 5 495 8 4
496 9 3 497 10 2 498 11 1 499 12 1 999
[0296] Enzymatic Reaction [0297] In a 96-well plate, Add 5 .mu.L of
compound or control. (positive control: 5 .mu.L of 5% DMSO;
negative control: 5 .mu.L of 500 mM EDTA) into desired wells;
[0298] Add 10 .mu.L of Enzyme/Substrate stock into each well;
[0299] Add 10 .mu.L of ATP Diluents to initiate the enzyme reaction
and votex the plate immediately on a plate shaker; [0300] For the
wells to make standard curve, add 5 .mu.L of 5% DMSO, 10 .mu.L of
assay buffer and 10 .mu.L of ATP standard curve stock. [0301]
Incubate the plate for 45 min at 28.quadrature. on a plate shaker
in a low speed.
[0302] Stoping Reaction and Detecting ADP [0303] Detection Mix
Preparation: The mixture is made by dilution with MilliQ water; as
following: ADP Alexa633 tracer (1:100), ADP antibody (1:158), and
stop & detect buffer (1:10); [0304] Tracer Only control
Preparation: The mixture is made by dilution with MilliQ water; as
following: ADP Alexa633 tracer (1:100), and stop & detect
buffer (1:10) [0305] No Tracer control Preparation: stop &
detect buffer is diluted with MilliQ water; by 10 fold. [0306] Add
25 .mu.L of detection mix, Tracer Only control and No Tracer
control into corresponding wells, respectively; [0307] Incubate at
28.quadrature. for 1 h, on a plate shaker in a low speed; [0308]
Measure florescence polarization (FP) on TECAN F500. Excitation
wavelength: 610 nm, Emission wavelength: 670 nm.
[0309] Data Analysis
Inhibition ( % ) = 100 - [ ADP ] in Compound well [ ADP ] in
Positive control well .times. 100 ##EQU00001##
Note:
[0310] [ADP] in Compound well represents the ADP concentration in
compound well. [0311] [ADP] in Positive control well represents the
ADP concentration in 5% DMSO well [0312] Conversion of mP value to
ADP concentration is calculated based on the formula which
determined by standard curve. And mP value is measured by following
the instruction provided by BellBrook Labs.
(www.bellbrooklabs.com). 6. IC.sub.50: calculated using XL-Fit 2.0
software.
Example 24
Transcreener Kinase Assay of FGFR2
1. Solution Preparation
[0312] [0313] Transcreenen.TM. KINASE Assay kit: Bellbrook Labs.,
3003-10K; [0314] Recombinant human FGFR2: Invitrogen, PV3368;
[0315] Poly E4Y (substrate): Sigma, P0275; 5 mg/mL, dissolved in
MilliQ water; [0316] Assay buffer: 67 mM HEPES, 0.013% Triton
X-100, 27 mM MgCl.sub.2, 0.67 mM MnCl.sub.2, 1.25 mM DTT, PH 7.4;
[0317] 10 mM ATP: Invitrogen, PV3227; [0318] 500 mM EDTA:
Invitrogen, 15575-038; [0319] 96 well black Greiner plate: Greiner,
675076.
2. Prepare Solution
[0319] [0320] Compounds were solved in DMSO and were diluted with
assay buffer to 5 folds of final concentration keeping the DMSO
concentration at 5%. Further dilution are needed to make final
concentrations are at 1, 0.33, 0.11, 0.037, 0.012, 0.004, 0.0014,
0.0005 .mu.M; (the final concentration of DMSO is 1%). [0321]
Enzyme/Substrate stock Preparation: Recombinant human FGFR2 and
Poly E4Y are both diluted in assay buffer. The final concentration
is 0.3 ng/.mu.L for FGFR2 and 62.5 ng/.mu.L for Poly E4Y. The
mixture is being kept in ice before use; [0322] Prepare ATP
Diluents, 10 mM ATP is diluted in assay buffer, the final
concentration is 25 .mu.M; [0323] Prepare ADP Diluents: diluted ADP
(500 .mu.M) in assay buffer, the final concentration is 25 .mu.M;
[0324] Prepare ATP standard curve stock as following:
TABLE-US-00025 [0324] ADP diluents ATP diluents Column (.mu.L)
(.mu.L) 1 50 0 2 25 25 3 10 40 4 5 45 5 5 95 6 5 195 7 5 495 8 4
496 9 3 497 10 2 498 11 1 499 12 1 999
3. Enzymatic Reaction
[0325] In a 96-well plate, Add 5 .mu.L of compound or control.
(positive control: 5 .mu.L of 5% DMSO; negative control: 5 .mu.L of
500 mM EDTA) into desired wells; [0326] Add 10 .mu.L of
Enzyme/Substrate stock into each well; [0327] Add 10 .mu.L of ATP
Diluents to initiate the enzyme reaction and votex the plate
immediately on a plate shaker; [0328] For the wells to make
standard curve, add 5 .mu.L of 5% DMSO, 10 .mu.L of assay buffer
and 10 .mu.L of ATP standard curve stock. [0329] Incubate the plate
for 45 min at 28.quadrature. on a plate shaker in a low speed.
4. Stoping Reaction and Detecting ADP
[0329] [0330] Detection Mix Preparation: The mixture is made by
dilution with MilliQ water; as following: ADP Alexa633 tracer
(1:100), ADP antibody (1:158), and stop & detect buffer (1:10);
[0331] Tracer Only control Preparation: The mixture is made by
dilution with MilliQ water; as following: ADP Alexa633 tracer
(1:100), and stop & detect buffer (1:10) [0332] No Tracer
control Preparation: stop & detect buffer is diluted with
MilliQ water; by 10 fold. [0333] Add 25 .mu.L of detection mix,
Tracer Only control and No Tracer control into corresponding wells,
respectively; [0334] Incubate at 28.quadrature. for 1 h, on a plate
shaker in a low speed; [0335] Measure florescence polarization (FP)
on TECAN F500. Excitation wavelength: 610 nm, Emission wavelength:
670 nm.
5. Data Analysis
[0336] Inhibition ( % ) = 100 - [ ADP ] in Compound well [ ADP ] in
Positive control well .times. 100 ##EQU00002##
Note:
[0337] [ADP] in Compound well represents the ADP concentration in
compound well. [0338] [ADP] in Positive control well represents the
ADP concentration in 5% DMSO well [0339] Conversion of mP value to
ADP concentration is calculated based on the formula which
determined by standard curve. And mP value is measured by following
the instruction provided by BellBrook Labs.
(www.bellbrooklabs.com). 6. IC.sub.50: calculated using XL-Fit 2.0
software.
Example 25
Z-Lyte Kinase Assay of FGFR3
1. Materials and Reagents:
TABLE-US-00026 [0340] Vender Cat Number Z-lyte assay kit-TYR4
Invitrogen PV3193 Z-LYTE Tyr 4 Peptide Invitrogen PV3279 Z-LYTE Tyr
4 Phospho-peptide Invitrogen PV3280 5X Kinase Buffer Invitrogen
PV3189 10 mM ATP Invitrogen PV3227 Development Reagent B Invitrogen
PV3298 Development Buffer Invitrogen P3127 Stop Reagent Invitrogen
P3094 FGFR3 kinase Invitrogen PV3145 384-well plate(black) Corning
3575 Victor3 PerkinElmer .TM.
2. Reaction Steps:
Plate Map
TABLE-US-00027 [0341] Ref cpd Cons Cpd 1 Cons Cpd 2 Cons Cpd N Cons
1 (.mu.M) (.mu.M) (.mu.M) . . . (.mu.M) C1 1.00E+00 1.00E+00
1.00E+00 1.00E+00 1.00E+00 1.00E+00 1.00E+00 1.00E+00 3.33E-01
3.33E-01 3.33E-01 3.33E-01 3.33E-01 3.33E-01 3.33E-01 3.33E-01 C2
1.11E-01 1.11E-01 1.11E-01 1.11E-01 1.11E-01 1.11E-01 1.11E-01
1.11E-01 3.70E-02 3.70E-02 3.70E-02 3.70E-02 3.70E-02 3.70E-02
3.70E-02 3.70E-02 C3 1.23E-02 1.23E-02 1.23E-02 1.23E-02 1.23E-02
1.23E-02 1.23E-02 1.23E-02 4.12E-03 4.12E-03 4.12E-03 4.12E-03
4.12E-03 4.12E-03 4.12E-03 4.12E-03 1.37E-03 1.37E-03 1.37E-03
1.37E-03 1.37E-03 1.37E-03 1.37E-03 1.37E-03 4.57E-04 4.57E-04
4.57E-04 4.57E-04 4.57E-04 4.57E-04 4.57E-04 4.57E-04
3. Solution Preparation
[0342] 1) 1.33.times. Kinase Buffer: Dilute 5.times. Kinase Buffer
to 1.33.times. with ddH.sub.2O. [0343] 2) 4.times. Test Compounds:
Serially dilute the test compounds to 4 folds of the concentrations
desired, keeping the DMSO concentration at 8%. The final
concentrations are 1, 0.33, 0.11, 0.037, 0.012, 0.004, 0.0014,
0.00046 .mu.M, and the final concentration of DMSO is 2%. [0344] 3)
Kinase/Peptide Mixture (P/K solution): Prepare Kinase/Peptide
Mixture by diluting the kinase to 0.7 .mu.g/ml and the Z-LYTE.TM.
Tyr 4 peptide to 4 .mu.M in 1.33.times. Kinase Buffer. Mix gently
by pipetting. [0345] 4) Phospho-peptide Solution (PP solution): Add
0.4 .mu.l of Z-LYTE.TM. Tyr 4 Phospho-peptide to 99.6 .mu.l of
1.33.times. Kinase Buffer. [0346] 5) ATP Solution: Prepare ATP
Solution by diluting the 10 mM of ATP in 1.33.times. Kinase Buffer
to 300 uM. [0347] 6) Development Solution: Dilute Development
Reagent B with Development Buffer as 1:128.
4. Reaction
[0347] [0348] 1) Kinase reaction (10 .mu.l of Volume) [0349] In a
384-well plate, add 2.5 .mu.l of 4.times. test Cpds to each well
except C1, C2, C3 wells [0350] Add 2.5 .mu.l of 8% DMSO to C1, C2,
C3 wells [0351] Put the plate on ice [0352] Add 5 .mu.l of P/K
mixture to each test Cpd wells and C1, C2 wells [0353] Add 5 .mu.l
of PP Solution to C3 well [0354] Add 2.5 .mu.l of 1.33.times.
kinase buffer to C1 and C3 wells [0355] Add 2.5 .mu.l of
4.times.ATP Solution to each test Cpd wells and C2 well,
respectively. Shake the plate for 30 Sec and centrifuge (1500 rpm,
1 min) [0356] Seal the plate to protect from the light and incubate
the plate for 1 hour at RT (25-30.quadrature.) [0357] 2)
Development reaction [0358] Add 5 .mu.l of the Development solution
to all wells [0359] Shake the plate for 30 Sec and centrifuge (1500
rpm, 1 min) [0360] Seal the plate to protect from the light and
incubate the plate for 1 hour at RT (25-30.quadrature.) [0361] 3)
Stop and read [0362] Add 5 .mu.l of the Stop reagent to all wells
[0363] Shake the plate for 30 Sec and centrifuge (1500 rpm, 1 min)
[0364] Measure the value of Coumarin (Ex400 nm, Em445 nm) and
fluorescein (Ex400 nm, Em520 nm), respectively.
5. Data Analysis
[0365] Emission Ratio(ER)=Coumarin Emission(445nm)/Fluorescein
Emission(520nm)%Phosphorylation=1-[ER.times.C3.sub.520nm-C3.sub.445nm]/[(-
C1.sub.445nm-C3.sub.445nm)+ER.times.(C3.sub.520nm-C1.sub.520nm)]
Inhibition rate(IR)=1-%Pho.sub.test Cpd/%Pho.sub.C2
6. IC.sub.50 Value:
[0366] determined with add-in software for Microsoft Excel,
XLfit.TM. (version 2.0) from ID Business Solutions (Guildford,
UK)
Example 26
Cellular Proliferation Assay
1. Cell Line
[0366] [0367] KG-1 (ATCC Accession No. CCL-246), [0368] SNU-16
(ATCC Accession No. CRL-5974), [0369] RT-112 (ECACC Accession No.
85061106)
2. Assay Protocol
[0369] [0370] FGFR related cancer cell proliferation is measured in
96-well plates using Cell Counting Kit-8 (Dojindo CK04-13). [0371]
Seed 30000 cells/well of KG1, 5000 cells/well of SNU16, and 1000
cells/well of RT112 in a volume of 100 .mu.L/well in growth media.
[0372] After 24 hours, dilute the compound to 10, 3.3, 1.1, 0.37,
0.12, 0.04, 0.013, 0.004 .mu.M, keeping the DMSO concentration at
5%. [0373] Add 10 .mu.L of 8-point compound series to the wells of
culturing cells. [0374] Incubate at 37.degree. C. and 5% CO2 for 72
hours [0375] Add 10 .mu.L/well of CCkit8 and incubate at 37.degree.
C. and 5% CO2 for an hour [0376] Detect the optical density of each
well at 450 nm on Labsystems Multiskan K3.
3. Data Analysis
[0377] Inhibition ( % ) = 100 - OD compound well - OD control well
OD cell well - OD control well ##EQU00003##
Note:
[0378] OD.sub.compound well represents the optical density of cells
treated with compound. [0379] OD.sub.cell well represents the
optical density of cells without compounds treatment. (only 0.5%
DMSO) [0380] OD.sub.control well represents the optical density of
culture media background
[0381] The concentration of compound providing 50% of proliferation
inhibition was calculated using Excel Fit.
Results:
TABLE-US-00028 [0382] FGFR1 FGFR2 FGFR3 (FP) (FP) (Z-lyte) KG1
SNU-16 RT-112 Compound IC50 IC50 IC50 IC50 IC50 IC50 No. (uM) (uM)
(uM) (uM) (uM) (uM) 1 0.024 0.019 0.028 0.049 0.095 0.612 2 0.017
0.010 0.017 0.017 0.031 0.019 3 0.028 0.028 0.188 0.072 0.134 0.370
4 0.201 0.233 0.795 5 0.013 0.012 0.047 0.024 0.056 6 0.922 0.986 7
0.143 0.169 0.590 8 0.006 0.005 0.014 0.011 0.014 0.019 9 0.038
0.028 0.064 0.098 0.044 10 0.025 0.005 0.008 0.018 0.022 0.029 11
0.018 0.009 0.007 0.040 0.028 0.034 12 0.098 0.025 0.128 13 0.029
0.010 0.007 0.498 0.021 0.059 14 0.003 0.004 0.004 0.009 0.007 16
0.012 0.008 0.016 0.013 0.017 17 0.004 0.006 0.009 0.009 0.012 18
0.012 0.006 0.008 0.077 0.003 19 0.005 0.005 0.011 0.019 0.022 20
0.043 0.034 0.128 0.589 0.340 21 0.009 0.006 0.014 0.040 0.016
0.052 22 0.009 0.005 0.020 0.028 0.026 0.084 23 0.009 0.006 0.013
0.029 0.018 24 0.047 0.027 0.094 0.122 0.151 25 0.015 0.008 0.030
0.039 0.023 0.218 26 0.020 0.012 0.027 0.048 0.029 0.093 27 0.256
0.042 0.021 0.340 0.293 0.402 28 0.360 0.245 0.347 29 0.003 0.002
0.007 0.005 0.005 30 0.029 0.010 0.040 0.055 0.068 0.241 31 0.042
0.023 0.287 0.178 0.236 0.491 32 0.018 0.006 0.005 0.057 0.030
0.104 33 0.022 0.007 0.017 0.047 0.019 0.135 34 0.033 0.013 0.046
0.132 0.058 0.308 35 0.030 0.009 0.083 0.189 0.157 0.455 36 0.021
0.616 0.031 0.052 0.029 0.160 37 0.010 0.007 0.016 0.046 0.044 38
0.008 0.003 0.020 0.028 0.030 0.086 39 0.043 0.041 0.043 0.049
0.071 0.342 40 0.012 0.010 0.039 0.031 0.048 41 0.004 0.006 0.009
0.038 0.024 42 0.002 0.004 0.008 0.011 0.015 43 0.016 0.010 0.048
0.069 0.033 44 0.005 0.004 0.009 0.009 0.015 0.051 45 0.014 0.007
0.010 0.388 0.034 0.094 46 0.132 0.034 0.061 0.059 0.113 47 0.006
0.006 0.008 0.063 0.074 48 0.005 0.005 0.015 0.011 0.016 49 0.006
0.005 0.008 0.075 0.018 0.062 50 0.014 0.015 0.029 0.045 0.132
0.352 51 0.103 0.113 0.175 52 0.001 0.002 0.005 0.004 0.005 53
0.005 0.004 0.008 0.014 0.019 0.049 54 0.006 0.003 0.006 0.018
0.010 0.031 55 0.002 0.003 0.002 0.003 0.004 0.016 56 0.004 0.004
0.009 0.007 0.017 57 0.008 0.009 0.014 0.016 0.032 58 0.325 0.123
0.509 59 0.003 0.002 0.002 0.002 0.004 60 0.016 0.007 0.023 0.051
0.046 0.137 61 0.054 0.017 0.062 0.400 0.158 62 0.020 0.009 0.033
0.046 0.049 0.152 63 0.195 0.027 0.243 0.427 0.419 0.895 65 0.048
0.028 0.112 0.203 0.055 0.296 66 0.018 0.007 0.025 0.194 0.055
0.201 67 0.037 0.027 0.044 0.089 0.071 0.263 68 0.031 0.013 0.025
69 0.042 0.020 0.042 0.268 0.085 0.337 70 0.027 0.016 0.022 71
0.126 0.053 0.591 0.398 0.708 0.101 72 0.058 0.024 0.038 0.195
0.094 0.554 73 0.034 0.011 0.040 74 0.009 0.008 0.025 0.070 0.065
0.493 75 0.041 0.033 0.061 0.123 0.094 76 0.005 0.004 0.008 0.043
0.016 0.067 77 0.005 0.003 0.004 0.011 0.012 78 0.044 0.018 0.031
79 0.006 0.006 0.006 0.013 0.014 0.034 80 0.024 0.016 0.019 0.033
0.039 0.024 81 0.008 0.005 0.011 0.016 0.025 0.010 82 0.012 0.005
0.003 0.030 0.024 0.050 83 0.015 0.009 0.035 0.053 0.055 0.201 84
0.019 0.007 0.016 0.248 0.239 0.122 85 0.015 0.009 0.017 0.030
0.093 0.026 86 0.017 0.010 0.010 0.042 0.016 0.012 87 0.010 0.010
0.036 0.025 0.050 0.084 88 0.015 0.006 0.009 0.214 0.013 0.027 89
0.012 0.008 0.008 0.130 0.029 0.046 90 0.011 0.005 0.007 0.031
0.009 0.026 91 0.020 0.016 0.017 0.032 0.019 0.064 92 0.164 0.040
0.198 0.255 0.238 0.831 93 0.018 0.009 0.011 0.125 0.047 94 0.161
0.053 0.213 0.344 0.170 0.287 95 0.034 0.012 0.033 0.044 0.033
0.072 96 0.063 0.044 0.119 0.161 0.150 97 0.011 0.006 0.012 0.026
0.022 0.159 98 0.032 0.015 0.026 0.048 0.024 0.225 99 0.014 0.007
0.012 0.030 0.017 0.110 100 0.012 0.005 0.013 0.021 0.024 0.094 101
0.008 0.004 0.015 0.022 0.042 0.257 102 0.012 0.007 0.018 0.033
0.055 0.461 103 0.032 0.021 0.047 0.138 0.139 0.659 104 0.015 0.009
0.044 0.053 0.038 0.142 105 0.031 0.011 0.030 0.201 0.048 0.428 106
0.010 0.007 0.035 0.040 0.033 107 0.010 0.007 0.014 0.028 0.026
0.090 108 0.005 0.003 0.010 0.110 0.112 0.562 109 0.379 0.275 0.311
110 0.068 0.014 0.024 0.095 0.046 0.197 111 0.107 0.033 0.061 0.162
0.127 0.570 112 0.009 0.007 0.008 0.018 0.017 0.036 113 0.048 0.018
0.146 0.148 0.089 114 0.012 0.005 0.014 0.071 0.088 0.591 115 0.014
0.006 0.011 0.012 0.019 0.053 116 0.027 0.010 0.028 0.020 0.045
0.019 117 0.028 0.005 0.013 0.031 0.026 0.188 118 0.023 0.012 0.034
0.026 0.029 0.220 119 0.011 0.006 0.019 0.022 0.027 0.124 120 0.015
0.007 0.017 0.032 0.031 0.165 121 0.009 0.006 0.015 0.007 0.018
0.065 122 0.014 0.006 0.009 0.020 0.013 0.067 123 0.009 0.005 0.013
0.026 0.018 0.135 124 0.010 0.007 0.013 0.029 0.018 0.166 125 0.028
0.019 0.020 0.030 0.029 0.750 126 0.015 0.008 0.017 0.045 0.018
0.112 127 0.009 0.005 0.009 0.022 0.020 0.066 128 0.020 0.010 0.014
0.047 0.015 0.112 129 0.031 0.012 0.049 0.064 0.043 0.127 130 0.008
0.005 0.010 0.028 0.032 0.048 131 0.019 0.008 0.011 0.037 0.013
0.131 132 0.012 0.006 0.006 0.020 0.010 0.059 133 0.020 0.008 0.016
0.345 0.051 0.713 134 0.071 0.008 0.024 0.033 0.034 0.084 135 0.022
0.019 0.022 0.368 0.046 0.230 136 0.023 0.011 0.018 0.092 0.025
0.037 137 0.012 0.006 0.007 0.319 0.029 0.086 138 0.009 0.007 0.008
0.617 0.032 0.202 139 0.012 0.006 0.008 0.064 0.022 0.146 140 0.038
0.016 0.060 0.152 0.062 0.438 141 0.011 0.005 0.017 0.015 0.017
0.112 142 0.020 0.011 0.028 0.060 0.028 0.208 143 0.041 0.007 0.203
0.803 0.100 0.991 144 0.013 0.006 0.016 145 0.037 0.013 0.032 0.154
0.052 0.260 146 0.012 0.010 0.014 0.009 0.019 0.142 147 0.019 0.010
0.022 0.048 0.046 0.334 148 0.009 0.005 0.014 0.024 0.059 0.495 149
0.015 0.008 0.033 0.067 0.017 0.021 150 0.015 0.006 0.006 0.031
0.033 0.062 151 0.015 0.016 0.152 0.071 0.149 0.626 152 0.019 0.012
0.038 0.056 0.029 0.088 153 0.015 0.007 0.016 0.177 0.059 0.240 154
0.012 0.005 0.009 0.370 0.016 0.021 155 0.010 0.004 0.004 0.461
0.018 0.012 156 0.006 0.002 0.004 0.002 0.004 0.004 157 0.020 0.010
0.019 0.048 0.048 0.254 158 0.008 0.008 0.006 159 0.008 0.006 0.008
0.290 0.075 0.759 160 0.015 0.010 0.016 161 0.017 0.009 0.012 162
0.017 0.010 0.014 163 0.007 0.006 0.008 0.201 0.060 0.584 164 0.008
0.008 0.008 165 0.011 0.007 0.007 0.056 0.023 0.106 166 0.020 0.013
0.015 0.069 0.057 0.592 167 0.018 0.010 0.015 0.062 0.048 0.382 168
0.016 0.011 0.015 0.032 0.016 0.414 169 0.015 0.014 0.015 0.017
0.018 0.539 170 0.099 0.087 0.132 171 0.043 0.041 0.050 0.128 0.048
0.655 172 0.009 0.006 0.006 0.022 0.014 0.064 173 0.008 0.007 0.028
0.041 0.020 0.135 174 0.010 0.006 0.005 0.040 0.017 0.065 175 0.009
0.006 0.008 0.023 0.014 0.057 176 0.007 0.007 0.008 0.066 0.017
0.100 177 0.006 0.005 0.009 0.025 0.019 0.086 178 0.014 0.015 0.018
0.072 0.027 0.186 179 0.069 0.056 0.091 0.284 0.202 0.952 181 0.019
0.005 0.009 0.026 0.008 0.035 182 0.027 0.009 0.010 0.008 0.019
0.033 183 0.007 0.005 0.007 0.009 0.008 0.014 184 0.009 0.007 0.009
0.005 0.010 0.053 185 0.005 0.003 0.004 0.002 0.002 0.005 186 0.005
0.004 0.005 0.010 0.007 0.007 187 0.271 0.132 0.227 188 0.008 0.005
0.010 0.020 0.006 0.012 189 0.023 0.020 0.013 0.038 0.028 0.023 190
0.012 0.009 0.007 0.037 0.016 0.017 191 0.181 0.068 0.334 0.647
0.534 0.540 192 0.012 0.006 0.008 0.008 0.002 0.014 193 0.008 0.005
0.011 0.062 0.017 0.021 194 0.014 0.014 0.020 0.060 0.031 0.027 195
0.012 0.006 0.012 0.025 0.016 0.025 196 0.006 0.005 0.009 0.051
0.014 0.020 197 0.008 0.007 0.009 0.026 0.008 0.025 199 0.013 0.007
0.008 0.020 0.018 0.041 200 0.009 0.006 0.006 0.091 0.020 0.034 201
0.029 0.012 0.019 01.103 0.019 0.066 202 0.015 0.006 0.007 203
0.011 0.008 0.014 0.011 0.023 0.037 204 0.009 0.005 0.008 0.018
0.007 0.015 205 0.036 0.025 0.028 0.068 0.037 0.097 206 0.038 0.013
0.021 207 0.045 0.016 0.029 208 0.010 0.005 0.009 0.060 0.017 0.021
209 0.007 0.006 0.007 0.013 0.008 0.016 210 0.119 0.027 0.690 211
0.018 0.009 0.021 0.084 0.053 0.163 214 0.010 0.011 0.017 220 0.010
0.004 0.010 222 0.022 0.008 0.027
* * * * *